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Background-Although prescribed to approximately 90% of persons with 
cardiovascular disease (CVD), it is estimated that adherence to aspirin therapy is 
only approximately 70%. Established psychosocial predictors of adherence include 
patient beliefs about medicines and illness, depression and social support. However, 
no study has assessed these simultaneously to determine the best predictor of 
adherence when using an objective measure of aspirin adherence. 
Method-After ethical approval was received we surveyed 106 patients with 
cardiovascular disease from Beaumont Hospital who participated in a study of 
aspirin effectiveness in patients with stable coronary artery disease using a direct 
assay measurement (thromboxane B2). The following measures were used to 
assess the psychological predictors of adherence:  Beliefs about Medicines 
Questionnaire, Brief Illness Perception Questionnaire, Patient Health Questionnaire-
2 and ENRICHD Social Support Inventory. These were administered either by post 
or by interview to patients who were willing and able to consent for the current sub-
study. Data was amalgamated with the initial study and analysed to determine the 
best predictors of aspirin adherence. 
Results-There was a 56% response rate to the survey (n=106). The mean age was 
63 years; 66% had an effective response and 34% had an ineffective response 
(defined as serum thromboxane B2 levels of greater than 2.2ng/ml). There was no 
significant correlation between psychological adherence predictors and thromboxane 
level or self-reported non-adherence. 
Conclusion-Although most psychological variables correlated significantly with each 
other as expected, no psychological variable was associated with thromboxane level 
or self-reported adherence. Patients who had higher weight and alcohol 





CHAPTER 1- General Introduction and adherence 
Introduction 
Cardiovascular disease (CVD) is the single largest cause of death in Ireland 
(1), and age-standardised death rates here are significantly higher than other 
European Union15 (EU15) States (1). CVD is the major cause of death in 
women in all European countries; below 75 years, 42% of women die from 
CVD compared with 38% of men (2). According to Versteeg et al. (3), low 
socio-economic status, lack of social support, stress at work and in family life, 
depression, anxiety, hostility, type D personality and behaviours contribute 
both to the risk of developing CVD and the worsening of  the clinical course 
and prognosis of CVD (3). These factors act as barriers to treatment 
adherence and efforts to improve lifestyle, as well as to promoting health and 
wellbeing in patients and populations (4). Our understanding of the reasons 
for changes in the behaviour of both populations and individuals remains 
incomplete, and the mechanisms whereby such changes in behaviour 
translate into changes in disease patterns are not completely understood (4). 
Patients with CVD are prescribed an extensive range of medications to 
reduce their risk of (recurrent) acute cardiovascular events. The Fourth Joint 
Task Force on cardiovascular disease prevention recommends a number of 
populations should take preventive medication (5): 
 - those with established CVD 
 - those at high risk for CVD, and their immediate family members. 
 
The Fifth Joint Task Force describes how in long-term secondary prevention 
after myocardial infarction, stroke, or peripheral arterial disease (PAD), aspirin 
is the most studied drug. In a meta-analysis of 16 trials comprising 17,000 
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individuals, the Antithrombotic Trialists' Collaboration, 2009 (6, 7) found that 
allocation to aspirin was associated with serious vascular events in 6.7% of 
patients per year compared to 8.2% of controls. The risk of total stroke was 
2.08% per year compared to 2.59% (P = 0.002) and coronary events 4.3% 
per year compared to 5.3% (P = 0.0001). Aspirin was associated with a 10% 
reduction in total mortality (RR 0.90, 95% CI 0.82–0.99), but was also 
associated with a significant excess of major bleeds; nevertheless, the 
benefits of aspirin exceeded the bleeding hazards. Few drugs have 
demonstrated similar efficacy with up to 50 major vascular events avoided per 
1000 patients treated per year, therefore aspirin has been recommended for 
persons with CVD as it is one of the most effective therapies (8).  
 
In Ireland, there has been a 4-fold increase in CVD medication prescription 
since 2000 (9). However, the results of EUROASPIRE III demonstrated that 
the secondary prevention profile of those with CVD was suboptimal (9). In the 
EUROASPIRE surveys, blood pressure management showed no 
improvement over the three surveys that were carried out over a 12 year 
period, despite increases in prescriptions for all classes of anti-hypertensive 
drugs. One explanation given for this finding is the rising proportion of 
overweight and obese patients. Other reasons were low dose prescriptions, 
inadequate titration of doses and poor patient adherence to their anti-
hypertensive medication (9). A recent systematic review by Chowdhury et al. 
(10) where they looked at adherence to cardiovascular therapy and the 
clinical consequences, showed overall 60% of patients had good adherence 
(more than or equal to)>=80% to cardiovascular medications. They concluded 
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that approximately 9% of all cardiovascular events in Europe could be 
attributed to poor adherence to cardiovascular medications alone. This study 
also showed a rate of only 70% of aspirin adherence. This figure appears to 
be supported by a recent study on the use of secondary prevention drugs in 
patients with an indication for aspirin therapy, investigators found that 
approximately only 25% of patients were actually taking it although the 
measurement of adherence appears to be mainly through self reporting. They 
found that rates of adherence were higher in high-income countries 62% 
compared to low-income countries 9%, and point out that compliance is a 
necessity prior to platelet function testing (8, 11, 12). A recent study by 
O’Carroll et al. (13) funded by the Scottish Government looking at secondary 
prevention of stroke with Aspirin therapy, describes the importance of a valid 
and reliable measurement of adherence as patients may respond in a way 
that is socially desirable and over report adherence. They used urine 
measurements of salicylate levels as an objective measure but found no 
significant difference between the levels of aspirin takers and non-aspirin 
takers which raised concerns of the sensitivity of the assay. Therefore the 
assay was not used as a measure of adherence in their final analysis. 
A previous study looking at the role of weight and enteric coating on aspirin 
response in cardiovascular patients has shown the thromboxane B2 ELISA 
assay a reliable measure in detecting aspirin ingestion and adherence, 
therefore this was the objective measure chosen for the current study (11). In 
this study they found 19% of patients were not responsive to their aspirin but 
when questioned by a nurse, half admitted to non-adherence and the other 
half were found to be responsive when observed ingesting their daily dose of 
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aspirin showing a possible resistance in only 1%. Recent researchers have 
also found this assay a reliable tool in cardiovascular patients with diabetes 
(14). Chowdhury et al. (10) advises that measures to enhance adherence are 
urgently required to maximise the effect of cardiac therapies pointing out that 
poor adherence is a worldwide problem that is diagnosable and treatable. 
They also state that cardiovascular medications such as statins, anti-
hypertensives and anti-thrombotics including aspirin, remain the most 
common medical interventions worldwide for both primary and secondary 
prevention of cardiovascular diseases.  
 
The next section will review the topic of adherence and the use of 
thromboxane B2 assay. Chapter 2 and 3 will review beliefs about medicines 
and beliefs about illness in the context of their importance for aspirin 
adherence. Chapters 4 and 5 will review depression and social support and 
the influences they both have on medication adherence. Chapter 6 is a 
summary of the literature and the present study. Chapter 7 describes the 
method used. Chapter 8 shows the results of the responders to the 
psychological questionnaires and the demographics of the patients looking at 
the correlations between the demographic variables, thromboxane, self-
reported adherence and the psychological variables. Finally in Chapter 9, 
there is the discussion and conclusion of the literature and the current study 





Definitions and controversies: 
Adherence or compliance to a medication regime is generally defined as the 
extent to which patients take medications as prescribed by their health care 
provider (10, 14). The word adherence is preferred because compliance 
suggests that the patient is passively following the doctor’s orders and the 
treatment is not based on an agreement between the patient and physician 
(15). 
Osterberg et al. (14) suggests that both terms are imperfect and uninformative 
descriptions of patient medication behaviour, and can stigmatise patients in 
their future relationships with health care providers, labelling patients without 
considering the possible psychological reasons for non-adherence (14). They 
also describe how adherence rates are typically higher in patients with acute 
conditions such as acute Myocardial Infarction (MI) compared with patients 
with chronic conditions such as heart failure. Adherence in patients with 
chronic conditions such as heart failure is disappointingly low, typically 
dropping off dramatically after 6 months (16) . Estimates of the extent of non-
adherence vary across different studies, largely because of differing methods 
of, and difficulties in, measuring adherence, and inconsistency in the 
definitions used for the term ‘adherence’ (17, 18). 
 
A second definition of adherence considers the duration of time a patient 
continues with a prescription regimen, even if intermittently, before 
discontinuing the medication prematurely. With this definition, patients are 
categorized as non-adherent if they discontinue a medication before a certain 
time period. Primary non-adherence refers to when a patient “discontinues” a 
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medication before filling a prescription even once (19, 20). Other authors 
argue that the cut off for optimal adherence may vary depending on the 
pharmacokinetic and pharmacodynamic effects of the individual drug and the 
clinical setting (19). 
 
Most definitions of adherence presume that adherence is a stable patient 
characteristic, yet Kronish and Ye (19) point out there is evidence that it may 
be more accurately understood as a dynamic process. They give the example 
of patients who have suffered an acute coronary syndrome (ACS), where the 
acute episode can serve as a teachable moment that leads to medication 
adherence improvement, whereas other patients may have reduced 
medication adherence due to the stress of the ACS. The review by Kronish 
and Ye. (19) seems to continually show that while the patient is acute this is a 
good opportunity to assess and promote adherence while the patient has the 
support of the multidisciplinary team.  
 
Across the different definitions and settings, it is suggested that around 50% 
of medicines are not used as intended by the prescriber (21). Medication 
adherence is estimated to be only approximately 50% for people with chronic 
conditions, although this estimate varies widely depending on the regimen 
assessed and the definitions used (22). However, the measurement of 
adherence can differ between studies and there is little consensus on what 
constitutes ‘good’ adherence (e.g. taking medications as prescribed 80% or 
more of the time – a binary variable; or the proportion of prescribed 




Most clinical trials consider 80% to be adherent but average rates of 
adherence in clinical trials can be remarkably high owing to the greater 
attention and selection criteria of patients (23). Kronish and Ye (19) point out 
that there are gaps in the knowledge of adherence that need to be addressed, 
stating that researchers commonly use a cut-off point of less than 80% of pills 
taken as prescribed to define poor adherence to cardiovascular medications. 
They describe how the optimal cut off points for categorizing adherence 
remains poorly understood and how this cut off point can be traced back to a 
small anti-hypertensive trial where the authors found that diastolic blood 
pressure declined significantly only when participants took more than 80% of 
their pills (24). There is strong reason to suspect that the optimal threshold for 
adherence between medications is quite different due to pharmacokinetic and 
pharmacodynamic properties. In some clinical settings, for example, 
immediately after coronary artery stenting, the optimal threshold for anti-
platelet therapy may be as high as 100%, whereas in other settings where 
patients are of low cardiovascular risk requiring statins, a clinically relevant 
threshold for defining adherence may be lower (24). Kronish and Ye (19) 
suggest that increasing our understanding of the optimal cut off points for 
adherence in cardiovascular medications may lead to a more precise 
understanding of the problem, the populations to which adherence 





Thus, as we can see with the above examples, defining adherence can be 
problematic and it may be appropriate to measure it in different ways 
depending on the pharmacodynamics and pharmacokinetics of the type of 
drug, patients and condition we are interested in monitoring. We can see from 
the literature and experience that patients who sign up for studies are likely to 
be more adherent as this is normally part of the inclusion criteria, that patients 
are willing to adhere to the protocol and medication regime, particularly in 
randomized clinical trials, therefore patients are “cherry picked”. It is also 
more unlikely in observational studies that patients who are non-adherent will 
volunteer for monitoring when they are aware that this will be monitored. 
Finally, good adherence should be seen as a means of achieving a 
satisfactory therapeutic result and not as an end in itself, as the patient’s 
perspective must always be considered (25). 
 
Prevalence and costs of non-adherence: 
Poor adherence has a significant human cost in terms of patient safety and 
quality of life; it also causes a serious problem for health systems in terms of 
reduced health outcomes, unnecessary treatments and hospitalisations, 
causing resource waste of prescribed medicines funded by the healthcare 
system. Low adherence is also connected to the development of resistance 
which is fast becoming an urgent global problem (10, 26). 
It is estimated that there are 194,000 deaths per year in the European Union 
due to wrong doses and non-adherence of prescribed medication at a cost of 
1.25 billion Euros to the economy annually (24). While similar reports estimate 
medication costs of £12 million due to non-adherence in England in 2004. It is 
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estimated that £100million each year is wasted on medication dispensed but 
then returned to pharmacies. 
 
Compared with the amount of resources spent on the development of new 
drugs, improving patient’s medication adherence with their cardiovascular 
medication has enormous potential for improving health outcomes while 
reducing healthcare costs (19). Kronish et al. (19) point out that even in 
clinical trial settings where patients are carefully selected, high rates of poor 
adherence have been documented and that irrespective of differences in how 
and when adherence is measured, poor adherence to cardiovascular 
medications is highly prevalent across patient populations and cardiovascular 
drug classes. 
Poor medication adherence has also been associated with a number of 
adverse health impacts where, for example, the clinician may be unaware that 
the uncontrolled risk factor is due to poor adherence. This can then lead to 
intensification of treatment and the potential for over treatment if the patient 
suddenly decides to take their complete regimen (27). This can then lead to 
serious adverse effects for example if a patient’s anti-hypertensive medication 
have been titrated up according to blood pressure readings and then suddenly 
they decide to take all of the medications as prescribed, this could lead to 
collapse, organ failure or even death (26).  
 
Poor adherence is also associated with worse health outcomes in several 
cardiovascular medication adherence studies (10). Rasmussen et al. (28) 
found that survivors of acute myocardial infarction (MI) who had poor to 
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intermediate adherence (measured by proportion of days covered <80%) to 
statins were at 25% and 12% increased risk of mortality compared to 
survivors with high adherence (>=80%). This study also found that 
advantages associated with improved drug adherence after an acute MI 
appear to be class-specific and due to drug effects rather than the “healthy 
adherer” behaviour. Likewise, another study looking at patients that 
prematurely stopped their thienopyridine anti-platelet medication within 30 
days of insertion of a drug eluting stent were 9 times increased risk of 
mortality in the subsequent year (28, 29). Kronish and Ye. (19) and other 
authors (30, 31) have found that savings from lower medication costs by 
patients who may have their medications paid for by an insurer or the state, 
are offset by increased medical costs which in turn increase overall medical 
healthcare costs. They suggest that programs to increase medication 
adherence may actually provide an opportunity for investment in health care 
services that can improve health outcomes and lower costs. Caulfield et al. 
(24) suggest strategies to tackle adherence need to take a multi-stakeholder, 
patient-centred approach. 
Adherence is a key priority for future health programmes, reducing unused or 
improperly used medications is a key factor in improving patient safety and 
satisfaction and the quality of healthcare while increasing cost effectiveness 
and chronic disease management. The World Health Organisation has 
stressed that “increasing the effectiveness of adherence intervention may 
have a far greater impact on the health of the population than any 
improvement in specific medical treatments” (24). The authors point out that 
priority areas with a close link to adherence include the development of 
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ehealth solutions (32). Lehane and McCarthy (33) point out that a 
considerable amount of research on this subject from a range of perspectives 
such as pharmacology, psychology and nursing have shown that health care 
interventions have not been cost effective or clinically effective in enhancing 
medication adherence when looking at systematic reviews, the authors also 
suggest that nurses are in a good position to assess and intervene in 
improving patient’s adherence by understanding the complexities.  
 
Healthy Adherer 
Researchers have questioned the extent to which poor medication adherence 
directly causes worse health outcomes or whether the association between 
the two is spurious (17, 27). They have speculated that medication adherence 
is likely a marker of other favourable health behaviours, for example, 
adherence to medical advice in general or to behaviours like exercise and 
smoking cessation or socioeconomic characteristics like access to health care 
or social support. They imply that the strong associations between medication 
adherence and outcomes are mainly due to a “healthy adherer” rather than to 
specific benefits of adhering to a particular medication. Evidence that supports 
the healthy adherer effect comes from several post-hoc analyses of 
randomized controlled trials in which patients that had better adherence to a 
placebo, had better health outcomes than patients who were less adherent to 
a placebo medication. For example, the Beta Blocker Heart Attack Trial 
showed that patients who were more adherent to placebo had 62% lower 
odds of mortality than patients who were non-adherent to placebo within a 
year of follow up (34). These researchers suggest then that if this hypothesis 
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is correct, then interventions that are directed toward increasing adherence to 
specific medications may not have the desired effect on health outcomes. 
 
Researchers have suggested another possible explanation for the health 
benefits of medication adherence is that the act of taking pills may activate a 
placebo effect (17). Finniss et al. (35) defines the placebo effect as a 
psychophysiologic effect that is derived from expecting a benefit from 
treatment. Laboratory studies have shown that the receipt of placebo 
medications can result in biological effects such as hormonal secretion and 
immune response. However, studies on the impact of adherence to placebo 
on health outcomes that adjust for adherence to other health behaviours like 
smoking and exercise, do not reliably weaken the strength of the benefits of 
patient’s adherence to placebo medication (36). 
 
Kronish and Ye (19) point out that these findings challenge the hypothesis 
that the benefits of adherence to placebo are due to a healthy adherer effect 
and increase the likelihood that improved adherence can amplify the 
biological benefits of the placebo effect. 
 
Further evidence contrary to the “healthy adherer” hypothesis can be seen 
from Rasmussen et al. (28). This retrospective study of 31,455 elderly Acute 
Myocardial Infarction (MI) survivors found that poor adherence to statins and 
rennin-angiotensin system inhibitors post-MI was associated with increased 
adverse events, whereas poor adherence to calcium channel blockers was 
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not associated with worse outcomes (a drug class not expected to have an 
impact on post MI prognosis). 
 
Overall, researchers have concluded that future studies should examine the 
association between adherence and health outcomes, determining whether 
the strong association between medication adherence and outcomes is 
mainly due to a drug effect or whether alternative mechanisms such as 
“healthy adherer” or placebo effect play a major role. This they suggest can 
be accomplished by carefully measuring potential confounders of the 
relationship between adherence and outcomes such as health behaviour, 
socioeconomic status, or susceptibility for the placebo effect. Researchers are 
very aware of the placebo effect, and as a result, in cases where there is a 
recognized strong placebo effect for example with anti-depressants, the drug 
must show a strong superiority compared to the placebo group in randomized 
clinical trials. We can see from the literature that medication adherence 
should be of concern to all groups including physicians, nurses, the 
multidisciplinary team, carers, patients and the wider community if treatments 
are going to be therapeutic and cost effective.  
  
Measurements of adherence:  
Measurement of adherence can be either indirect or direct. Indirect methods 
are for example using a self-report where the patient or their relative answers 
questionnaires or interview questions or use diaries. Direct methods are those 
that demonstrate drug ingestion using measurement of drug or metabolite in 
urine or blood (37). Direct methods are less prone to bias, but to date have 
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not been practical enough to include in large studies of adherence (23). This 
is likely to be related to costs of the extra man power and labour but also due 
to lack of patient or end user friendliness. Clinical judgment appears to be the 
most common way of measuring medication adherence which is generally an 
indirect measure (19) but studies have shown that clinicians and patients 
themselves overestimate their adherence (38, 39). A number of self report 
instruments for measuring adherence have been developed and have the 
advantage of being brief, inexpensive and can provide immediate feedback to 
the clinician. However researchers have shown that these scales are at best 
moderately related to objective measures of adherence and overestimate 
adherence by 10-20% compared to objective measures (40). 
 
Physiologic or laboratory markers have the advantage of being objective but 
these are unavailable for all medications and may reflect pharmacodynamics 
and pharmacokinetics rather than adherence, for example, cholesterol levels 
with statins and platelet function tests in the case of anti-platelet therapy such 
as clopidogrel (19). Studies have consistently found that up to 30% of patients 
are resistant to clopidogrel (41). Pharmacy refill monitoring as outlined earlier 
has the advantage of being objective and quantifiable in a similar manner to 
pill counts. Furthermore it is also unobtrusive and inexpensive to obtain from 
large populations. Unfortunately it is difficult to obtain outside a closed 
pharmacy system which is not available for all Irish patients, generic refills 
and over the counter drugs such as aspirin will not always be captured and 




Medication Event Monitoring System-MEMS 
MEMS medication bottles contain a microelectronic chip that registers the 
date and time of every bottle opening (42). This device is currently the gold 
standard to measure adherence (43) although this assumes that each time 
the patient opens the lid of the container they are ingesting the medication 
that is contained in the bottle. 
 
Hugen et al.’s 2002 study (44), “Interventions for helping patients to follow 
prescriptions for medications assessment of adherence in patients with HIV” 
looked at the various methods of medication adherence including MEMS, 
patient report, nurse report and therapeutic drug monitoring. Twenty eight 
patients were included and the data for twenty six patients was evaluated. 
According to MEMS data 25% of the patients took fewer than 95% of all 
doses. Patients self report and therapeutic drug monitoring were significantly 
correlated with the MEMS data, and the authors point out that the clinical 
nurse specialist also plays a role in identifying patients who are non-adherent. 
MEMS has been recognised as not being feasible for use in routine clinical 
practice due to the high cost but Boogaard et al.’s study (42) was designed to 
determine the validity of several direct and indirect adherence measures of 
potential use in resource limited settings. 
 
Electronic medication monitoring, where an electronic chip is attached to the 
medication blister pack and records when the medication is dispensed from 
the pack, is also objective and quantifiable, providing a daily pattern of pill 
taking while also having the possibility of being able to transmit remotely. 
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They have the disadvantage of being costly and not readily integrated into 
clinical pathways (17), they also have no advantage for socio-economic 
factors such as, social support, insurance or financial problems that may be 
causing the interrupted medication supply (45). In other words, they show us 
non-adherence but not the reason why. 
 
Assays 
Biological assays measure the concentration of a drug or its metabolite and 
trace compounds in the blood or urine but these measures are often costly 
and patients who know they will be tested may consciously take medication 
that they had been skipping, close to the time of the test being administered. 
Physiological factors and the half-life of the drugs may also have an effect on 
the results and Vik et al. (111) point out that assays have high costs that limit 
their feasibility in clinical practice. Osterberg et al.(15) agree stating that 
assays that reflect the target of medications are more costly and have limited 
applicability to the broad range of medications that are commonly prescribed, 
although the literature on adherence includes several studies that show the 
strengths of assays compared to other measures of adherence -particularly 
self-report measures. An example of this, is the study carried out by 
Pappadopulos et al. (46), where they looked at 254 children with Attention 
Deficit/Hyperactivity Disorder (ADHD) who were being treated with 
medication. Their aim was to examine the discrepancy between parents’ 
verbal reports of medication adherence and a physiological measure from 
saliva assays. These were collected from four time points during a 14month 
treatment period. They found that nearly a quarter of the saliva samples 
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indicated non-adherence and that 25% were non-adherent 50% or more of 
the time. The authors concluded that the same day saliva assays suggest that 
nearly half of the parents were inaccurate of their child’s ADHD medication 
adherence and that parents may overestimate adherence. Interestingly an 
eight year follow up of the children who took part in the study (47) found that 
type or intensity of treatment in the 14 months at age 7-9 does not predict 
outcomes 6-8 years later. Vik et al. (48) remarks that few high quality 
investigations have examined associations between non-adherence and 
subsequent health outcomes, although there is data that provides some 
support for increased health risks with non-adherence. However, interventions 
to improve adherence have seldom demonstrated positive effects on health 
outcomes.  
It is accepted that there is no “gold standard” for measuring medication 
adherence, however, because medication adherence is a complex health 
behaviour, the authors suggest that it may be more beneficial to focus on 
which specific aspects of medication adherence each measure is actually 
measuring (49). 
 
Pharmacy re-fill data reports on the amount of medication the patient has in 
their possession and not the actual medication taking itself. Self report 
measures are a low cost measure but have the potential for a response that 
has social desirability bias, although the authors suggest if this is assessed in 
an appropriate non-accusatory way, self report measures can help us 
understand the reasons for non-adherence which may identify areas for 
immediate intervention compared to impersonal measures such as pharmacy 
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claims. Medication event monitoring systems MEMS do not provide 
information on the actual amount of pills ingested, although studies have 
shown that there is at least a moderate correlation between self report and 
MEMS in previous research. 
While recognising the limitations for each method, the most robust approach 
may be to use multiple measurements in order to capture a broader range of 
adherence information. The authors suggest that in practice in the clinical 
setting all healthcare providers should be at least asking patients simple 
questions about any problems they may be having with their medications at 
each visit, this may be a simple way of assessing patient’s beliefs about their 
medicines and possible reasons for non-adherence. This however, may be a 
somewhat idealistic approach in the clinical area where pressures with the 
staff shortages and an ever increasing emphasis on measurable deliverables 
such as assessing a certain amount of people in a certain length of time in 
clinics.  Most clinicians will be aware of the increase in time of a consultation if 
asking patients about their medications and all the perceived possible side 
effects they may be experiencing. Therefore it may be more appropriate and 
effective for patients that are non-adherent to be identified and then targeted 
for a multidisciplinary approach including pharmacy, psychologists, social 
workers, doctors and nurses.   
 
Garber et al. (50) found in their literature search that the concordance 
between the different measures of adherence varies widely depending on the 
different measures used. Questionnaires and diaries have moderate to high 
concordance with other measures of adherence. Interviews and self reporting 
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have low concordance to electronic monitoring. They suggest that 
questionnaire and diary methods are preferable to interviews for self-reported 
medication adherence, due to patients responding in a socially desirable way 
or not remembering accurately when asked in interviews. It is important to 
remember that each measure will have its limitations and benefits with 
promoting adherence but only with the patient’s agreement will any measure 
be effective and this may have to be assessed on an individual basis 
depending on the patient’s individual circumstances and what measures are 
available to them in terms of finance, support and beliefs.   
Kane et al. (51) point out that medication adherence is a complex 
multifactorial issue with factors varying between patients and changing over 
time. They suggest that the first step in planning interventions to improve 
adherence is identifying patients at risk. They acknowledge that evaluating the 
perceptual barriers and the role of the patient’s beliefs and concerns 
regarding treatment provide valuable insights into the causes of non-
adherence. Adherence to treatments for most medical conditions is likely to 
affect the outcome for the treatment, since maintaining blood levels is 
necessary for efficacy (52). Poor health outcomes following low adherence 
can in turn have an effect on the cost to society because of subsequent 
unresolved or worsening conditions.  
 
Aspirin  
Although prescribed to approximately 90% of persons with Cardiovascular 
Disease (CVD), adherence to aspirin therapy has been estimated at 70% (9, 
10) (53). This may be due to the simplicity of the regimen, with typically one 
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tablet per day being prescribed (23). However, given that from 1998 to 2006 a 
two- to four-fold increase has occurred in prescribing in primary care for 
cardiovascular conditions, with associated cost increases (54), it is imperative 
that adherence to such medications be maximised to ensure value for money 
is achieved. Evidence suggests that reducing dosage demands is the most 
effective single approach to enhancing medication adherence (3). 
 
Aspirin non-response 
A further complication regarding aspirin adherence is the issue of ‘aspirin non-
response’. There is a growing awareness that aspirin therapy is ineffective in 
large numbers of patients who are prescribed the drug (55). The failure of 
response to aspirin whether defined in terms of platelet response, recurrent 
ischaemic events or using biochemical parameters has led to the concept of 
aspirin “resistance”. There is no consensus on a definition of “aspirin 
resistance”. Despite this lack of consensus, several studies have shown that 
patients, who for whatever reason are not responding to aspirin therapy, have 
a much higher incidence of adverse events than those that do respond to 
therapy. 
 
Evidence from a previous study (12) where investigators looked at the role of 
enteric coating and weight on aspirin response in 244 patients with stable 
coronary artery disease who were prescribed aspirin, showed that 
approximately 19% of patients with proven cardiovascular disease attending 
routine clinics, have platelet function tests that are consistent with “non 
response” to aspirin(using serum thromboxane B2 levels). Of this 19%, 
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approximately half can be identified by a brief questionnaire completed by a 
nurse and the reason for their non-response is non-adherence with 
medication. However, similar to other studies that use self reported adherence 
measures, this is still likely to overestimate adherence (56). The exact 
reasons behind lack of response in the other half of patients are not clear. 
However, when these patients were brought back to the clinic and given 
aspirin and witnessed taking it, the incidence of failure to respond dropped 
dramatically to about 1%. Moreover, of this small amount of patients (1%) who 
were apparent non-responders, when they were given 150 mg of soluble 
aspirin they did respond, when using Light Transmission Aggregometary (11). 
This leads us to conclude that the lack of response is more likely to be due to 
non-adherence. 
 
Assay measures of aspirin 
Thromboxane A2 is the main product of arachidonic acid metabolism through 
the action of cycloxygenase (COX-1) in platelets and COX-2 in monocyctes 
and other nucleated cells including endothelial cells where COX-2 can be 
expressed in the inflammatory response to stimuli. Thromboxane A2 is a 
vasoconstrictor and platelet agonist with a central role in platelet aggregation 
and thrombosis. The inhibition of this process by low dose aspirin is estimated 
to give a 21-25 % risk reduction in the secondary prevention of vascular 
disease (57, 58). In Berger et al.’s meta-analysis (48) they found that low 
dose aspirin in patients with stable coronary artery disease had a 21% 
reduction in the risk of cardiovascular events (non-fatal MI, non-fatal stroke, 
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and cardiovascular death) and a 13% reduction in all-cause mortality in six 
studies of 9853 randomised patients.    
 
Anti-platelet medication such as aspirin have been administered to patients at 
standard doses in clinical practice without monitoring their pharmacological 
effects by means of laboratory tests (59). Research however has revealed 
inter-patient response variability to aspirin and patients that display no or 
negligible response have been considered poor responders or resistant to 
treatment.  Cattaneo (59) suggests that the term “resistance” to a drug should 
be used when a drug is unable to hit it’s pharmacological target, due to 
inability to reach the target due to reduced bioavailability, in vivo inactivation, 
negative interaction with other substances, or due to alterations of the target. 
Based on this definition, resistance to aspirin should be limited to situations in 
which aspirin is unable to inhibit Cox-1- dependent Thromboxane A2 (TxA2) 
production and consequently TxA2- dependent platelet functions, such as 
Thromboxane B2 (TxB2).  
In other words, the term “aspirin resistance“ should be limited to situations in 
which failure of the drug to hit it’s pharmacological target has been 
documented with specific laboratory tests (60). A review of the literature 
shows agreement among authors in recent years that serum Thromboxane 
B2 (TxB2) reflects the total capacity of platelets to synthesize Thromboxane 
(TxA2), and because the contribution of other blood cells to its synthesis is 
small, serum TxB2 is the most specific test to measure the pharmacological 
effect of aspirin on platelets (61-64). Suboptimal response to aspirin, as 
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determined by specific assay tests (serum thromboxane B2) appears to be 
rare and in most cases is caused by poor adherence (65). 
 
Thromboxane B2 – Validated and Reliable measure of aspirin adherence  
Over the years researchers have repeatedly found that lack of platelet 
inhibition from aspirin post-myocardial infarction is associated with poor health 
outcomes (66). Cotter et al. (210) designed a study to examine if the increase 
in cardiovascular adverse events were due to non-adherence or aspirin 
resistance. They concluded that poor outcomes were mediated by non-
adherence. Several studies since have shown aspirin resistance to be only 
one percent and generally due to patients requiring an increase in dose or 
frequency due to increased body mass index or diabetes (12, 14, 67, 68). 
Meen et al. (68) describe their study of two hundred and eighty nine patients 
with stable Coronary Artery Disease where they looked for aspirin resistance 
with two different types of measurement for aspirin effectiveness. The first, 
using light transmission aggregometry and the effect of Arachadonic acid, 
where patients who are adequately inhibited have an aggregation response 
less than twenty percent. The other test is measuring serum thromboxane 
(using a similar assay to the current study), where the authors state the 
sensitivity and specificity for detecting subjects taking aspirin is ninety percent 
and eighty nine percent respectively. The authors advise aspirin resistance 
should not be diagnosed unless adherence is ensured, pointing out that many 
studies fail to provide adherence data, and only a few studies have witnessed 
aspirin ingestion (69, 70). They suggest that when in doubt, witnessed 
ingestion of aspirin followed by arachodonic acid induced testing is the best 
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method for deciding if there is true aspirin resistance or not. They conclude 
from their study that aspirin resistance is rare in patients with stable Coronary 
Artery Disease but acknowledge there are some clinical conditions that may 
affect patients inhibition with aspirin. They cite studies that have shown this in 
patients undergoing cardiac surgery (71) or carotid surgery (72), suggesting 
high oxidative stress may be a cause. They also suggest that it may be 
conceivable that patients with extreme advanced atheromatosis may have a 
very high turnover of platelets due to continued platelet activation on 
atheromatus ulcers.  
 
Adherence or Resistance  
Schwartz et al. (69) investigated the theory that aspirin resistance is often due 
to non-adherence. They looked at one hundred and ninety patients from a 
pool of three hundred and fifty patients who met the inclusion criteria of, a 
history of myocardial infarction and having been prescribed aspirin for greater 
than one month before consenting to participate. The patients were given a 
detailed description of the study before being invited to take part; therefore 
patients who tend to be non-adherent may have been deterred from taking 
part in the first place. Even still, from the one hundred and ninety patients, 
seventeen showed an ineffective response to aspirin using the standard light 
aggregometry and arachodonic acid. Of these seventeen patients, ten 
admitted being non-adherent. When these seventeen patients were 
administered aspirin and tested two hours post witnessed ingestion, only one 
patient showed lack of inhibition and then admitted to taking a non-steroidal 
anti-inflammatory twelve hours before testing, which is known to reduce the 
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effect of inhibition from aspirin (73). The authors concluded from their study 
that testing patients’ platelet inhibition with arachadonic acid aggegometry 
detected a significantly larger number of non-adherent patients than verbal 
questioning. The authors also suggest that there was no difference in the 
formulations either by dose or enteric coating between those that were 
inhibited and those that were not adequately inhibited. They also note from 
their previous studies that a single dose of aspirin (either 81mgs or 325mgs) 
will inhibit arachodonic acid stimulation for greater than or equal to three days, 
suggesting the patients that were not adequately inhibited were non-adherent 
to aspirin for at least three days. This study is also supported by the recently 
published study by Grosser et al. (73) who found not a single incidence of true 
resistance from four hundred volunteers taking aspirin, although enteric 
coated doses had a lower absorption rate as expected. Patients who take 
their daily dose should still be adequately inhibited as shown by standard light 
transmission aggregometry (LTA) and serum thromboxane B2.  
 
Schwartz et al. (69) state that previous studies showing aspirin resistance, 
even if associated with poor adherence, are associated with poorer outcomes 
and highlight the importance of assessing patients for lack of adherence. 
Particularly patients with multiple conditions, such as diabetes, heart failure 
and obesity that have previously been associated with higher resistance.  
Cotter et al. (210) concludes that significant adverse events and poorer 
outcomes due to lack of aspirin effect is mediated through non-adherence, 
and this contention is supported by studies that show the effect of aspirin is 
beneficial but not as large as one would expect. They suggest if the lack of 
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aspirin effect is due to non-adherence, then poorer outcomes may be due to 
features that are also associated with non-adherence to aspirin, not lack of 
effect alone. They point out that patients who are not taking their aspirin are 
more likely to be non-adherent to other medications, consistent with Newby et 
al.’s (74) previous study looking at long term adherence in secondary 
prevention therapies in Coronary Artery Disease, and also health 
recommendations including diet and exercise. They may also be more at risk 
of other psychosocial problems such as depression and social isolation which 
are also linked to increased morbidity. 
 
Predictors of adherence 
The literature on prediction of non-adherence has inconsistent findings, 
depending on the area being studied. Socio-demographic factors and lifestyle 
including alcohol intake, disease severity, and patient education and 
knowledge about regimen, have all been shown to predict adherence (22, 75, 
76) with one study showing improvement in adherence when the education 
was given by nurses, but not physicians. 
 
With the decreasing amount of time acute Cardiovascular Disease (CVD) 
patients spend in hospital for treatment (77), this lessens the opportunity for 
patient education regarding medication adherence which some studies have 
shown does have a positive effect on patient’s adherence (12, 53). Studies 
assessing knowledge may fail to take into consideration the deliberate non-
adherence to medications. More consistent predictors of adherence appear to 
be: beliefs about medicine, beliefs about illness, depression, forgetting, 
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prescription costs (depending on the broader health system) and social 
support (22, 78, 79). 
 
 
Factors influencing adherence 
It is estimated that there are over two hundred variables that can be linked to 
patient’s medication adherence (33, 80). In order to make sense of this large 
number of factors, researchers have attempted to categorize them into groups 
which include personal characteristics, cognitive and interpersonal factors.  
Jin et al. (81) conducted a systematic review in order to identify the most 
common factors that contribute to non–adherence from a patient’s 
perspective. From patient-centred factors they considered age, ethnicity, 
gender, education and marital status. They found that most studies showed a 
positive correlation between increasing age and adherence and those studies 
that did not, had confounding variables such as physical disability, location, 
and education thus limiting generalisability of the findings. The authors argue 
that non-adherence in the studies on elderly patients appears more likely to 
be non-intentional, suggesting if the elderly are assisted by health care 
providers or family this can be overcome. They also suggest that middle-aged 
patients tend to be less adherent, due to other commitments and priorities in 
their daily lives, while also being less concerned about their health. 
 
Their review found contradictory findings regarding gender and educational 
level, suggesting these were not good predictors of medication adherence, 
where education has previously been discussed this may be surprising but 
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they hypothesise that less educated patients may be more trusting of the 
physician. They did find correlations with non-adherence and ethnicity but 
advise that this may be due to language barriers and socio-economic status. 
They also found a generally positive relationship with marital status and 
adherence but this can be altered by disease factors. For example younger 
renal patients that were reliant on a spouse for their medications were less 
likely to be adherent whereas older married cardiovascular disease patients 
were more likely to be adherent. Smoking and alcohol consumption were 
generally related to increased lack of adherence as well as forgetfulness and 
lack of health literacy. The main findings from their literature search were that 
psychological indicators such as social support, beliefs about medicines and 
illness, the patient’s attitude (negative or positive) and the patient-prescriber 
relationship were strong factors influencing adherence.  They concluded that 
health care providers should consider therapy related problems when 
designing therapy plans such as accessibility, costs, frequency and 
complexity of treatments and the family and patient should be involved in the 
process of the plan for treatment in order to minimise these barriers. They 
suggest future studies should not only focus on demographic factors but also 
psychological factors. 
 
Interventions to improve adherence 
Interventions to improve adherence in CVD populations have met with modest 
success (23). Various strategies have been employed, which can be grouped 
into various themes. Of these, best current evidence suggests that prompting 
mechanisms and simplified dosing are likely to be beneficial, patient health 
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education is unlikely to be beneficial, and interventions such as prescriber 
education or reminder packaging are of unknown effectiveness (23). It may be 
surprising that patient education is ineffective; however, as outlined above, 
interventions have typically failed to take into account patients’ own beliefs 
about medicines, illness or their mood states. A reminder is unlikely to prompt 
a patient to take aspirin if for example; they have no intention of taking the 
medication; they don’t believe that they need aspirin; they are concerned that 
they may get addicted to the drug and are more concerned about the side 
effects (22, 82, 83). Although a substantial body of research has addressed 
these issues individually, the quality of the studies in this area have been 
criticised due to their heavy reliance on indirect measures such as pill counts 
and patients’ self- reported compliance which Newell et al. (84) point out, is 
disappointing considering numerous studies and reviews have identified 
problems with their sensitivity and specificity for the last 20 years. 
Interventions employed to improve adherence must be multifaceted, and 
together with practical approaches (reducing unnecessary drugs and 
simplifying dosage regimens), most importantly acceptable to the patient (85). 
Dulmen et al. (86) found in their review that there is evidence to support the 
simplification of dosages and packaging to improve medication adherence 
and the simplification of a regimen appeals to one’s intuition. They also point 
out that initially researchers sought the reason for non-adherence in 
dispositional characteristics such as personality traits however there was lack 
of evidence to support this. They advise medical and social psychology 
scientists should connect with fields such as human engineering, ergonomics 




Over the past few decades it has been recognised that adherence to 
medications is a shared responsibility between the health care professional 
and the patient and, in a review of the literature, the only demographic 
characteristic consistently associated with adherence has been age, but the 
direction is inconsistent depending on the population (81). It appears cognitive 
factors such as beliefs about illness and medications are better predictors of 
adherence than personal characteristics and it has been shown that patients 
who believe the treatment will have benefit and generally have a positive 
attitude regarding the treatment and illness are more likely to adhere to the 
prescribed regimen. Researchers such as Levesque (87) point out that social 
support has been shown to have a consistent influence on medication 
adherence (88). 
 
We can see from the literature that overall adherence is poor (10), even with 
aspirin therapy which is generally only once a day. The measurement of 
adherence is imperfect but thromboxane B2 ELISA has previously shown to 
be the best objective measure available. Hundreds of factors have been 
shown to correlate with adherence but the following chapters will critically 
review what appear to be the most important ones that may have an influence 
on aspirin therapy in cardiovascular disease patients. 
While some consideration of the magnitude of the predictive relationship 
between the factors outlined and the time frame for such prediction is 
required. There is no clear distinction between factors associated with 




CHAPTER 2 - Beliefs about medicine 
Introduction 
This Chapter will outline the theoretical framework for beliefs about medicines 
and outline how the beliefs about medicines questionnaire (BMQ), was 
developed along with its psychometric properties. It will then review studies 
that have used the beliefs about medicines questionnaire, mainly focusing on 
patients with coronary artery disease and look at the different measures of 
adherence used. 
 
Theoretical approaches to non-adherence, and the necessity-concerns 
framework 
Previously, Psychology has used models such as the Theory of Planned 
Behaviour, the Common Sense Self-regulatory Model of Illness and the 
Health Belief Model, to try to explain adherence and non-adherence to 
medicines (52). The theory of planned behaviour can be used to predict 
whether a person intends to do something or not (89). Ajzen (90) suggests 
that this involves three things; firstly whether the person is in favour of doing it 
(attitude) and the beliefs about the consequences of the behaviour, secondly, 
how much the person feels social pressure to do it (subjective norm - how 
other people important to the person would like them to behave). Lastly 
whether the person feels in control of the action in question (how much control 
they have over the behaviour and how confident they feel about situational 
and internal factors), which Ajzen calls perceived behavioural control. We can 
increase the chances that the person will behave in a certain way by changing 
one of these predictors but the authors admit that there isn’t a perfect 
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correlation between intention and actual behaviour and that the theory of 
planned behaviour is a model of human action provided that the action is 
intended or planned, therefore this doesn’t account for non-intentional non-
adherence, e.g. a patient forgetting to take their medications and the various 
reasons why people forget. Sniehotta et al. (91) discussed how a  systematic 
review of 237 independent prospective tests found that the theory of planned 
behaviour (TPB) accounted for 19.3% variability in health behaviour with 
intention being the strongest predictor in longitudinal studies, but there was 
considerably less prediction when the studies were shortitudinal in design, 
participants were not university students, and the outcome measures were 
objective rather than using a self reported measure. 
  
The Common Sense Regulatory Model states that illness beliefs are 
structured and that coping reactions depend on the way the person feels 
about the health threat (92) and unlike other models, considers the influence 
of emotional variables on health and illness behaviours. Horne et al. (16) also 
point out that perceived views of significant others such as family, friends and 
doctors may also influence patient beliefs; this model is considered in more 
detail in chapter 3.  
 
The Health Beliefs Model considers variables such as perceived threat, the 
way the person feels they are susceptible to a condition or how severe it is; 
the perceived benefits of the treatment to reduce the threat of illness, and the 
perceived barriers, which are the negative consequences that may result from 
taking particular health actions. This model also considers cues to action, 
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events that motivate people to take action and other variables like socio-
psychological or demographic that affect a person’s perception and thus their 
behaviour. This health model like the previous two considers self efficacy, the 
person’s belief that they can carry out the behaviour (93). However, Horne et 
al. (94) believed that there was a need for a psychometrically sound method 
for scoring commonly held beliefs about medicines in general and specific 
medications, as patients may have a negative belief about medicines in 
general but a positive belief in a medication that gives them relief from a 
symptom, for example analgesics.   
 
Horne et al. (16) argued that patients’ decisions about taking medications are 
likely to be influenced by beliefs about medicines as well as beliefs about the 
illness. This contention was supported by a report from the Royal 
Pharmaceutical Society of Great Britain (95) and Marinker (96). They pointed 
out that comparisons from findings from qualitative and quantitative studies 
previously, observing beliefs about medicines is difficult due to different 
questionnaires and differences in whether beliefs about medicines in general 
or specific beliefs are being measured. Beliefs about medicines in general are 
for example a belief that medicines are harmful or overprescribed, beliefs 
about medicines specific are patients’ beliefs about a particular medicine for 
example their own specific medication for their own diagnosis or illness. The 
patient tends to then do a necessity concerns assessment of whether the 
benefits outweigh the risks before they decide on taking the medication. They 
found from reviewing the literature that a systematic comparison was difficult 
due to few studies using questionnaires to quantitatively assess beliefs about 
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medicines. A review of the literature on lay beliefs about medicines showed 
that there were three questions that needed to be addressed: could the nature 
of the beliefs ranging from general to specific be summarised into common 
themes which are relevant to different illnesses and different cultural groups; 
who holds them and how strongly are they held; and how they relate to each 
other with regards to specific versus general beliefs about medicines. 
Research has shown that country of birth for example has an important factor 
on beliefs about medicines (97), those from the Nordic countries have been 
shown to have a more positive belief in medicines in general, also people may 
have a negative belief about medicines in general but a positive belief about a 
particular medicine for their particular ailment, as mentioned earlier.  
 
Horne et al. (16) believed there was a need for a specific gauge to measure 
patient’s beliefs about medicines that would inform the development of 
interventions to improve medication adherence. The beliefs about medicines 
questionnaire (BMQ) was developed as an aid to understanding people’s 
perceptions about medicines and their adherence to prescribed regimes (17).. 
As shown from the previously mentioned research and theories (82, 83, 98), 
the cognitive processes are simply more complicated. Decisions are likely to 
be informed not only by beliefs about medicines but also beliefs about illness 
which will be described in the next chapter.  
 
Development of the BMQ (Beliefs about Medicines Questionnaire)  
The BMQ was therefore developed to address this theoretical gap in the 
literature with the aim to assess the broad range of common beliefs about 
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medicines that people hold from a pool of 34 statements (94). This pool of 
statements was generated from the previous literature which appeared to be 
common to patients with a range of chronic illnesses and from interviews that 
they conducted with 35 patients - 20 haemodialysis patients and 15 patients 
post myocardial infarction that were chronic and currently prescribed regular 
medication. The interviews were carried out using open ended questions in 
order to identify beliefs that had not emerged in previous research. 
General and specific - beliefs about medicines   
The “beliefs about medicines questionnaire” contains two sections, the BMQ 
specific and BMQ general. The questions were developed from interviews 
with chronically ill patients. A chronic illness sample of 524 patients of 
asthmatic, diabetic and psychiatric patients from hospital clinics and cardiac, 
general medical and renal in-patients were invited to take part in a study of 
patients’ views about their illness and treatment. The patients were reassured 
that the researcher was independent of the hospital and the responses were 
confidential and would not be seen by any of the staff involved in their care. 
This was with the aim of avoiding response bias, which is known to happen 
when the researcher is associated with the clinical team. 
 
The cardiac sample of 120 in-patients was chosen for the initial analysis of the 
beliefs about medicines specific questionnaire, as it was the largest diagnostic 
group within the main sample. The rationale for choosing a single group was 
that patients with one illness might receive very different medication from 
those with another diagnosis, e.g. psychiatric patients. The primary aim was 
to simplify the fairly broad range of beliefs into core themes, which could then 
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be analysed.  This was done from a 34 statement pool of commonly held 
beliefs about specific and general medication identified in the literature and 
from interviews with 35 chronically ill patients (haemodialysis and post 
myocardial patients), as mentioned earlier. Twelve items were positive and 22 
were negative or neutral statements about medicines. The aim was to explore 
beliefs about medicines as a broad concept rather than beliefs that might be 
unique to a particular illness. The rationale for limiting initial factor analysis in 
the specific beliefs about illness groups did not apply to the general group, as 
the aim was to explore medication beliefs as a broad concept (16). Data were 
combined from asthmatic, diabetic and renal patients to investigate themes 
which would be common across chronic illness populations. Principle 
component analysis showed an 18-item, 4-factor structure which was stable 
across six illness groups – asthmatic, diabetic, renal, psychiatric and general 
medical (17). The BMQ specific subscale consists of two 5 item factors 
assessing beliefs about the need for the prescribed medication and concerns 
that an individual is prescribed for a particular illness (-see Appendix B). The 
BMQ general consists of two 4 item factors assessing beliefs that medicines 
are harmful, addictive, poisons which doctors over-prescribe, and that 
perhaps should not be taken continuously, this is their beliefs in general and 
not necessarily about those that are prescribed (16) (Appendix B). 
 
In summary, the four item factors for general and specific beliefs about 
medicines are concerns, necessity, harm and overuse. It was hypothesised 
that the stronger the beliefs in the necessity of prescribed medications the 
higher the reported adherence. It was also hypothesised that people who 
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believe medicines to be harmful or overused in general by doctors may be 
more inclined to seek alternative treatment. The 8-item BMQ general 
questionnaire was administered to the pharmacy clients and the alternative 
therapy group to see if there were differences between the two groups. The 
BMQ scales were able to distinguish between patients in different disease 
groups as predicted. The diabetic patients had a higher specific necessity 
score while the asthmatic and psychiatric patients had higher specific 
concerns scores. The alternative therapy group had higher concerns about 
medications than the pharmacy group as predicted.  
 
Psychometric properties of the BMQ 
Psychometric evaluation was carried out from the results of the above and the 
BMQ was then administered to participants from a community pharmacy and 
participants who were attending complimentary care.  
A matched group of 72 patients attending a community pharmacy and a 
complementary therapist (homeopathic/herbal clinic) were recruited to 
compare medication beliefs between the two groups. There were no 
significant differences between the two groups in terms of age and gender. 
There was a significant difference in educational experience with the group 
attending the alternative therapists in that it was higher than the group 
attending the pharmacy for conventional medication; this has been shown in 
similar studies (98) where people attending alternative therapists had on 
average more years of formal education than the typical person. This group 
also made more visits to their homeopath in the previous 6 months before the 
study although there were no differences in attendance to the general 
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practitioner or hospital admissions. Thus both samples were considered 
comparable in terms of illness severity. The hypothesis here was that the 
homeopathic group would have higher scores than the pharmacy group, when 
asked questions regarding general harm of medicines and overuse and over 
prescription (16). Results showed patients attending complementary therapy 
had significantly higher scores on the general harm (P<0.05) and overuse  
(P<0.001) scores than those presenting to the community pharmacy.  
 
The authors report that the internal consistency of the general harm sub-scale 
was disappointing in the asthmatic, cardiac and general medical groups but a 
greater degree of consistency was found with the other data sets. (16). 
Examination of the data showed that this was not due to a single outlier item 
but a true reflection of low internal consistency, and they suggest that this 
may be due to certain illnesses producing different beliefs about medicines 
depending on past experiences with prescribed medications. Despite this, 
they state that the discriminant reliability and validity of the BMQ support its 
use in research. 
 
Furthermore, beliefs about medicine appear to be stable over time. The 
findings from the study by Porteous et al. (52) to compare beliefs about 
medicines over time where they looked at the BMQ general given to the same 
people between 2002 and 2005. They found that general beliefs about 
medicines appear to remain stable over time, irrespective of changes in health 
status. The authors suggest that the observed stability in general beliefs about 
medicines is consistent with previous research that showed that health beliefs 
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are stable from a young age, therefore, further supporting the theoretical 
construct as it is stable over time (99). 
Intentional and non-intentional adherers 
Clifford et al. (100) found in their study of patients that were newly started on 
medication for a chronic disease, that patients who did not adhere to their 
medication intentionally had lower perceptions of the need for the medication 
compared to adherers and more concerns , unintentional non-adherers were 
not significantly different from adherers. This may be due to the reasons 
outlined above, that socio-psychological, perceived behavioural control and 
emotional factors such as stress may have an effect on non-intentional 
adherence. Intentional non-adherers were more likely to rate their concerns 
as high relative to their need for treatment compared to both adherers and 
unintentional non-adherers (101). In this study they found that patients with 
strong concern beliefs in medicines were more likely to report an adverse 
drug event while controlling for confounding variables such as socio-
demographic, clinical and behavioural factors. The authors suggest that these 
patients may be more sensitive and pay particular attention to unwanted 
reactions possibly making them more likely to report an adverse effect. Socio-
psychological variables such as concerns in beliefs about medicines may be 
more important than the number of medications, (which the researchers state 
was not significant in any of the studies) in the self reporting of adverse drug 
events, because symptom cause and relatedness to medicines may be based 
on the patients motivation to tolerate the adverse effects or the patient’s past 
experience with using the medicine.  
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Overall, this research shows the patient’s belief about medicines appears to 
be an important variable associated with adherence, symptom reporting and 
adverse drug events (102) . 
 
 
Beliefs about medicines in patients with Coronary Heart Disease (CHD) 
The following section reviews literature published from 2000 onwards that has 
assessed the Beliefs about Medicines Questionnaire (BMQ) and adherence in 




TABLE 1- Beliefs about medicines a review of the literature 





Allen LaPointe 2011 
USA  




follow up 3mths 
post ACS 
973 pts BMQ-specific Non-adherence 23-26% In adjusted 
analysis greater perceived necessity 
for heart medications was significantly 




adherence. LL-OR1.09,95%CI 1.05-1.14 
non-adherence23%. 
Self report measure of 
adherence-known to 
overestimate adherence 
but higher adherence 
was found in cardiac 
rehabilitation patients 
and younger age was 
significant with non-
adherence. 





Cohort of pts from 




groups of achievers 



















48% reported not fully adherent, 25% 
non-adherent intentionally. 
BMQ significant predictor P- .036 
adjusted of self report adherence but 
not LDL-C goal achievement. 
 
Only 17.5% had CAD, 
only 45% male (not 
representative of other 
CAD samples). Only 65% 
answered the call and 
completed 
questionnaire. Only 34% 
goal achievers. 
MMAS not BMQ-G was 
predictive of LDL-C goal  
Self report-not objective 
 
Byrne et al.,, 2005 
Ireland 
Established CHD 
from 35 GP 













Medication beliefs only moderately 
related 
to self reported non-adherence, 
explaining 7% of the variance,  
Good response rate from 
questionnaires no 
significant correlation. 
Pts >80yrs were 
excluded.  illness 
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returned perception only weak 
predictor perhaps due to 
low symptoms and 
threat 
Calvert 2012 USA 
 
Documented CAD 

















No sig. difference between Control 
and intervention groups. 
BMQ did not predict adherence.  
 
 
24% didn’t complete 
follow up. 
Self report – accuracy 
although 71% of pts 
reported long term 
adherence to aspirin . 
Level of agreement 
between both measures 
(MAS and refill) was poor 
for adherence but shows 
the need for more robust 
measures in practice. 




collecting a new 
medication for a 
chronic condition 
with an inclusion 
criteria of one of 
the following- 

















BMQ-specific 70% adherence 30% non-adherence (if 
they missed a dose in the last week). 
There were sig. differences in beliefs 
between adherent and intentionally 
non-adherent pts having more 




adherence as its self 
report over the 
telephone(no. of non-
adherence was too small 
for subgroup analysis at 
4mths) 
Horne et al. 2010 UK 
and Scandanavia 
A subset from the 
ASCOT study that 
RCT comparing 2 
pharmaceutical 




40% were adherent 
45%complete adherence. 




 weren’t recruited 



































4 item MAS 
55% were adherent by self report, 
non-adherent pts were in stronger 
agreement in general overuse-P=0.01 
and general harm-P=0.04 
Only 34% completed 
questionnaire and an 
objective measure was 
not used. 
Mardby et al.((2007) 
Swedish 
Pharmacy clients, 








54% were non-adherent 
An association was found between 
general harm and adherence (Odds 
ratio) OR=0.46,CI=0.30-0.70 
Country of birth was 
found to be an important 
factor for beliefs about 
medicines, those from 
the Nordic countries 
believed medicines to be 
more beneficial 
Muntner et al. 2011 
USA 
 
Post  PCI pts before 
discharge from 
hospital 




11% low adherence to clopidogrel OR 
6.13 CI(1.34-28.2) 
Similar results to our 
study with regards  to 
















12% non-adherent-scored lower on 
positive beliefs about medicines 
OR=0.90,95%CI 0.83-0.98 




different type of pts 
 
Sud et al. 2005 
USA 




208 BMQ –specific 
and general 
4 item MAS 
87.4% adherence to Aspirin-final 
regression model showed R(2)=0.132 
and included health related status and 
specific necessity P=0.02 as predictive 
Self report of 87.4 % 
adherence to Aspirin is 
probably an over 
estimate-   not objective. 
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variables that were significant. 
Van der Wal(2006) 
Netherlands 
 
Heart failure pts Descriptive cross 
sectional 
501 HF 
  pts 
BMQ- appears 
to be general 
















72% compliant 98% compliant with 
medication 
Beliefs about medicines in general 
OR=1.78;C.I 1.18-2.69-asscociated with 
better adherence.  Compliant patients 
had less depressive 
symptoms OR=0.53 C.I 0.35-0.78 
 
The self report of 1.4 % 
non-compliance is 
unusually low 
ACS=Acute Coronary Syndrome, BMQ=Beliefs about Medicines questionnaire, B-blocker=Beta blocker, ACE=Angiotensin Converting Enzyme, 
ARB=Angiotensin receptor blocker, LL=Lipid Lowering medications, LDL=Low-Density Lipoprotein, CHD=Coronary Heart Disease, CAD=Coronary Artery 
Disease, RCT=Randomised Controlled Trial, MAS=Medication Adherence Scale, MMAS=Morisky Medication Adherence Scale, ASCOT=Anglo-Scandinavian 




Overall, the studies in Table 1 show the following important finding. Firstly, 
medicine beliefs appear predictive of adherence, with 9/12 studies 
demonstrating this (97, 100, 103-109). However, the studies also show a 
number of limitations: only two studies used objective measures of cholesterol 
level (104) and blood pressure reduction (103) which may also be affected by 
diet and exercise. Therefore, a study which assesses aspirin adherence using 
the best objective measure could be a real addition to the literature, as the 
effect of diet and exercise do not affect the inhibition of thromboxane B2 by 
aspirin (12). The fact that there are few studies that have used an objective 
measure is a major limitation. As Allen Lepoints state (103) in 2011, that the 
application of the beliefs about medicines questionnaire within clinical practice 
is untested and additional research is needed in translating this or similar 
instruments into clinical practice to assess their feasibility and outcomes. The 
authors at this time suggested that this was the first evaluation of the BMQ 
specific in patients with ischaemic heart disease.  
 
Horne et al. (2) have demonstrated that beliefs about medicine were more 
powerful predictors of self-reported adherence than the clinical and socio-
demographic factors in patients with heart disease. Gender, education, or the 
number of prescribed medicines, did not predict reported adherence (2). A 
recent study in a similar cohort of patients with Cardiovascular Disease (CVD) 
looking at adherence to cholesterol control medication found that 25% of 
patients who reported non-adherence were intentionally doing so. Patients’ 
beliefs about medicines were a significant predictor of self-reported 
adherence but not of the cholesterol goal achievement (104). This may be 
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due to the measure of adherence which was self-reported and previously 
shown to consistently under estimate non-adherence. This may also be due to 
other confounding variables such as exercise and diet changes in behaviour, 
which are known to have an effect on cholesterol levels. This was shown in a 
recent study by Ho et al. (110) where in a randomised controlled trial using a 
multifaceted approach intervention to increase adherence of cardiac 
medications  found an increase in medication adherence in the intervention 
group, but not in the outcomes of blood pressure reduction or cholesterol level 
or major adverse cardiac events (MACE). The authors admit the limitations of 
this study were the measure of adherence, which was pharmacy refill data 
which doesn’t prove ingestion and the study should have continued past 
twelve months when adherence was likely to reduce significantly.   
 
The recent similar study(to the proposed study) carried out by O’Carroll et al. 
(13) found a relationship between beliefs about medicines and adherence to 
aspirin therapy but were not able to use their objective measure as it was 
deemed an unreliable measure, as mentioned above. This was due to 
measuring thromboxane level in the urine as an indicator of adherence but 
during the study the investigators found that the measure was unreliable as it 
was unable to differentiate between those that were on aspirin therapy and 
those that were not. 
Horne et al. (111) have recently completed a meta-analysis of studies that 
have used the BMQ to assess patients beliefs about medicines in long term 
conditions including some with Acute Coronary Syndrome (ACS) but most use 
a self-assessment method of measuring adherence. They also fail to point out 
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the major limitation of the O’Carroll (13) study which used an objective 
measure of aspirin in the urine but the measure was found to be inaccurate 
therefore not a valid measure of adherence. 
 
BMQ used in Coronary Heart Disease - specifically 
Byrne et al. (112) study looked at the charts of 1611 established coronary 
heart disease patients and was designed to evaluate the use of illness 
perception and medication beliefs in predicting secondary preventative 
behaviour among patients with coronary heart disease. They found that an 
illness perception approach did not predict secondary preventative behaviour 
among this group of patients, while beliefs about medicines appeared to be a 
reasonable predictor of medication adherence, although the measurement 
used was a self reported measure. The authors also suggest that their study 
reinforces the need for a holistic approach in designing interventions to 
increase secondary prevention of heart disease, agreeing with previous 
research that attendance at cardiac rehabilitation clinics is more likely in 
patients who perceive their illness as controllable, serious and caused by 
lifestyle factors (113, 114). Byrne et al. (70) suggest that findings from their 
study again emphasize that lifestyles are complex and influenced by many 
factors.  
Birmingham et al.’s (104) prospective study of LDL-C goal achievement and 
self reported medication adherence among statin users in primary care, used 
the beliefs about medicines questionnaire and the Morisky Medication 
Adherence Scale to observe for relationships. They found that 25% of patients 
who were non-adherent were non-adherent intentionally and beliefs about 
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medicines were a significant predictor of self-reported adherence but not of 
LDL achievement. 
Bane et al. (115) also used the beliefs about medicines questionnaire in their 
study looking at the impact of depressive symptoms and psychosocial factors 
on medication adherence in cardiovascular disease in 122 patients attending 
a cardiac clinic. They found 14.8 % of patients were non-adherent using a self 
report and 41.7% had scores of depressive symptoms measured by the 
centre for Epidemiological studies Depression Scale. They found that high 
scores on the depression scale and high scores on the concern scale of the 
BMQ were found to be associated with self- reported non-adherence. Again 
one of the limitations of this study is that non-adherence is self-reported which 
may underestimate non-adherence.  
 
Self Report Adherence in Cardiovascular studies 
A recent example of self reported adherence used in cardiovascular disease 
(CVD) patients is the UMPIRE study (116), where the effects of the “polypill” 
with a fixed dose combination of drugs for blood pressure, cholesterol, and 
platelet control were compared to usual care resulted in significantly improved 
medication adherence at 15 months and statistically significant but small 
improvements in systolic blood pressure and cholesterol LDL- C. 
The fact that this study used self report for medication adherence could be the 
reason for only a small improvement in blood pressure and cholesterol level. 
Rinfret et al.’s study (117) looking at the effects of telephone contact to 
improve adherence to dual anti-platelet therapy after drug-eluting stent 




They found that in 300 patients randomised to two groups with the 
intervention group receiving four phone calls in 1 year, adherence was 99 % 
in the intervention group and 90 % in the control group. The obvious limitation 
with this study is the non-objective direct measures used to measure 
adherence and the fact that adherence was so high in both groups compared 
to adherence in other studies, including clinical trials where the patients are 
monitored and reminded on a more regular basis and adherence of 90% 
would be considered high and unlikely.  
 
Kripilani et al.’s (118) study of age, health literacy and medication 
management strategies with cardiovascular medication adherence found that 
age less that 65 years and marginal or inadequate health literacy, were 
independently associated with medication non-adherence using refill and self 
reported adherence but they also found that medication strategies did not 
explain these relationships. 
 
A meta-analysis by Demonceau et al. (119) with the aim of identifying and 
assessing adherence enhancing interventions through electronically compiled 
dosing histories, found that their analysis was limited due to the heterogeneity 
and disparities in the data and the different measures of adherence. The 
authors suggest the limitations of their analysis highlight the urgent need for 
defined guidelines for research protocols that will guide researchers in 






Overall from this Chapter, we can see that there has been a large amount of 
research on the beliefs about medicines and the theoretical approaches that 
support it make good “common sense” but self-regularity behaviour is very 
individual with many influences. What makes good common sense to one 
person may not seem like good common sense to another person i.e., not 
taking one’s prescribed aspirin when you have a history of coronary artery 
disease .If a patient looks up contra-indications to aspirin they will be advised 
not to take it with alcohol, therefore it may make sense to an individual not to 
take aspirin when they are on holidays and taking alcohol. There are many 
studies that have used the beliefs about medicines questionnaire but none 
that have used it with a reliable objective measure of adherence in Coronary 
Artery Disease patients. The next chapter discusses how illness perceptions 
also has an influence on adherence and how the beliefs about illness and 











CHAPTER 3 - Illness Perceptions 
 
Introduction 
As described in the previous chapter, the social cognitive models, the health 
belief model (HBM), the theory of planned behaviour (TPB) and the necessity-
concerns framework have been used to describe adherence and non-
adherence in patients. This chapter concentrates on the self -regulation model 
by Leventhal, where the decision to take the prescribed medication makes 
“common sense” to the patient, in light of their experience and how this may 
be influenced by past or current symptoms, or the views of significant others 
(120). The chapter will also describe the development and psychometric 
properties of the illness perception questionnaire and show the studies that 
have used illness perceptions in relation to adherence, mainly concentrating 
on studies with patients with coronary heart disease.  
 
Self-regulatory model 
Leventhal’s self-regulatory model of illness (SRM) has been used in the study 
of medication adherence whereby the decision to take prescribed medication 
or not, is conceptualised as a coping response to a perceived health threat 
(120). Leventhal’s theory is a system of conscious personal health 
management where self-regulation includes impulse control and the control of 
short term desires; the theory implies that people with low impulse control are 
prone to acting on immediate desires. When this is related to health 
behaviours, a patient will only take a doctor’s advice with a certain amount of 
self-regulation, and for medical treatment to be effective, the patient needs to 
be interested in improving their own health. The patient will then evaluate their 
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own behaviour and the effect this is having on their health, altering their 
behaviour to achieve the desired effect (121). Self-regulation has been 
described by authors (122) in relation to humans controlling their thoughts 
feelings and desires in anticipation of higher goals. The authors point out that 
most studies have concentrated on self-control failure which may be due to 
the large amount of people that fail to act out their intentions or stick to their 
goals after their initial attempts to change their behaviour. Some theories 
suggest that people try harder to attain their goals when they are confronted 
with difficulties but these authors have questioned this theory with the 
argument of how people with a particular health goal i.e. giving up smoking, 
will give up easily if they don’t see an immediate positive result or perceive 
obstacles (101). 
 
Leventhal’s theory of self-regulation model is one of the few models that looks 
at coping (123). The model suggests that mental representations of actual or 
future health threats are ways that patients deal with the health threat. 
Research suggests that patients develop their ideas about illness around 
different components which consists mainly of; identity – which labels the 
illness and which the patient relates to symptoms, cause – what the patient 
thinks may have precipitated the disease, and timeline – how long the illness 
will last. Adherence is more likely if the patient perceives the advice to take 
the medication prescribed makes common sense to them in light of their past 
experiences and may be related to symptoms and their beliefs about their 
illness. This theory proposes that the patient is guided by beliefs about the 
nature, duration, causes, consequences and potential for cure or control of 
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the illness (70). Regarding causal attributions, higher use of primary 
healthcare facilities has been associated with psychological stress and 
lifestyle attributions for all patients, whereas accident or chance attributions 
were associated with higher use for patients with a chronic disorder but lower 
use for patients without a chronic disorder. In general causal attributions have 
been less successful in predicting health outcomes than the other illness 
perceptions (124). Psychological and lifestyle attributions have been shown to 
be significantly associated with previous and succeeding healthcare use. The 
literature suggests that attributing symptoms to stress may be an expression 
of transient strain, whereas psychological and lifestyle attributions may reflect 
dispositional patterns of reacting i.e. smoking, alcohol and bad diet. The 
decision to take medication or not is likely to be informed by beliefs about 
illness as well as beliefs about medicines, and this has been recognised by 
the Royal Pharmaceutical Society of Great Britain 1997 with other 
researchers (82, 96). Horne et al. (82) believed there was a need for a 
psychologically sound method for measuring these beliefs in order to 
understand common themes with illness groups and cultures while 
understanding how they relate to other beliefs such as beliefs about 
medicines as well as adherence behaviour. 
 
Development and Psychometric properties of the illness perception 
questionnaire 
Researchers since the 1960’s have studied illness representations mainly 
using open ended interviews, but as knowledge has developed and 
Leventhal’s self-regulatory model has been more widely used, more objective 




The illness perception questionnaire (IPQ) was administered at the same time 
as the Beliefs about Medicines questionnaire in order to measure its 
constructs by Horne, Weinman and Hankins as described above (17). The 
psychometric properties were previously evaluated by Weinman et al. (94) in 
seven different disease groups of patients including patients with diabetes, 
rheumatoid arthritis, asthma, chronic fatigue syndrome, chronic pain, recent 
myocardial infarction,  and renal patients, thus the patients were a 
combination of chronic and acute conditions. Data from myocardial and renal 
patients showed good levels of both internal consistency and test-retest 
reliability. The authors expected this as control cure and consequences have 
higher levels of test-retest reliability than identity and timeline as patients’ 
perceptions of the cure and consequences of their illness are less likely to 
change over time. Patients with a stronger illness identity are more likely to 
perceive more serious consequences from their illness with less likelihood of 
a cure or control over it (65).  
 
A revised version of the illness perception questionnaire (IPQ) scale, the IPQ-
R added more items to the questionnaire looking at control dimensions of 
personal control and treatment control while exploring emotional aspects 
more. The IPQ-R has over eighty items and therefore has been recognised as 
not a practical tool in the clinical setting, in particular for elderly or acutely ill 
patients or when the researcher is measuring several constructs, as this can 
be a large burden not only on the researcher but more importantly the patient 
(100). The IPQ-R has been found to be beneficial to researchers who are 
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mainly looking at specific symptoms and associated illness perceptions and in 
particular provides more information on cyclical timelines (100).  
 
Broadbent et al. (100) saw the need for a shorter questionnaire- the BIPQ 
(Brief Illness Perception Questionnaire) that would be more practical in the 
clinical setting using a 9 item questionnaire that summarised the content in 
each subscale of the IPQ-R, with a scale of one to ten rather than the Likert 
scale. The first five items on the BIPQ questionnaire assesses illness 
representations, while question six and eight assess emotions (see Appendix 
B). Question seven assesses illness understanding. The last item, number 
nine assesses the three most important factors that the patient perceives as 
the cause of their illness, which can be grouped into categories for analysis. 
The psychometric properties were then assessed in different disease groups 
of patients with a diagnosis of Myocardial Infarction, renal disease, type 2 
diabetes, asthma, and a group with minor illnesses such as an allergy or a 
cold. There was also a group of patients undergoing stress tests that were 
having angina symptoms. 
 
The test re-test reliability of the BIPQ was assessed in renal patients 
attending out-patient clinics at baseline, three weeks, and six weeks, this 
showed good reliability over the different time periods. The construct validity 
of the questionnaire was assessed in the renal, diabetic and asthma sample 
that completed the IPQ-R and the BIPQ, this showed the equivalent scales to 
correlate appropriately although correlations between personal control and 
treatment control were low. Broadbent et al. (100) point out that previous 
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research has found higher perceived control and self-efficacy to be related to 
better self reported adherence to diet, medication and exercise, although the 
research appears to be conflicting when looking at glucose monitoring levels 
in the diabetic patients, possibly due to the disparities between self reported 
adherence and actual behaviour as described by Sniehotta (91). 
The predictive validity of the BIPQ has been shown in patients following 
myocardial infarction, where a multivariate analysis of variance found that 
patients who attended rehabilitation classes had a higher identity score 
measured at hospital discharge than those patients that did not attend cardiac 
rehabilitation. They also found that patients with higher scores on the concern 
scale and treatment control beliefs were significantly slower to return to work 
(126).  The BIPQ at discharge also predicted anxiety and quality of life.  
Discriminant Validity 
To assess the discriminant validity and the extent the BIPQ questionnaire 
could distinguish between different illnesses, the mean scores were compared 
between the illness groups, which the authors point out differ in clinical 
presentation and symptoms. As hypothesised, the personal and treatment 
control beliefs were highest in the post myocardial infarction patients who 
would have been the most acute of the groups and therefore receiving new 
treatments and lifestyle advice at a time when they are likely to feel 
medication has saved their life and relieved acute symptoms. Patients with 
the lowest personal and treatment control scores were as expected, the 
patients with the minor illnesses such as colds and allergies who may feel that 
they have a virus and that medication may not relieve symptoms for, for 
example antibiotics. This group of patients tended to report the highest 
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identity, lowest understanding, shortest timeline and highest emotional 
response, which the authors suggest is a fear response to an unknown 
diagnosis and effective treatment. The authors point out that while there were 
differences in sampling methods between patient populations, some were 
sent the questionnaire by post and some were recruited in the clinical area, 
this is unlikely to have caused a major effect on patient’s perceptions (106). 
 
Illness perceptions and adherence  
Petrie et al. (126) suggest from their study of an early intervention in changing 
perceptions after a myocardial infarction that if negative thinking about a 
myocardial infarction can be identified early while the patient is in hospital, this 
may improve illness perceptions and levels of functioning and therefore 
promote an earlier return to work. Patients are often reluctant to discuss their 
beliefs about their illness in medical consultation because they fear being 
seen as stupid or misinformed (125). Fischer et al. (127) concluded in their 
studies that coping with an illness is a continuous process and the 
achievement of desired outcomes during treatment is likely to enable patients 
to adopt a more positive representation of their illness. 
 
Illness perceptions have not only been linked to self-reported adherence (22, 
82), but also to more objective measures of adherence (79). In the study by 
Molloy et al. (61), beliefs about heart failure appeared to be associated with 
objectively measured adherence to ace inhibitors by measuring serum levels 
of angiotensin-converting enzymes. They found that 72% were non adherent 
using this as an objective measure, and 19% of this variance was associated 
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with beliefs about illness. In this study of patients with heart failure, patients 
who believed that their illness had a longer-term duration, and had beliefs 
about greater consequences of heart failure on their lives, were less likely to 
adhere to medication. These patients had a diagnosis of heart failure, which is 
a condition that is typically chronic in nature, with a high percentage of 
patients with psychological contributing factors such as depression (128), 
therefore it is unclear whether these beliefs would survive adjustment for 
depression. 
 
Brandes and Mullen (129) recently completed a meta-analysis to explore 
whether mental representations derived from the common sense model were 
able to predict adherence in chronically ill patients. Twenty eight out of thirty 
studies used a cross sectional design and adherence to medication was 
assessed in twenty six studies with none using an objective measure of 
adherence, making it difficult to make causal relationships. 
Aalto et al. (130) point out that very little work has systematically explored 
illness perceptions in homogenous or specific illness groups and the self-
regulatory theory has found many factors that influence illness perceptions but 
has not defined ways in which these influences occur. They explain the 
importance of understanding how illness perceptions are developed and how 
they may be modified and to which type of patients interventions should be 
tailored towards. Interestingly they found that older patients perceived fewer 
symptoms of Coronary Heart Disease and shorter expected timeline. It could 
be argued that the older patients may have developed effective coping skills 
and self-efficacy than the younger patients. They also found that illness 
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perceptions were related to both personal and social resources, in particular 
patients with strong perceived self-competence or self-efficacy, perceived less 
CHD-related symptoms, felt more control and perceived less consequences of 
their Coronary Heart Disease. They explain that those who feel more control 
and competence over their life may use more effective coping strategies to 
deal with the challenges of a chronic disease. Although the authors did not 
measure adherence in this study, their theories do have implications on 
medication adherence suggesting that if we modify patients’ perceptions on 
self efficacy and resource support this may have a positive effect on 
medication and behavioural adherence.   
 
Illness Perceptions and Coronary Heart Disease.  
The literature on patient education appears conflicting and has not always 
shown to be effective, although education specifically targeting patients’ 
beliefs about illness have shown some promise in improving outcomes. These 
studies have consisted of exploration and clarification of illness beliefs. A 
previous randomised trial showed that such a brief psycho-educational 
hospital intervention designed to alter cardiac patients’ illness perceptions 
succeeded in improving functional outcomes post-MI (131). Those who 
received tailored education/clarification depending on their illness perceptions 
reported they were better prepared for leaving hospital, returned to work at a 
significantly faster rate, and reported significantly lower rates of angina 
symptoms and control. Such an intervention could theoretically be augmented 
by also including clarification about medicines (132), which is hypothesised to 
extend and improve the predictive ability of the illness perceptions models 
(22, 82, 83). As little research has to date assessed such beliefs alongside 
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objective measures of aspirin adherence, it is difficult to calculate the numbers 
of participants who could be targeted in subsequent intervention. 
 
Studies that assess illness perceptions and adherence in patients with CHD 
















Byrne et al., 2005 
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IPQ-R,MARS-5 
BMQ Specific and 
General. 
 Extended version of 
illness perception 
questionnaire. 
Medication beliefs only 
moderately related 
to self reported non-
adherence, explaining 7% 
of the variance,  
illness perception only 
weak predictor perhaps 
due to low symptoms and 
threat 
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Patients with Familial 
Hypercholesterolemia 
Descriptive study using 
questionnaire 
336 patients MARS 5, Anxiety, 
Depression, IPQ 
Overall pts reported high 
levels of adherence 
although 63% reported 
some level of non-
adherence. History of 
CHD, no formal 
qualification and 
perceiving genes to be 
important determinants 
of heart attack were 
significant from the IPQ-
causal effect. 
Self report measure- 
no participant 
reported poor 
adherence. The 63% 
reporting some level 
of non-adherence are 






CVD patients Cross sectional 
questionnaire at 1 week 
and 6 months 
317 patients IPQ-R, MARS, 
behaviour. 
Perceiving medication as 
an effective strategy for 
risk reduction was 
associated with being 
totally adherent OR=1.94 
but didn’t predict 
Only 50% of this 





Effects of illness 
perception very small  
CHD=Coronary heart Disease, IPQ-R=Illness Perception Questionnaire Revised, IPQ=Illness Perception Questionnaire, MARS=Medication Adherence 




There are few studies that have looked at illness perceptions in Coronary 
Heart Disease (CHD) and even fewer that have measured adherence with 
objective measures. Only two studies are shown in Brandes and Mullen’s 
(111) meta-analysis from patients with Coronary Artery Disease looking at the 
correlation with medication adherence and neither of these studies used an 
objective measure of adherence. The study by Senior and Marteau (133) is 
included in the table above as some of these patients would have coronary 
artery disease also. Brandes and Mullen (129) advise that future studies need 
to consider the use of other theories and must pay particular attention to the 
measure of adherence behaviour as their literature shows only one objective 
measure out of the thirty studies that they reviewed. 
 
Byrne et al. (112) designed their study to evaluate the degree to which 
variations in secondary preventative behaviour, including medication 
adherence, could be explained by illness perceptions and beliefs about 
medicines in patients with established Coronary Heart Disease. Previous 
research in patients with asthma had shown these two measures to be 
predictive of non-adherence to preventative medication. They found that older 
patients and medical card holder patients (for whom medications cost less) 
reported higher medication adherence and only a longer expected timeline 
was a significant illness predictor of medication adherence. They found that 
the stronger the perception that the illness was chronic, the higher the 
medication adherence. This appears conflicting to the literature, as most 
studies have shown the more chronic the disease the more non-adherence, 
although this may be due to differences in perceptions of different disease 
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groups. Patients with heart failure for example would be more chronic in 
nature than patients with chronic coronary artery disease. The authors 
concluded from their study that an illness perception approach did not prove 
helpful in predicting secondary preventive behaviour, including medication 
adherence. The only illness perception dimensions that proved independently 
predictive of behaviours were found to be emotional representations which 
possibly links to the correlations found with depression (see next chapter); a 
stronger belief that one’s own behaviour was a cause of the illness was 
related to higher consumption of alcohol. Their findings were conflicting 
regarding the findings between emotional representations and health related 
behaviours, lower levels of emotional representations were related to more 
exercise activity. Finally, the medication adherence in this study again was 
self reported and particularly high which the authors acknowledge is a 
limitation due to conducting such a large scale study with a postal survey. 
       
  
Conclusion 
The literature on the theories that underpin social cognition models (SCM), 
such as the health belief model (HBM) and the theory of planned behaviour 
(TPB) have recently come under scrutiny and criticism (91, 134) suggesting 
that they are only predictive of affluent young people when they are self 
reporting in the short term i.e. university students. They propose that 
psychological theories should define their range of applications rather than 
claiming that they can explain all human behaviour. Despite these criticisms 
researchers such as Broadbent, Weinman and Horne (22, 94, 135) believe 
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that Leventhal’s self-regulation model (136) can be used as a good indicator 
of  whether a patient will decide to take their medication or not if it makes 
common sense to take the prescribed medication based on their beliefs. 
Broadbent has shown good reliability and validity of the brief illness 
perception questionnaire (BIPQ) and it has been used in several studies 
across a wide range of illnesses as shown by Brandes and Mullen’s meta-
analysis (129). Unfortunately there are only two examples of illness 
perceptions used in coronary artery disease in their meta-analysis, with 
neither of them using the BIPQ and both using a self report measure. 
Therefore the use of an objective measure of aspirin adherence would fill a 





This chapter will describe depression and its outcomes and its relationship 
with adherence. It will then explain the patient health questionnaire, its 
psychometric properties and its development into the brief patient health 
questionnaire. Finally, it will show the research that explores the relationship 
between depression and adherence to medications in patients with 
cardiovascular disease.  
 
As mentioned in the previous chapter, emotional factors may also be 
important for adherence. Depression is one such factor. Depression is a 
common mental disorder characterized by sadness, loss of interest or 
pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, 
feelings of tiredness and poor concentration (43). It can be long lasting or 
recurrent, impairing a person’s ability to function at work or school, or cope 
with daily life. At its most severe, depression can lead to suicide. When the 
depression is mild, depression can be treated without medicines but, when 
moderate or severe, people may need medication and professional talking 
treatments. Non-specialists can reliably diagnose and treat depression as part 
of primary health care. Specialist care is needed for a small proportion of 
people with complicated depression or those who do not respond to first-line 
treatments (137). 
 
Depression is associated with several unhealthy behaviours including 
smoking, physical inactivity and medication non-adherence (138, 139). 
Patients with depression have many risk factors that can contribute to non-
adherence to their medications including changes in cognition and 
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expectations about the benefits or harms of their treatments, lack of energy 
and motivation, withdrawal and social isolation with feelings of hopelessness 
(140). DiMatteo et al. (7) explain that affective disorders, in particular 
depression, are among the most common disorders seen in medical practice, 
with depression occurring in at least 25% of patients and more likely in 
patients with significant health problems. The authors found in their meta-
analysis of the effects of anxiety and depression on patient adherence, that 
anxiety had an unclear relationship with medication adherence. They suggest 
that anxiety can be heterogeneous and range from panic, which may have no 
direct effect on compliance, to obsessive compulsive disorder with 
generalised anxiety about health, which may promote compliance. Depression 
may be associated with higher rates of healthcare utilization and severe 
limitations in daily functioning (7) . For example, a meta-analysis by Meijer et 
al. (141) showed an independent relationship between depression and 
mortality and cardiovascular events in post-MI patients after adjusting for 
disease severity. Previous reviews were only able to provide unadjusted 
associations or limited estimates of adjusted associations.  
 
DiMatteo (7) advises that once clear non-adherence is established, this 
should raise suspicion to clinicians of possible coexisting depression and 
steps should be taken to enhance medication adherence. There is a need for 
further research to determine whether treating depression will result in 
improved patient adherence (142, 143) but as the authors point out, this gives 
us the potential to improve medical practice, enhance patient functioning and 
improve health care outcomes. Ye et al. (144) have found that a conceptual 
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framework for medication non-adherence can guide assessment and 
treatment. 
 
There is likely to be a vicious circle type link between depression and non- 
adherence whereby depression causes non-adherence and non-adherence 
further exacerbates depression. Therefore a clinical focus (7) concentrating 
research on testing the theoretical and clinical models to examine the direct 
effects of depression on patient adherence and patient outcomes is advised 
(7, 145). There is currently insufficient evidence from randomised clinical trials 
to demonstrate improved cardiovascular outcomes from psychological and 
pharmacological interventions in cardiac patients, but such interventions have 
been shown to reduce depression and improve quality of life (146). 
 
The Patient Health Questionnaire-2 
Summers et al. (147) advises that only psychometric instruments validated in 
the cardiac population should be used for depression screening and 
diagnosis, and any instrument that has been validated in this population can 
be justifiably used, as recent literature reviews have concluded that no 
particular instrument is superior to another in identifying depression. However, 
the PHQ-2 (patient health questionnaire) and PHQ-9 have proven to be the 
most specific among other instruments, and is recommended as a first step 
tool in identifying patients with depression, with a diagnostic interview 
afterwards(148),149). Barth et al. (149) state that there is insufficient evidence 




The PHQ-2 which is a brief version of the PHQ-9 item questionnaire is 
recommended by the American Heart Association (AHA) prevention 
Committee of the Council on Cardiovascular Nursing (CCCN) as a first step 
approach for identifying currently depressed patients (150). The PHQ-9 is a 
self-administered version of the PRIME-MD diagnostic instrument for common 
mental disorders where the PHQ-9 is the depression module (151); major 
depression is diagnosed if five or more of the nine depression symptoms have 
been experienced for more than half the days in the past two weeks, and if 
one of the symptoms of depressed mood or anhedonia have been present. 
Other depression is diagnosed if two to four depressive symptoms have been 
present with one of the symptoms of depressed mood or anhedonia being 
present. If item nine “ thoughts that you would be better off dead or of hurting 
yourself in some way” is found to be present at all, regardless of duration, this 
counts as a diagnosis for depression (151). However, a recent study by 
Razykov (152) of one thousand and twenty two coronary artery disease 
outpatients concluded that item nine on the PHQ9 does not appear to be an 
accurate suicide screen, and the PHQ-8 might be more suitable for this group 
of patients. Kroenke (153) is wise to recommend that before making a final 
diagnosis, clinicians are expected to rule out physical causes of depression, 
normal bereavement, and a history of manic episode (the PHQ-9 is included 





Development and psychometric properties of the Patient Health 
Questionnaire. 
Previous researchers have shown that a single question about depressed 
mood has a sensitivity of eighty five to ninety percent for major depression 
and the sensitivity increases to ninety five percent by adding the question 
about  anhedonia (154). The PHQ-9 was developed from the full PHQ (patient 
health questionnaire-which assess depression)  which looked at six thousand 
patients from primary care clinics and seven obstetrics/gynaecology clinics in 
the United States. All patients completed the full Patient Health Questionnaire 
and the medical outcomes short form general health survey (155) while 
estimating the number of physician visits and sick days in the last three 
months. The construct validity was assessed using the twenty item short form 
general health survey, self reported sick days, clinic visits, and symptom 
related difficulty. The criterion validity was assessed against an independent 
structured mental health professional interview in a sample of five hundred 
and eighty patients (120), these patients were interviewed within forty eight 
hours of completing the full PHQ, and the mental health professional was 
blinded to the results of the PHQ. The authors state that patients that were re-
interviewed were similar to patients that were not re-interviewed in terms of 
demographics, functional status and diagnosis.  
The results of this study, and the validity of the PHQ-2, showed that of the 
forty one subjects who were diagnosed with major depressive disorder by the 
mental health professional, ninety three percent reported at least a score of 
one or greater which showed some depressed mood and ninety five percent 
reported some anhedonia. Patients with no depressive disorder (95% of them) 
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had a PHQ-2 score less than three, while most patients with a major 
depressive disorder (83%), had scores of greater than three (153). The PHQ-
2 had a likelihood ratio for major depression nearly identical to the overall 
likelihood ratio for nine other depression instruments (2.92 vs. 2.86) in a meta-
analysis of the literature (156). In this study they looked at questionnaires 
ranging from two to twenty eight questions with administration times of 
between two to six minutes. They found from the literature that if a case 
finding instrument was administered to one hundred patients in the community 
with a five percent prevalence of major depression, clinicians would find 31 
patients would screen positive, four would have major depression and one 
with major depression would not be identified. No significant differences were 
found and the choice depends on the clinical situation and feasibility. Other 
authors have shown (122) that the predictive value of the PHQ-2 is similar to 
other instruments noting predictive value is not only related to measures of 
sensitivity and specificity but to the prevalence of depression.   
Construct Validity-PHQ-2 
Kroenke (153) found a strong relationship between increasing depression 
scores on the PHQ-2 and decreasing functional status on the short form 
general health survey, noting that the relationships observed were similar to 
previous studies where mental health functioning, social functioning and role 
functioning had the strongest inverse relationship (157), with a lesser direct 
relationship between pain and physical functioning. Results were the same for 
the primary care patients and the obstetric/gynaecology patients. Greater 
levels of depression severity were associated with an increase in healthcare 
utilization, sick days, and symptom related difficulties. The authors advise that 
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the PHQ-9 would still be the preferred instrument for diagnosing depressive 
disorders or assessing outcomes after treatment, however in many settings, 
when the aim is to screen for depression in combination with other 
questionnaires, as a first step approach or for research purposes brief 
versions are more suitable.  
Kroenke (153) explains that this study builds on Whooley et al.’s previous 
study (154), where they looked at five hundred and thirty six mostly male 
veteran’s mood over the past month. The answers to the questions were 
either yes or no to maximise sensitivity but this also decreases specificity, 
compared to the PHQ-2 which is more specific with only a modest decline in 
sensitivity. The authors point out that specificity is an important consideration 
when screening for depression particularly with large numbers, as false 
positives are difficult to handle efficiently with time and cost constraints (122).  
Monahan et al. (158) assessed the validity and reliability of the PHQ-9 and the 
PHQ-2 in three hundred and forty seven patients living with HIV/AIDS in 
Kenya, and recommended its use as well as Osorio et al.’s (159) recently 
carried out a study in brazil on two hundred and twenty seven patients to 
consider if the two questions on the PHQ-2 were sufficient enough to screen 
for depression within a hospital context. They found that the PHQ-2 proved to 
have good psychometric properties in comparison to the PHQ-9 giving less 
false positives while being patient and clinician friendly in a practical setting. 
Arroll et al. (160) claim to have carried out the largest validation study of the 
PHQ-2 in a primary care setting at that time, where they looked at two 
thousand six hundred and forty two patients in Auckland New Zealand. The 
patients completed the PHQ-9 and the Composite International Diagnostic 
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Interview (CIDI) and the sensitivities and specificities were analysed for both 
the PHQ-9 and the PHQ-2 compared with the standard interview. They found 
that a PHQ-2 score of two or higher had good sensitivity but poor specificity in 
detecting major depression.  
 
Conclusion on the PHQ-2 
There appears to be controversy surrounding the use of routine depression 
screening in clinical practice (160) and good arguments for and against. 
Previously the United States preventive services task force believed there 
was enough evidence to support the case for routine depression screening 
(161). Gilbody et al. (148) argued that there was substantial evidence from 
their Cochrane Database Systematic review that routine screening for 
depression had minimal input on the detection, management and outcomes of 
depression by clinicians and advised against adopting this practice into 
guidelines and recommendations, until the costs and benefits have been 
sufficiently proven. There is, however, agreement that screening in high risk 
groups, such as chronic conditions like coronary heart disease, can be 
recommended if there are staff assisted depression care supports in place to 
ensure accurate diagnosis, and effective treatments with follow up care (148, 
150, 161).  
From the above literature there appears to be sufficient evidence for the use 
of the PHQ-2 in screening for depression in patients with coronary artery 





Depression and adherence 
Significantly lower rates of medication adherence have been reported in those 
with depression (7, 162-164). Systematic reviews have shown this previously 
(165). DiMatteo et al.’s meta-analysis correlated medical patients’ treatment 
non-adherence with depression. Studies were included if they measured 
patient compliance and depression, involved a medical regimen 
recommended by a non- psychiatry physician to a patient not requiring 
treatment for depression, anxiety or a psychiatric illness. Twelve articles about 
depression and thirteen about anxiety met the inclusion criteria. The 
associations between anxiety and non-compliance were variable and non-
significant as mentioned above. There was a substantial significant correlation 
between depression and non-compliance with an odds ratio of 3.0, with three 
times greater odds that depressed patients will be non-compliant using a 
binary cut off point of less than eighty percent was considered non adherent 
(47). Grenard et al. (140) found in their meta-analysis an odds ratio of 1.76 
times  depressed patients being non-adherent than non-depressed patients in 
thirty one studies with over eighteen thousand participants. The association 
was not as strong in studies that used pharmacy refill data compared to self- 
report and electronic cap measures. The main measures were self reported or 
physician reported, again showing the need for more studies with more 
objective measure of adherence. 
DiMatteo (7) concluded non-adherence is a complicated phenomenon where 
decades of research have attempted to understand the variables connected in 
order to improve patient care, depression maybe one such important treatable 
variable. Positive beliefs and expectations are known to be essential for 
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patients to be adherent to healthy behaviours and prescribed medications. 
Depression often involves hopelessness and negative thoughts that make it 
difficult for patients to make the effort to take actions that they feel may not be 
worthwhile. Depression is often accompanied with social isolation which 
research has previously shown is an important factor in a patient’s attempts to 
be adherent with medical treatments and to adopt healthy habits. The studies 
included in Di Matteo’s meta-analysis are correlational studies that cannot 
explain whether depression causes non-adherence or non-adherence causes 
depression but this should not deter clinicians to be aware of depression as a 
risk factor for non-adherence. Grenard et al. (140) suggests factors 
influencing medication adherence are different to those that effect adherence 
to other therapies such as diet and exercise, and a focus on medication 
adherence was needed. Thus, they carried out a meta-analysis to evaluate 
the strength and direction of the association between depression and non-
adherence. They included only studies that were performed in the United 
States, justifying this decision with the hypothesis that culture and the 
healthcare system are likely to influence the effect of depression on 
adherence. They noted that there is currently no gold standard for assessing 
medication adherence, so a variety of measures, such as self-report, 
electronic cap monitoring and examination of pharmacy records, were 
included in their review. They selected measures that were more objective of 
adherence or depression, for example pharmacy records over self- report, or 
a continuous scale over a dichotomised one that claims either adherent or 
non-adherent, which they suggest would provide more statistical power to 




Depression in Cardiovascular disease 
The American Heart Association (150) and the European Cardiovascular Joint 
task force (166) have recognised that patients with coronary artery disease 
have a higher prevalence of depression than those without coronary artery 
disease, and over the past forty years, more than sixty prospective studies 
have looked at the link between depression and CAD. The literature shows 
that there is an independent association between increased depression and 
increased cardiovascular morbidity and mortality, and most studies have 
found the more severe the depression, the earlier and more severe the 
cardiac events  (120,165). Rugulies (167) looked at cohort studies with clinical 
depression or depressive mood as the exposure and myocardial infarction or 
coronary death as the outcome. The conclusions that were drawn from this 
study were that depression predicts the development of coronary heart 
disease (CHD) in initially healthy people and there was a dose response 
relationship between depression and CHD. 
 Depression is three times more likely in patients after an acute myocardial 
infarction than in the general community and available studies suggest that 
depression is higher in patients with cardiovascular disease in the community 
than those without (168).  It has been mentioned earlier in this chapter that 
researchers believe that there is a vicious circle between depression and 
coronary artery disease (150, 169, 170), which can lead to depression and 




Not all studies have shown a significant link between depression and 
prognosis when there is statistical adjustment for cardiac severity and some 
have tried to argue that this association is explained by cardiac disease 
severity (171). The literature appears more convincing that there is a 
pathophysiological link between depression and coronary artery disease 
(172). Researchers have found hyperactivity of the noradrenergic system as 
well as increased catecholamines which has an effect on the heart, blood 
vessels and platelets in patients with major depression (173) which is thought 
to be related to the increased sympathetic outflow in patients with ongoing 
depression. There have also been studies to show increased levels of 
catecholamine levels in the urine of patients with negative emotions and 
decreased perceived social support which correlate with high nor-adrenaline 
and low platelet serotonin, which are associated with myocardial infarction 
and depression (173).  
 
Halaris (169) explains how inter leukin-6, an inflammatory biomarker, and 
other stress hormones are associated with cardiovascular disease which can 
be caused by depression and lead to atherosclerosis, causing coronary heart 
disease. This can then lead to depression and a lack of joy and pleasure 
which can then lead to patients neglecting their health and possibly missing 
their medications. He proposes that psychiatrists and cardiologists work 
together in a multidisciplinary team to effectively treat patients with both 
conditions. Lett (174) supports this hypothesis, adding that behavioural and 
medication non-adherence add to the risk factors of further adverse events in 




Depression and adherence in Cardiovascular Disease 
Whooley et al. (156) in their study of over a thousand patients with stable 
Coronary artery disease from the heart and soul study found the association 
between depressive symptoms and adverse cardiovascular events was 
largely explained by behavioural factors mainly physical inactivity. 
Oestergaard et al. (165) describes how single component interventions have 
failed to improve outcomes for patients with depression and how collaborative 
care and additional psychotherapy have been shown to provide more benefits 
for patients with depression than pharmacology alone. Both interventions 
have been shown to provide benefits in the short term, with psychotherapy 
having the most effect in the long term, preventing relapse. They state that 
conclusions regarding the effects of medication adherence improvements are 
fairly certain, although again a literature search did not find a direct objective 
measure of medication adherence (175) which may be due to the 
practicalities and ethical considerations of taking direct objective measures in 
this vulnerable group of patients. Table 3 below shows a review of the 
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monitoring device.  
10 of the 55 pts were 
diagnosed as having 
depression and adhering 
to aspirin twice a day only 
45% of the time while 
non-depressed patients 
adhered 69% of the time 
P<.02  
 This study used an 
objective measure of 
adherence but the 
numbers were small 
and there is no way of 
knowing did the 
patients actually 
ingest the aspirin. 
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were less adherent 62.4% 
days, asymptomatic 
patients were adherent 
77.3% days 
P<0.03. Symptomatic 
patients were more 
depressed P<.10. 
Approaching significance 
in a small sample. 
Symptom status was not 
an independent predictor 
of adherence when 
controlling for 
depression. 
Patients over 75 yrs 
were excluded. 
Symptomatic patients 
were less likely to be 
married. 
Social support, beliefs 
about illness and 
medicines were not 
measured and may be 
confounding 
variables. 
Depression may have 




Gehi et al. 2005 
U.S 
 CHD patients from 2 
veteran affairs medical 
centres, 1 university 
medical centre, 9 
community health clinics. 
Prospective cohort 
study 






adherence of  
- Not taking meds 
- Forgetting 
- Skipped dose 
204 pts-(22%) had 
current depression, 7% of 
all patients reported non-
adherence and theses 
with depression were 
more likely to report non-
adherence-adjusted OR 
(95% CI 2.2(1.2-3.9)P 
value .009. 
PHQ .003 for trend.  























23% had poor adherence 
to aspirin and poor 
adherers were more 
likely to be depressed 
P=0.01 
Of the depression 
vulnerabilities only role 




Patients included in 
the study were aware 
that aspirin 
adherence was being 
measured therefore 
this was likely to 
improve adherence. 
Lin et al., 2012 
U.S 








15% of patients screened 
positive to the PHQ-2. No 
medication adherence 
differences were 
observed between the 
intervention group and 
the usual care group. 
Medication was high 
at baseline for both 
groups 79-86% and it 
is not clear how many 
of these patients 
were actually CAD 
patients.  
May et al., 2010. 
U.S  
ACS patients from the 
(IHCS) Intermountain 
Prospective cohort 585 patients ICD-9 depression 
scale. 
All time points 6mths, 
1yr, 18mths, 2yrs-those 




Heart Collaboration Study Pharmacy refill data 
measure of 
adherence. 
with depression had 
significantly lower 
medication adherence 
compared to those 
without depression. 
patients ingested the 
Aspirin. 
Rieckmann et al., 
2006 
U.S 
ACS patients Prospective cohort 165 BDI scale at baseline 





significantly less adherent 
than non-depressed 
patients P<.01 
Patients were aware 
that aspirin 








204 patients Beck Depression 
Inventory (BDI) 







15.2% patients with 
major depression 
reported significantly less 
adherence to their 
medication P<0.03. 
Also low fat diet P<0.01, 
regular exercise<0.03 and 
increasing social support 
P<.003 
The total score for 
adherence behaviours 
was significantly 
lower in patients with 
major depression 
than those without 
P<.001. 
Validity of self report 
data may be 
influenced by a more 
negative description 
of self in depressed 
patients. 
PHQ-9=Patient Health Questionnaire 9, PHQ-2=Patient Health Questionnaire 2, ACS=Acute Coronary Syndrome, MI=Myocardial Infarction 
 
 
Literature on depression and adherence in heart disease was identified using key search terms in PubMed, and checking Google 
Scholar for other relevant articles which cited the studies found with the PubMed search. More details on keywords and searches 




Carney et al. (163) looked at major depression and medication adherence in 
patients sixty five or older with a diagnosis of Coronary Artery Disease. He 
acknowledged that depression is less common in the elderly patients than 
younger patients (176), but a high percentage of medical patients suffer from 
clinically significant depression, with fifteen to twenty two percent of CAD 
patients suffering from depression (163). Carney et al. (134) also noted that 
depression was associated with a higher rate of non-adherence in younger 
chronically ill or disabled patients, but research on the effects of depression 
on adherence in the elderly was lacking. In this study by Carney et al. (134) 
they found that major depression was associated with non-adherence in ten of 
fifty five patients over the age of sixty five with a diagnosis of CAD. Although 
this study used an objective measure of adherence (i.e. a medication 
monitor), the sample size was relatively small and there is no way of knowing 
if the patients ingested the aspirin. In a separate study (177) they then looked 
at differences in medication adherence between symptomatic and 
asymptomatic patients with Coronary Artery Disease with a view to determine 
if patients with asymptomatic CAD were less depressed than patients with 
symptomatic CAD. They explain that previous studies have shown 
asymptomatic conditions have related to poor adherence in other populations, 
but depression is more common in patients with symptomatic CAD. Their 
results concurred with previous studies showing asymptomatic patients were 
significantly less depressed than symptomatic patients using the Beck 
Depression Inventory scale (BDI) and depressed patients were more likely to 
be less adherent, however the relationship was only approaching significance 
in this small study. Symptoms were not an independent predictor of 
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adherence after controlling for depression in a multiple regression model. 
They concluded that depression may be a factor in non-adherence in 
symptomatic patients but other factors must be considered. Symptomatic 
patients were less likely to be married therefore may have less perceived 
social support. Finally they acknowledge limitations of this study are 
measures regarding beliefs about illness or medicines were not measured, 
which are likely to be important factors. 
 
Lin et al. (178) conducted a randomised controlled trial looking at treatment 
adjustment and medication adherence in complex patients with diabetes, 
heart disease and depression. They developed a patient centred team based 
intervention, with the aim of improving patient self monitoring, medication 
adherence and treatment adjustments in patients with multiple conditions and 
depression, with poor control of their hypertension, blood glucose and 
cholesterol. Patients were eligible if the blood pressure and blood values 
showed poor control and they had a depression score of ten or higher on the 
PHQ-9. Patients were then randomised into either the usual care group or the 
intervention group. Pharmacy refill data was used to measure medication 
adherence twelve months before and after baseline. Medication adherence 
was found to be unusually high in both the intervention group and the usual 
care group (79-86%) as can be seen in Table 3. There was no significant 
difference in adherence between the control group of usual care and the 
intervention group (which was team care), a surprising result to the authors. 
Medication alterations and initiations were significantly higher in the 
intervention group, particularly in the first two months after randomisation and 
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the authors point out that previous observational studies have found that lack 
of physician treatment adjustments can be more problematic than medication 
adherence among patients that are poorly controlled with their diabetes or 
heart disease (148). This study did show improved self monitoring, glucose, 
cholesterol and blood pressure control and recognised the effect of the team 
care approach of monitoring patient progress, supporting self-care activities 
and a multidisciplinary case review all contributed to better control. The 
authors suggest that the study shows an integrated approach in treating 
mental and physical illness can be applied to most patients with chronic 
conditions regardless if they have depression or not.  
 
Kronish (179) looked at the psychosocial impacts on medication adherence in 
Acute Coronary Syndrome (ACS) patients that were recruited within one week 
of their coronary event. Patients’ depression was measured with the Beck 
Depression Inventory (BDI) scale and adherence was measured with a 
medication event monitoring device on the aspirin container (TABLE 3).  
Other measures used were the Dysfunctional Attitude Scale (DAS-24), the 
pleasant event schedule for the elderly, role transitions and interpersonal 
conflict. The results from this study showed twenty three percent of patients 
were non adherent (took aspirin <80% of the days) to their aspirin using the 
medication event monitoring device which shows how many times the aspirin 
container was opened each day, although it is acknowledged that this does 
not necessarily show ingestion of the aspirin. It is possible that this cohort of 
patients may have a higher than usual adherence rate as they were recruited 
within one week of their Acute Coronary Syndrome (ACS) event and were 
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also aware that adherence was going to be measured.  The study found that 
poor adherers to their aspirin were significantly more likely to be depressed- 
(P=0.01) but of the depression vulnerabilities only role transitions and 
interpersonal conflict predicted poor adherence when adjusted. The authors 
explain that depression is a multifactorial psychological disorder that can arise 
from a combination of genetic, biological and environmental factors in patients 
with underlying vulnerabilities. The authors hypothesised that patients who 
are not inclined to schedule pleasurable activities may also have low self-care 
activities including adhering to their medications. They also hypothesised that 
patients who experience psychosocial vulnerabilities, through either 
interpersonal conflicts or major life events, may lack the social support and 
habit that supports medication adherence.   
 
Ziegelstein et al.’s study (180) previously had looked at over two hundred 
patients recovering from Acute Coronary Syndrome (ACS) to determine 
whether patients with depression were less likely to follow recommendations 
to reduce cardiac risk including adhering to prescribed medications. When 
interviewed at four months after their acute episode, patients that had been 
diagnosed with at least mild to moderate depression with a BDI score of 
greater than or equal to ten or with major depression determined by the SCID 
during their recovery time in hospital, reported less adherence to a low fat 
diet, regular exercise, stress reduction and regular socialising than non-
depressed patients. Patients with major depression or dysthymia reported 
less medication adherence. Patients who dropped out of cardiac rehabilitation 
were found to be more depressed, anxious, hyperchondriacal and socially 
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introverted at enrolment than those that completed the programme. The 
authors discuss one of the limitations of this study is all measures of 
adherence were self reported and not independently verified, noting that self 
report data may be influenced by a more negative description of one’s self in 
depressed patients. Other authors have argued that this negative response 
bias observed in depressed patients may be a more realistic value (181). 
Ziegelstein et al. (152) recommend further research is required to establish 
whether treatments on depression or adherence interventions will improve the 
prognosis for Acute Coronary Syndrome patients. 
 
Only four studies looked at coronary artery disease, two of these used self 
reported measures of adherence (164, 180) and two used the more objective 
measure of a medication event monitoring device (177, 179) see Table 3. 
Although the medication event monitoring from the containers does not 
necessarily mean the medication was ingested.  
 
Conclusion  
The research from the above literature shows significant associations 
between depression and medication adherence in different disease groups 
including Coronary Artery Disease. These studies show consistency whether 
the disease is chronic or acute, symptomatic or asymptomatic. The authors in 
table 3 agree that depression is multifactorial and may have other influencing 
variables such as social support, beliefs about illness and medicines that 
need to be considered. The inconsistency of measurements between studies 
also makes it difficult to compare studies with no gold standard measure of 
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adherence or depression, although there appears to be more use of validated 
questionnaires, like the PHQ-2, that are brief and appropriate for use in 
clinical settings with other questionnaires. There are also improvements in 
measuring adherence with more objective measures, rather than relying on 
self report which researchers agree is generally over reported and does not 
take into account patients forgetting. While depression has been consistently 
associated with poorer adherence, it is unclear how or whether it is related to 
beliefs about medicines or illness, or whether it may account for the 
associations between these cognitive factors and adherence.        
 




CHAPTER 5-Social support 
 
Chapter overview 
This chapter will look at social support and its effect on health, cardiovascular 
disease and adherence. Defining social support and the theory behind it, 
reviewing studies of social support and its effect on health, by biological 
mechanisms, but also behavioural factors, including adherence. Then, 
reviewing studies that have looked at correlations of social support and 
adherence, in patients with coronary heart disease. Finally, critiquing the 
previous literature, the significant relationship between social support and 
adherence that has led researchers to suggest that adherence is an important 
mediator between social support and health (182).   
 
Defining social support  
Yohannes (183)states that there is no precise definition of social support in 
the literature but uses the Umberson et al. (184) definition of “the 
commitment, caring, advice and aid provided through relationships or network 
of people”. 
Langford et al. (185), describes social support as the assistance and 
protection given to others, where assistance may be tangible such as financial 
aid or intangible as in emotional help.  Protection may come in the form of 
shielding people from adverse events or the effects of life stresses. The 
authors point out that social support is a resource given with the expectation 




DiMatteo (182) has described in his meta-analysis of social support and 
patient adherence to medical treatment, how the relationship between social 
support and health has received a great deal of attention. He and other 
researchers point out that there is an effect on the immune, endocrine and the 
cardiovascular system, influencing health maintenance and recovery from 
illness or injury. The exact mechanism of how social support has an effect on 
these systems is still not completely understood. 
Lack of social support is associated with increased morbidity and mortality in 
patients with ischaemic heart disease (186, 187), and Uchino et al. points out 
that that the most compelling evidence to date of the effects of social support 
on all-cause mortality has been shown by Holt-Lunstad et al. (188) where a 
meta-analysis of the existing literature found that perceived support was 
related to significantly lower risk even after statistically controlling for other 
variables such as demographics, health behaviours, exercise and obesity.  
 
Patients with low practical social support have shown a correlation with lack of 
adherence (189), this was shown in the literature review of 122 studies that 
were found to correlate social support with patient adherence to medical 
regimens, again these studies mainly used self reported adherence rather 
than an objective measure. Those who do not receive practical social support 
(e.g. reminders, assistance); have a relative risk for non-adherence almost 
double that of those who do receive practical support. Furthermore, 
adherence is 70% higher in patients from cohesive families, but over 50% 
lower in patients from families in conflict (189). These results highlight the 
impact of social and emotional factors on medicine adherence.  
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The Theory of Social Support 
Researchers have recognised the positive relationship between social support 
and health for many years including patients post myocardial infarction. The 
theoretical foundations of social support include social comparison, social 
exchange theory and social competence. Social comparison theory believes 
that people develop their self-concept by comparing themselves to others in 
their close reference groups which enhances coping abilities, emotional 
adjustment, self-esteem and emotional well-being. However it appears to 
depend on social exchange (185). Social exchange theory describes human 
behaviour as an exchange of mutually rewarding activities, where there is a 
positive relationship between life satisfaction and the exchange of social 
support. If there is social comparison and social exchange, Langford et al. 
(185) suggest that this implies there is some degree of social competence. 
Social competence is described as the ability to effectively interact with the 
environment and is essential in the building and maintenance of relationships 
which leads to social, psychological, physiological health and prevents social 
isolation which can lead to negative health (34, 186, 190). Social climate is 
defined as the personality of the environment and it is within this climate of 
assistance and protection that the theoretical foundations of social 
comparison, social exchange and social competence operate (185) . 
There are four attributes of social support that have been described by 
Langford et al. (185). Emotional support, which is generally considered the 
most important, involves love, trust, empathy and caring. Instrumental 
support, which is tangible and concrete, such as financial assistance or 
practical help, which may also suggest caring and love. Informational support 
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which involves the giving of advice, guidance and helpful information, and 
lastly, appraisal support where some-one offers information that allows the 
person to make an informed decision on their own, for example “I trust your 
judgement “ or “you are doing the right thing”.  
 
Some authors argue that one of the most effective forms of support is invisible 
support where the person is unaware of the support and therefore promotes a 
sense of self-efficacy (191, 192). In a study carried out by Bolger et al. (192) 
where they looked at data from a daily diary study of support provision and 
receipt in couples, they found that many supportive actions reported by 
providers were not reported by recipients, and this type of  invisible support 
can promote adjustment to major stressors. A later study (191) to investigate 
this type of support looked at two hundred and fifty seven females before a 
stressful speech task where a peer provided either visible or invisible support 
either practically or emotionally. Invisible support either practical or emotional 
was found to be more effective in reducing emotional reactivity than visible 
support. There has been extensive research showing the benefits of a 
romantic partner particularly for men (193), with some researchers 
hypothesising that this is due to men being able to delegate emotional stress 
(185) whereas women may be better providers of support and more likely to 
seek it out and therefore gain more benefit (188). Other researchers argue 
that higher coronary artery disease is linked to more ambivalent (perceived as 
having upsetting aspects as well as positive) relationships between couples 
than those that are perceived more positive (187). The researchers 
hypothesise the reason for no link between negative social support and 
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coronary artery disease is people are unlikely to stay in a relationship that 
they perceive completely negative. Early familial support has also been shown 
to be an important factor in peoples’ abilities to develop social competencies 
and thus coping skills which are linked to behaviours, habits and 
psychological health (194). This may also have a role in adherence. 
 
Researchers more recently have argued for a distinction on the context of 
support in understanding the links between social support and health, stating 
that primary and secondary groups differ (195). Primary groups which are 
considered typically long lasting, informal and consist of significant others are 
thought to be more effective for emotional support. Whereas secondary 
groups are considered less personal and members can exit or enter at their 
own discretion, are likely to be more formal and are thought to be more 
effective for informational support (195). This can be seen when a patient with 
a chronic disease may gain more benefit from information from a secondary 
support, for example a health professional rather than a spouse who may lack 
insight into their partners pain of physical symptoms which can lead to 
problematic support (196). The same author suggests that a sense of 
“mattering” is also an important factor in social support that is linked to self- 
esteem and control. 
Perceived and received support 
Researchers have also made a distinction between perceived and received 
support where perceived support is a recipients subjective judgement that 
they will receive the support if or when required, whereas received support is 
supportive actions or an exchange of resources emotional or instrumental 
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given when needed (197). Perceived support has been consistently 
associated with improved mental health whereas received or social integration 
have not (198). It appears from the literature that it’s the perception of the 
support whether it is received positively or negatively that has the influence on 
health, and researchers have described the importance of perceived 
responsiveness where it seems beneficial if it appears responsive to the 
recipient. Uchino et al. (197)  points out that it is one of the most researched 
psychosocial factors that has an influence on health outcomes, in particular 
low levels of support have higher rates of mortality in cardiovascular disease 
(199). 
 
Laboratory studies looking at cardiovascular reactivity and received social 
support have repeatedly found a positive correlation between the two and it is 
hypothesised that receiving support over time has a long term positive 
cardiovascular effect (200), although recent laboratory reactivity findings have 
not been able to consistently identify the negative mechanisms unsolicited 
support can sometimes have. Whereas there seems to be significant 
variability between received support compared to perceived support and 
health (188), researchers suggest that this may be due to negative 
psychological mechanisms if the recipient feels a threat to their independence 
and this reaction may cancel out the positive influence of actually receiving 
support. 
 
Rational Regulation Theory is another theory that hypothesises that the link 
between perceived support and health comes from people regulating their 
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emotions through ordinary conversations and shared activities rather than 
conversations on how to cope with stress (177).  
 
Social support and Health 
In general Uchino et al. (197) suggest that the available literature shows the 
positive influence of perceived or received social support on cardiovascular, 
endocrine and the immune system even when controlling for other variables 
such as life stress, depression and anxiety. This review reflected on a 
workshop that brought together experts working in the area of social support 
and cardiovascular disease. They noted three distinct ways that social support 
might relate to cardiovascular disease. Support impacts directly on emotions, 
which in turn produce haemodynamic responses. Support affects behaviour 
which influences physiological responses, and support directly alters 
cardiovascular risk indicators. The author advises though that researchers 
may need to measure these processes over time as most studies use a cross 
sectional design assuming that the health related state is measured 
accurately at that point in time when there may be other variables such as 
time of day (circadian rhythm) or the environment (negative/stressful) . 
Although these studies are costly and time consuming they are important 
given the associations between social support and cardiovascular disease 







Social support has been found to have a positive influence on the 
cardiovascular system as well as the neuro-endocrine and immune system 
(198) lowering levels of inflammatory markers, stress hormones and 
cardiovascular reactivity measured by blood pressure and heart rate. Uchino 
et al. (201) also looked at the relationship between positive, negative and 
ambivalent relationships with telomeres ( which are found on chromosomes 
and deteriorate with the aging process). They looked at one hundred and 
thirty six people aged 48-77yrs from a community sample of patients and 
found that the higher number of ambivalent relationships the shorter the 
telomeres as measured in peripheral blood. They also found that gender 
moderated these links with more of a link found in women. They suggest that 
cellular aging provides the framework for measuring telomeres as they help to 
promote the stability of the chromosome but with each successive replication 
of the cell, telomeres shorten which can ultimately lead to unregulated cellular 
activity. Importantly shortened telomeres have been linked to three times 
more mortality risk from heart disease and eight times greater risk from 
infectious disease up to twenty years later (182). The authors point out that 
the theory behind the harmful effects of the ambivalent relationships is that 
they are unpredictable and therefore associated with more interpersonal 
stress, they also point out that age did not moderate the links between 
telomeres and relationships. This study provides mechanistic information on 





Measuring social support: The ENRICHD Social Support Instrument - 
ESSI 
In response to the large amount of research showing the effects of 
psychosocial influences on patients’ recovery post myocardial infarction the 
Enhancing Recovery In Coronary Heart Disease ENRICHD trial clinical trial 
was initiated. This was a multicentre, randomised, trial looking at a 
psychosocial intervention on patients with clinical depression or social 
isolation and the effects on cardiovascular morbidity and mortality (202). The 
study used the ENRICHD social support instrument which is a measure 
derived from the medical outcomes survey and previous work that has shown 
the influences of social support on health outcomes (202) (203, 204). The 
investigators stated that existing studies didn’t provide a clear guide of the 
social support being measured, for example, marital status, type of support 
and the clinical outcomes associated. This led the investigators to develop the 
seven item questionnaire with a scale of one to five- (see Appendix B) to 
accurately assess social support (202). Before this study no clinical trial had 
tested the effects of increasing social support on clinical endpoints in patients 
post MI. 
Vagilo et al. (204) carried out a study to test the validity and reproducibility of 
the ESSI in one hundred and seventy four patients undergoing percutaneous 
coronary intervention (PCI). Patients were administered the ESSI with the SF-
36 mental health and social functioning subscale which was a widely used 
generic measure of health status and the Seattle Angina Questionnaire (SAQ)  
which is a disease specific measure of health status for patients with coronary 
disease, at baseline and every month after for six months post percutaneous 
coronary intervention (PCI). The authors state that in the absence of a gold 
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standard measure for social support, construct validity was assessed by 
comparisons of the ESSI with depression, social mental and physical 
functioning, symptom severity and quality of life in order to support the use of 
the ESSI in examining the relationship between social support and 
cardiovascular outcomes. Test re-test analysis carried out at five and six 
months showed no significant differences in the ESSI scores and excellent 
reproducibility. The mean ESSI score at baseline among depressed patients 
was significantly lower than those that were not depressed, as well as people 
that were living alone rather than living with someone had lower ESSI scores. 
The questionnaire showed acceptable internal consistency and correlated 
with other social support instruments, while also suggesting that patients with 
greater social support have greater social functioning, improved symptom 
control and better quality of life (196). Overall this study found that the ESSI is 
a valid and reliable measure of social support in coronary artery disease 
patients.  
 
Social Support and adherence 
Researchers have hypothesised that the link between social support and 
health may be patient adherence to healthy behaviours as well as adherence 
to medications (167). Adherence involves patients accepting they have a 
condition and can have an effect on the outcome by following advice and 
treatments. As discussed previously non-adherence rates can range between 
25% - 75% and can have a significant effect on outcomes. Adherence is 
thought to be mediated through family support and friends by improving 
optimism and self-esteem, buffering the effects of ill health, reducing 
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depression and giving practical assistance. Researchers agree that 
quantitative studies exploring the effects of the different types of support, for 
example marital, practical and emotional support on adherence are essential 
in understanding the link between social support and health (179-181).  
 
Di Matteo (182) carried out a meta-analysis of studies that looked at social 
support and patient adherence across one hundred and twenty two studies. 
He found a significant relationship between adherence and all types of 
support including practical, emotional, family cohesiveness, marital status and 
living arrangements. The risk for non- adherence was almost twice as high 
among patients with low practical support compared to those with high 
practical social support, however, smaller samples reported significantly 
higher correlations of practical support with adherence than the larger 
samples, possibly eluding to more bias in the smaller samples. However, the 
author points out that there would have to be one thousand and eight hundred 
unpublished research papers that found no effect of practical support on 
adherence to make the P value of 0.05 insignificant. Studies using self 
reported adherence showed higher correlations than those that did not use 
self reported adherence. The odds of adhering were found to be three times 
higher among patients in close cohesive families than families experiencing 
conflict, and the odds of adherence were also higher if patients were married, 
but support such as practical, emotional and family cohesiveness were 
significantly stronger than marital status or living arrangements. He also notes 
that the presence of other people does not matter as much as the quality of 
the relationships which has been supported recently by Yohannes (183) who 
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explains that strong social support networks enhance self efficacy, identity 
and self management behaviours including medication adherence. Group 
activities improve physical and psychological health, which in turn can reduce 
cardiovascular disease. Whereas, a non-supportive social network can 
interfere with healthy habits limiting the patients time for healthy behaviour 
and introducing stress.   
 
DiMatteo states that there is surprising consistency in the relationship 
between social support and adherence in the literature suggesting that the link 
between social support and health is mediated though adherence, although 
he acknowledges that adherence is mainly self reported and the significance 
is reduced when other measures of adherence are used (182), there is no 
evidence that the mean effect of the result is due to self reported adherence. 
He also acknowledges that although social support influences adherence, it is 
also possible that adherence influences social support as patients that adhere 
are likely to receive more support for their efforts than those that are non-
adherent. Conversely, lack of social support or the wrong type of support can 
interfere with healthy lifestyles and introduce stress that compromises the 
healthy behaviour and attitude required for adherence (175,176). 
Although patient adherence is related to social support lifestyles and 
outcomes, researchers accept that patient depression is strongly related to 





Social support and medication adherence in patients with Coronary 
Artery Disease (CAD) 
The table below shows the studies from 2000 to the present date that could 




























1,432 pts Questionnaire 
asking if the 
patient would have 
a paid professional 
caregiver or a non-
paid family 
caregiver. 
Adherence was self 
reported if they 
missed a dose in a 
week in the last 6 
months. 
One in four patients 
admitted to being non-
adherent to their 
medication. Patients 
who were planning to 
have a paid caregiver 
were 40% less likely to 
be non-adherent than 
their counterparts. 
Significance remained 











women but not 
men. There was a 
similar relationship 
with informal 
caregiving but not 
significant. 
Gehi et al., 
(2005) U.S 
CHD patients from 2 
veteran affairs 
medical centres, 1 
university medical 
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7 % of patients 
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interview at 12 
mths.   
29.8% of patients 
had no practical 
supports. Patients 
with more practical 
support were more 
likely to adhere to 
medications which 
remained significant 
after adjustment for 
age, gender, marital 







self reported and 
the study suggests 
that if the patient 
admitted to 
forgetting one 














It can be seen from the table above that Aggarwal et al. (205) found a 
significant correlation between patients who reported planning or having a 
paid caregiver and a forty percent less likelihood of non-adherence to cardiac 
medications. Cardiac patients often rely on reminders from family, friends or 
paid caregivers with daily tasks such as medication taking and the authors 
speculate that paid givers are more accountable and trained than informal or 
family caregivers. The previous literature on this appears conflicting where the 
presence of a spouse increases adherence in heart failure patients (206), but 
in contrast, another study among patients with kidney disease found patients 
who relied on a family member were more likely to be non-adherent (207). 
The authors (186) suggest that training family caregivers with aids such as 
pillboxes and automated alerts may have the potential to enhance medication 
adherence in cardiac patients.  
 
In the study by Gehi et al. (164) they found an association between social 
support and self reported non-adherence to cardiovascular medications, even 
though they only asked one question assessing social support “ Do you have 
some-one you feel close to, some-one in whom you can trust and 
confide?(yes/no)”. Also, Gehi acknowledges that the self reported rate of 
seven percent non-adherence is unusually low, therefore is not likely to be 
representative of the general cardiovascular population pointing out that 
patients included in this study were likely to be more motivated in adherence 




Molloy et al. (208) notes that the odds ratio of death in the first six months 
following myocardial infarction were 2.9 times more likely in patients who 
lacked social support than those with two or more sources of support, 
independent of clinical and socio-economic factors. Williams et al. (209) found 
that unmarried or patients that lacked a close confident were three times 
greater risk of dying, five years post coronary angiogram than those that were 
married or had a close confidant. This is supported by a recent look at the 
data of the perceived social support that was measured in the ENRICHD 
study which showed a direct relationship between social support and clinical 
outcomes over four and a half years following myocardial infarction. This 
relationship was independent of other risk factors but only in patients without 
elevated depression scores (210). In the Molloy et al. (201) study, emotional 
and practical support were assessed within the first five days of admission 
using measures devised by Berkman et al. (211), patients were asked “can 
you count on anyone to give you emotional support” and “when you need 
extra help, can you count on anyone to help you with daily tasks like 
shopping”.  Adherence to medication was assessed by telephone interview at 
twelve months post hospitalisation. If the patient reported any problems with 
missing doses or adherence this was considered non-adherent. Half of the 
patients were considered adherent at twelve months following discharge. 
There were two hundred and two men and sixty women in the study and there 
was no significant difference in practical support found between the two 
genders. Unmarried patients were more likely to have no practical supports 
available to them. The final results of the study were that patients with two or 
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more sources of practical support were two fold more likely to be adherent to 
their medications as well as adherent to cardiac rehabilitation, although there 
was no association with emotional support. This correlation was no longer 
significant when controlling for depression. 
 
In summary, there were only three studies that measured social support and 
non-adherence. All found social support predictive of adherence but none of 
these studies used an objective measure of adherence. 
 
Conclusion of social support and medication adherence 
Social support has been defined as the assistance and protection given to 
individuals which may be tangible as in financial aid or intangible as in 
emotional help and this protection may protect people from the adverse 
events of life stress, it is generally given with the expectation of reciprocation 
(185) (208). The literature shows that some of the effects of social support 
are; personal competence, coping ability, positive affect and a sense of 
stability, recognition of self-worth, decreased anxiety and depression, while 
promoting healthy behaviours and physical and psychological well-being. One 
of these healthy behaviours is medication adherence, where studies have 
shown a direct correlation between social support, both emotional and 
practical, and medication adherence (164, 212). Uchino (197) points out that 
although social support has proven to be a robust predictor of mortality and 
morbidity decades of research have been unable to demonstrate the 
mechanisms responsible for these links adequately and advises strongly on 
improving the statistical design of studies, specifying the difference between 
perceived and received support and looking for correspondence between self 
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reported affects and biological measures. Direct associations between low 
social support and activation of inflammatory markers has been linked to the 
physiological processes involved in poorer outcomes of coronary artery 
disease patients (213). It can be seen from the above table that there appears 
to be a lack of research on social support and medication adherence in 
coronary artery disease patients, with no studies measuring a direct measure 
of medication adherence with other important variables such as depression 




















CHAPTER 6 - The Present Study 
   
Introduction 
This thesis is a review of the current literature in medication adherence in 
particular, focusing on medication adherence in patients with coronary artery 
disease. This included examining the measures of medication adherence 
explored in previous studies. Using the psychological variables that have 
previously been identified in systematic reviews, the relationships between 
beliefs about medicines, beliefs about illness, depression, social support and 
aspirin adherence were explored.  
 
The above literature demonstrates how beliefs about medicines, beliefs about 
illnesses, depression and social support all purport to have an influence on 
adherence to medications. However, the research is limited in coronary artery 
disease patients and also limited by the measures of adherence used, and 
non-adjustment for potentially mediating effects of each of the variables. 
Any interventions to improve adherence should be derived from the best 
predictors of adherence in the population, which evidence suggests are the 
psychosocial variables listed above. However, few studies have 
simultaneously measured these variables while using a direct method of 
adherence measurement (214) and the literature appears somewhat 
conflicting at times. The proposed study provides a unique opportunity to 
assess predictors of a direct-measure of adherence, with the hope that it will 
provide information that will guide subsequent intervention–planning in 




Previous measures of adherence 
There are limited examples of objective measures of adherence particularly in 
CAD patients and there are no studies that measure aspirin adherence 
objectively while also looking at the psychological variables of depression, 
social support and beliefs about medicines and illness to our knowledge at 
present. The current study will therefore look at these psychological factors of 




The aim of study is to determine the best psychological predictor of 
adherence to aspirin therapy as measured by the best available assay 
available. To do this, the plan was to recruit patients who took part in the 
aspirin effectiveness in Ireland study with stable coronary artery disease who 
have been prescribed aspirin and who took part in the national study looking 
at aspirin adherence.  
 
From this cohort, it is expected to identify approximately 20% of patients who 
are non-responsive to aspirin, as this is the percentage of patients that were 
found to be non-responsive in the national study of 700 patients with stable 
coronary artery disease (using the same assay and cut off point of 2.2ng/ml 
(215). It is then proposed to characterise the reasons for lack of response in 
this cohort. Specific objectives are as follows: 
 
- Recruit over 100 patients from the national study of aspirin 
effectiveness in Ireland. 
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- Assess adherence using the Thromboxane B2 ELISA assay. 
- Correlate the results with the results from the psychological 
questionnaires. 
 
Hypotheses are as follows: 
1) Correlation between self-report non-adherence, (measured by asking 
patients have they missed any aspirin doses in the last week, or do they ever 
forget to take, or purposely miss doses), and the current most specific and 
viable assay response to aspirin using thromboxane B2 (216). 
2) Psychological aspects which have predicted adherence in previous studies, 
which may provide useful pointers for interventions in the future, specifically.  
 
 Beliefs about medicines –that patients with negative beliefs about 
medicines will have a direct correlation with an ineffective response to 
aspirin (above the cut off point for thromboxane B2 of 2.2ng/ml) 
suggesting non-adherence to aspirin.    
 Beliefs about illnesses – patients with a negative view of their illness 
and its treatment control will have a direct correlation with lack of aspirin 
response (above the cut-off point of thromboxane B2 2.2ng/ml) thus 
suggesting lack of adherence to their aspirin. 
 Depression – higher scores of depressive symptoms will correlate 
directly with a lack of aspirin response (above the cut-off point of 




 Social support – lower perceptions of social support will correlate 
directly with a lack of response to aspirin therapy (above the cut-off 
point of 2.2ng/ml for thromboxane B2) indicating lack of adherence to 
aspirin therapy. 
 
Exploratory multivariate analyses will also be used to determine which of the 





Chapter 7- Methods 
This chapter will describe the sample, design, measures, procedure, ethics 
and statistical analysis that were used in the current study “An exploration of 
the Psychological Indicators of Aspirin Adherence, in Patients with Stable 
Coronary Artery Disease, Using a Direct Assay Measurement”. It will also 
explain the initial national study “Aspirin effectiveness study in patients with 
stable coronary artery disease “and the inclusion exclusion criteria that were 
used for both the national study and the sub-study. 
 
The national study had a total of 700 patients (189 from Beaumont) recruited 
in total. At the time of commencement of the sub-study, the national study had 
600 patients recruited (156) from Beaumont who had already consented to 
the national study and had their blood sample taken. These 156 patients from 
Beaumont were sent their psychological questionnaires in the post rather than 
wait for their next outpatient visit as patients who are stable are more often 
than not discharged back to their general practitioner or would not have 
another outpatient appointment until the following year. The subsequent 33 
patients were recruited from Beaumont outpatients department and were 
asked the questionnaires face to face.  
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National study-Aspirin Effectiveness in Stable Coronary Artery Disease 
Patients in Ireland 
The inclusion and exclusion criteria for the national study are listed below. 
 
Inclusion Criteria: 
 Age 18 years or older 
 Patients with documented CAD (defined by the presence of lesions on 
coronary angiography, history of myocardial infarction, or positive 
stress test) 










 Able to provide written informed consent based on competent mental 
status. 
 
Exclusion Criteria:  
 Myocardial infarction, unstable angina or stroke during the preceding 
three months 
 Platelet count <125,000/mm 
 Known haematological disorder such as myelofibrosis 
 Active malignancy on current chemotherapy or a recent (<3 months) 
diagnosis of cancer 
The cut off point for an effective Thromboxane B2 response for this study 
was >2.2ng/ml as defined by Maree AO et al. (217). 
The main findings from this study and previous similar studies were that 
patients who were younger in age, overweight, and had a high alcohol 




As the sample population were all patients of Beaumont Hospital, an 
application for approval was submitted to “Beaumont Hospital (Medical 
Research) Ethics Committee” on the 21st of May 2012 and reviewed on the 
15th of June 2012. The Ethics Committee responded on the 28th of June 2012 
requesting some clarifications and amendments (See Appendix B). The main 
recommendation to affect the study was that the questionnaires were not 
suitable to be administered over the phone; therefore the questionnaires were 
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only administered by post to those people who had already taken part in the 
initial study and by interview or post to future recruited patients. The title was 
also amended to “adherence” rather than “compliance” as suggested by the 
Ethics committee and in the literature (218). 
 
Inclusion criteria for sub-study 
The sample were all the patients that were included in Beaumont Hospital 
“Aspirin effectiveness study in patients with stable coronary artery disease”, 
who were willing and able to sign the consent form and complete the study 
questionnaires. The total number for the sample was 189 patients, 156 had 
already been recruited into the national study by the time the ethics approval 
for the sub-study came through. A further 33 patients were then recruited into 
the national study and asked to take part in the sub-study at the same time. 
These patients were given the choice either to complete the psychological 
questionnaires in a face to face interview or to return the questionnaire by 
post. The inclusion exclusion criteria can be seen below. 
 
Exclusion criteria-for sub-study 
Patients who were unable or not willing to consent to, or complete the study 
questionnaires. 
 
Measures were amalgamated with the data collected from the initial national 
study measuring aspirin effectiveness in patients with stable coronary artery 
disease-these measures were-Demographics, risk factors for coronary artery 
disease, medical/ surgical history, medications; self reported adherence and 
Thromboxane B2 ELISA assay result.  
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All psychological predictor measurements can be found in Appendix B. 
 
Study setting and access 
The first 156 patients were sent the information leaflet, consent form and 
questionnaires in the post as this is the number of patients that had already 
been recruited into the initial national study- “Aspirin Effectiveness in Stable 
Coronary Artery Disease Patients in Ireland”, recruitment for this study was 
still ongoing and the inclusion/exclusion criteria was as above.  The 
subsequent 33 patients were given the questionnaire by interview in a private 
room in the out-patient’s department after agreeing to take part in both studies 
and signing the informed consent form. All patients were informed that both 
studies were voluntary and they were free to withdraw anytime as described 
in the information leaflet-(see Appendix B). Patients were reassured that their 
responses were confidential and would not influence their future treatment. 
 
Study Design- 
This study combined a cross-sectional, observational design along with a 
retrospective design. The cross sectional design was used for the initial stage 
of randomly selecting patients with coronary artery disease from the 
outpatients department, and the retrospective design was used for the 
patients that had already consented to the initial study but not the sub-study.  
 
Procedure 
Cross-sectional – interview 
Retrospective - postal 
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The blood sample to measure the thromboxane level and the self reported 
adherence questions were measured at the same time with all patients (as the 
self report question was part of the national study). The psychological 
questionnaires were only measured at this same time point in the patients 
recruited after patient 156, as previously mentioned this is when we received 
ethical approval for the current sub - study. The first 156 patients were sent 
the psychological questionnaires in the post but the questionnaires have been 
shown to be reliable over time (219) as shown in the literature review. This 
was considered not to be a significant influencing factor on how patients 
would respond but would be analysed in the results. 
Blood collection procedure 
When performing platelet function studies, it is important to limit inadvertent 
platelet activation. 
Veno-puncture can cause a degree of platelet activation. Multiple sticks and 
patting on the veno-puncture were avoided as per protocol. 
Blood was drawn by veno-puncture using a slow drawing back of the plunger 
using the starstedt monovette blood collection system and a 22g needle  
It was ensured that the tourniquet was not too tight or on for too long (less 
than 30 seconds) and released as soon as the blood flow started as 
recommended by the protocol, in order to avoid platelet activation. 
Samples were placed at 37 degrees Celsius within thirty minutes of blood 
draw (min of 30 minutes and max of 60 minutes on hot block) 
Note -“Arm to centrifuge time”- samples reached the centrifuge within 60mins 
of the blood draw. 
The sample was centrifuged at 900g (900rcf) for 10 minutes. 
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Serum was removed from the centrifuged sample using a pipette and divided 
into 3 serum aliquots which were clearly labelled with the individual patient 
identifier number for the study. 
All samples were stored at -80 degrees Celsius. 
All samples were meticulously managed to ensure the integrity of the samples 
and correct labelling storage, tracking and delivery to RCSI (215). 
Recorded variables 
The following demographic and clinical variables were recorded: age, gender, 
living with spouse /partner, employment status, education, private health 
insurance, alcohol intake, smoking history, hyperlipidaemia, weight, 
hypertension, diabetes, family history of coronary artery disease, physical 
activity, history of myocardial infarction, history of coronary artery bypass 
grafts, history of coronary stents. 
Employment is shown as a categorical variable (yes/no) by collapsing the 
subgroups down to the binary variable, as well as subgroup employment 
status in order to give a good overall picture of the responders and non-
responders, although there was no significant difference between the groups, 
or on adherence. 
Although smoking was divided into never, current, previous and cigar/pipe in 
the original questionnaire looking at demographic data, this was converted 
into a categorical variable of history of smoking or not. There was no 
significance in adherence between those that smoked and those that did not. 
Family history was also converted into a yes/no variable (although there was 
also an unknown option). These variables are shown as categorical for 
presentation purposes collapsing the above variables did not show or hide 
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any significant associations among the various versions of these variables 
and adherence.  
 
Questionnaires 
Beliefs about medicines questionnaires 
The necessity-concerns framework was assessed using the BMQ. The BMQ 
consists of two subscales - beliefs about medicines in general (BMQ-General) 
and specific beliefs about medicines a person is taking themselves, (BMQ-
specific) assesses patient’s beliefs about their prescribed medication. It 
consists of two subscales: firstly, the specific-necessity scale assessing 
beliefs about the necessity of their prescribed medication for controlling their 
illness and maintaining their health and secondly, the concerns about the 
adverse consequences of taking prescribed medication are assessed using 
specific concerns scale (132). Patients score their degree of agreement with 
each statement on a five-point Likert scale ranging from ‘strongly disagree’ to 
‘strongly agree’ (score range 1-5 for each question).  
 
The beliefs about medicines specific is divided into two sub-scales: specific 
necessity scale 5-25, with 5 being the lowest possible score and 25 being the 
maximum score and the specific concerns scale 5-25, also, with 5 being the 
lowest score and 25 being the highest score. A necessity-concerns differential 
score was calculated by subtracting the specific concerns scale from the 
specific necessity scale –range -20 to +20 as described by Horne et al. (17, 
132). A positive differential score indicates stronger necessity beliefs than 
concerns and a negative score indicates the contrary i.e. stronger concerns. 




The beliefs about medicines questionnaire - (BMQ) general consists of eight 
questions with a Likert scale ranging from strongly disagree to strongly agree 
(scores 1-5 for each question), thus the score can range from 8-40 with a 
higher score indicating a more negative general view regarding medications  
(See Appendix B).  
 
Brief Illness Perception questionnaire 
This questionnaire is based on Levanthal’s self-regulatory model of health 
management that describes the process by which patients respond to a 
perceived health threat (136). The questions relate to identity, timeline, 
consequences, and cause, looking at control and emotional factors showing 
the patient’s beliefs about the perceived symptoms of the condition, its 
duration, and nature. Negative beliefs surrounding the illness and treatment 
may lead to non-adherence to medicines (16). High scores regarding control 
and cure and illness understanding show positive beliefs about the 
controllability of the condition. This may lead to adherence to medicines (83). 
The brief illness perception questionnaire works in the same way as the 
illness perception questionnaire revised, but is much shorter and simpler and 
therefore more practical in the clinical setting (125).  
 
The Illness perception questionnaire suggests patients cluster their ideas 
about their illness around the components above to provide a framework for 
patients to make sense of their symptoms, assess health risk, and direct 
action and coping. The source of people’s perceptions of illness is diverse and 
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ranges from first hand experiences with a family member who may suffer from 
an illness, to information from their relatives and friends as well as the media. 
These perceptions may lie dormant until they are activated by their own 
illness or someone close to them (125). Each item of the Brief Illness 
Perception Questionnaire assesses one of the dimensions of illness 
perceptions as shown in Appendix B, and scores range from 1-10. The 
internal consistency of the score has previously been validated in patients 
with coronary artery disease (219).  
 
The Patient Health Questionnaire-2 (PHQ-2) 
As described in Chapter 4, Summers et al (147) advises only psychometric 
instruments that have been validated in the cardiac population such as the 
PHQ-2 should be used for depression screening.  
The PHQ-2 inquires (164) about the frequency of depressed mood and 
anhedonia over the past two weeks (220, 221). The PHQ-2 includes the first 
two items of the PHQ-9 and the purpose is to screen for depression in a first 
step approach rather than diagnose or monitor depression. Reducing 
depression evaluation to two screening questions enhances routine enquiry 
(153), keeping to a minimum the number of items asked about a single 
disorder is an important factor to ensure a reasonable length for such 
questionnaires and it has been suggested that this may be particularly 
relevant for research studies where asking a few questions rather than many 
questions can reduce the respondent  burden. A PHQ-2 score ranges from 0-
6. A cut-off score of 3 is suggested by authors (153) as the optimal point for 
screening purposes and state that a cut point of 2 would enhance sensitivity, 
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whereas a cut point of 4 would improve specificity. For the purpose of this 
study the PHQ-2 will be analysed as a continuous variable. Patients that are 
considered to be particularly vulnerable at the time of consent (patients 
showing visible signs of stress where the procedure of consent and 
phlebotomy would cause further distress, assessed by experienced clinical 
qualified nurses and doctors) would not be included as recommended by 
Fulford and Howse (223) and the Beaumont Hospital Medical Ethics 
Committee and HSE guidelines 2014 (approval letter Appendix B). 
It is recommended that unless vulnerable groups are going to benefit directly 
from the research they should not be specifically targeted. As the clinic is an 
outpatients cardiology clinic the amount of patients considered vulnerable 
would be minimal 1-2 and unlikely to bias the sample.     
 
 
ENRICHD- ESSI social support questionnaire 
As described in Chapter 5, the ENRICHD study (Enhancing Recovery In 
Coronary Heart Disease) was designed in response to the large amount of 
research showing the effects of social support on health outcomes. The 
questionnaire has shown good reliability and validity in cardiac patients in a 
later study by Vagilo et al. (204), thus the ESSI (ENRICHD Social Support 
Instrument) was chosen to assess social support. The majority of questions 
on the ESSI consider general feelings about being loved and valued rather 
than instrumental types of support. This assesses the theory that social 
support is more about patient’s belief that others care about them and are 
available if needed, rather than actual support services and that quality rather 
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than quantity seems to be more important in patients with chronic disease 
(183, 185). The social support is measured using a Likert scale of 0-4 with a 
possible maximum score of 24 and possible lowest score of 0 (See Appendix 
B). The final question assesses whether the patient is married or living with a 
spouse which will be assessed in conjunction and also separately to the other 
measures of social support. The ESSI appears to be a valid and reliable 
measure of social support in patients undergoing treatment for coronary artery 
disease (183).  
 
Adherence 
Adherence was assessed in two ways –self-report and objective. 
Self-reported adherence was assessed by asking the question: -“Number of 
days missed in the past week for whatever reason?” with an answer range of 
0-7. This question has previously been shown to be an effective measure of 
adherence in brief interviews (12, 222), this was looked at both dichotomously 
as yes/no and as a linear scale of 1-7. 
Objective adherence as assessed by using thromboxane B2 ELISA with a cut-
off point of > 2.2ng/ml indicating non-adherence as advised by Maree et al. 
(217). Adherence (i.e. <2.2ng/ml) is indicated with the value of 1 when 
dichotomised for statistical purposes, with non-adherence being classified as 
0 (greater than or equal to 2.2ng/ml).  
 
Statistical Analysis 
The collected data were entered into an Excel spread sheet and then checked 
for errors by simple inspection of the original questionnaires and the code 
book. The data was then imported into SPSS version 21 and combined with 
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the data from the original aspirin study. The data was examined using 
descriptive statistics and missing data was minimal (one or two questions in 
less than ten patients), therefore the mode for that person’s other items was 
entered as suggested by Tabachnick and Fidell (223), missing data was cross 
referenced with thromboxane level to ensure there was no correlation with 
missing data and lack of thromboxane result, i.e. were the patients that left out 
questions non-responders to aspirin and likely to be non-adherent. There was 
no correlation seen as the patients with missing data were all responders. 
 
Statistics were carried out on both groups separately (those that were 
interviewed and those that were sent the questionnaires by post) as well as 
one whole group to observe for any significant differences between the two 
groups. 
 
Data were analysed using descriptive statistics and Pearson’s correlations (for 
continuous variables). Logistic regression and t-tests were used to predict 
adherence or not to aspirin using demographic and clinical variables (binary 
variable: 1<2.2ng/ml, 0>2.2ng/l). T-tests were also used to assess differences 
in the psychological variables among those who were adherent and those that 
were not as determined by self-report and thromboxane effectiveness. Finally, 
a multivariate logistic analysis was conducted, including all significant 
predictors of adherence, in order to build a multivariate model that could be 
used to determine if these variables accounted for any potential psychological 
correlates of adherence. (Thromboxane was also analysed as a continuous 
variable - see Appendix B). Diabetes, smoking history and family history of 
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A total of 189 patients were approached to participate in the survey, and 106 
(56%) provided consent and completed the questionnaires. Of those 
approached, a total of 156 patients were sent the questionnaires via post and 
75 of these responded (48%). Patient recruitment for the national study was 
still ongoing at the time of ethics approval for the current study (sub-study), 
therefore the final 33 patients were asked to take part in both studies face to 
face in the cardiology outpatient clinic. When asked to complete the 
questionnaire face to face, 31 out of 33 (94%) of patients agreed to take part 
in the sub study, with most patients preferring to complete the questionnaire 
during their time in clinic although given the option to take the questionnaire 
away and return via post. Two patients took the questionnaire home from 
clinic with one subsequently returning the questionnaire by post. 
 
Table A1 in Appendix A, shows the demographic differences between the 
postal and interview groups. The only significant difference that can be seen 
between the postal and interview group in the sample who were approached 
to participate is in the employment status (see Appendix A). The combined 
sample (n=106; postal and interview groups) is compared to non-responders 
















Age (years) 63.1 (SD12.1) 67.6 (SD8.7) t=2.96,df=185 .003** 
Male Gender 81 (60%) 55 (40%) χ² =1.9,df=1 .168 
Living with spouse/partner 76 (58%) 54 (42%) χ²=2.23,df=3 .52 
Employed (yes) 
Employment status 
Disability retirement  





















































Private health insurance 38 (67%) 19 (33%) χ² =4.6,df=2 .097 
Alcohol intake in 4wks 52 (SD 64.5) 41 (SD 58). t=.95,df116 .340 
Smoking History 71 (68%) 57 (70%) Cramer’s v 
=.099,df=4 
. 763 
Hyperlipidaemia 95 (90%) 75 (90%) Cramer’s v 
=.085,df=2 
.959 





86 (54%) 73 (46%) χ² =.09,df=2 .394 
Diabetes 16 (50%) 16 (50%) Cramer’s v 
=.104,df=2 
.843 
Family History of CAD 41/106 (39%) 37/83 (45%) Cramer’s 
V=.067,df=3 
.840 
Moderate physical activity 
mean days/wk 
3.31 (SD 2.67) 2.76 (SD 
2.42) 
t=-1.47,df=185 .142 
History of Myocardial 
infarction 
53/106 (50%) 42/83 (50.6%) Cramer’s 
V=.030,df=3 
.982 
History of CABG 16/106 (15%) 16/83 (19%) Cramer’s 
V=.087,df=3 
.697 
History of Coronary artery 
stents 














Table 8.1 shows responders to the questionnaire were significantly younger in 
age, and significantly more likely to have a higher weight and higher 
education levels overall. No other significant differences were found. 
 
Potential differences between postal and interview groups for responders are 
assessed in Table 8.2 
 
There were no significant differences between the postal and interview groups 
in the sample of responders to the questionnaire, although those in the postal 
group were marginally more likely to be married. As no significant differences 
were found between the recruitment methods, the entire recruited sample will 
be analysed together from now on.
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Table 8.2 - The demographic difference between postal and interview 














Tbx effective<2.2 53/75 (71%) 17/31 (55%) Χ²=.1.79,df=1 .180 
Age (years) 64.1 (SD9.9) 60.5 (SD16.2) t=1.16,df=39.7 .250 
Male Gender-Male 58/75 (77%) 23/31 (74%) Χ²=.009,df=1 .920 
Living with spouse/partner 59/75 (79%) 18/31 (58%) Χ²=3.7,df=1 .054 
Employment status 
Disability retirement 



































Private health insurance 30/75 (40%) 8/31 (26%) Χ²=4.0,df=2 .131 
Alcohol intake in 4wks 50 (SD70) 61 (SD34) t=-.589,df=70 .558 
Smoking History 52/75 (69%) 19/31 (61%) Cramer’s 
V=.179,df=4 
.492 
Hyperlipidaemia 68/75 (91%) 28/31 (90%) Cramer’s 
V=,164df=2 
.241 
Weight mean (kgs) 87 (SD14) 85 (SD17) T=.676,df=104 .501 
Hypertensive/on anti-
hypertensive medication 
62/75 (83%) 24/31 (77%) Cramer’s 
v=.155,df=2 
.280 
Diabetes 11/75 (15%) 5/31 (20%) Cramer’s 
V=.269,df=5 
.177 
Family history of CAD 27/75 (36%) 14/31 (45%) Cramer’s 
V=.258,df=3 
.071 
Moderate physical activity 
mean days/wk  
3.5 (SD2.6) 2.6 (SD2.5) t=1.58,df=103 .117 
History of Myocardial 
infarction 
38/75 (51%) 15/31 (48%) Cramer’s 
V=.165,df=3 
.408 
History of CABG 9/75 (12%) 7/31 (23%) Cramer’s 
V=.220,df=3 
.163 






= Chi- Square, CAD= Coronary artery disease, CABG=Coronary Artery Bypass Grafts 
 
Adherence 
To investigate whether demographic or clinical factors were associated with 
thromboxane effectiveness, these data were stratified in Table 8.3. 
There was no significant difference between responders to the questionnaire 
and non-responders to the questionnaire in terms of thromboxane 
effectiveness/adherence-70/106 (66%) of responders to the questionnaire 
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were adherent compared to 61/83 (74%) of non-responders to the 
questionnaire- Χ²=.891, df=1, p=.345.  




Adherent Tbx<2.2 Non-adherent 
Tbx>2.2 
 
Statistic result TxB2 
effective p 
value 




60.4 (SD11.4) t=-1.61, 
df=104 
.109 
















































29/70 (41%) 9/36 (25%) Χ²=3.5,df=2 .173 










Smoking history 45/70 (66%) 26/36 72%) Cramer’s 
V=.222,df=4 
.266 
Weight (mean kgs) 82.5 (SD13.6) 93.9 (SD14.6) t=3.89,df=66 .001*** 








































3.42 (SD2.63) 3.11 (SD2.76) t=.561,df=103 .576 
History of myocardial 
infarction 
35/70 (50%) 18/36 (50%) Cramer’s 
V=.167,df=3 
.396 
History of CABG 9/70 (13%) 7/36 (19%) Cramer’s 
V=.189,df=3 
.286 
History of coronary 
stents 











Table 8.3 shows there were significant relationships between male gender, 
higher weight and alcohol intake as well as living with spouse/partner and 
response to thromboxane showing aspirin effectiveness. 
The Χ² value for self reported adherence and thromboxane adherence is 
Χ²=.239, df=1, p=.62.  
 
Five of the thirty six non-responders to aspirin therapy admitted to missing at 
least one dose in the previous week when asked directly regarding adherence 
at the time of blood draw. Six of the responders to aspirin therapy admitted to 
missing a dose in the last week. 
TABLE-8.4-The association between self –reported adherence and 









70/106(66%) 36/106(34%) Cramer’s 
V=.080,df=1 
.409 
Self reported  
 
94/106(89.5%) 11/106(10.5%) 
There was no significant correlation between self-reported non-adherence 
and non-adherence measured by thromboxane B2, in the responders to the 
questionnaire. Rejecting the hypothesis that self-reported non-adherence 
would correlate with non-adherence measured by thromboxane (although 
there was a significant correlation found when looking at the whole Beaumont 
sample of 189-Table A4). The demographic differences between the 
adherence measures are shown in Appendix A6 
 
Correlations between the psychological variables. 
The correlations among the psychosocial measures are shown in Table: 8.5 
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.35** -0.3 .31* .21* .18 .23* .40** .19 .68** 
ESSI Tot 
 -.10 -.21* -.10 .01 -.19 -.26* -.12 -.32** -.19 -.41** 
BMQ specific 
  -.58** -.11 -.04 -.24* .33** .39 -.12 -32** -.32** 
BMQ general 
   .37** .00 .38** .33** .39** .39** .26** .21* 
BIPQ-1 
    .17 .20* .07 .66** .49** .07 .47** 
BIPQ-2 
     .24 -.05 .19 .13 .00 .11 
BIPQ-3 
      .11 .34** .32** .32** .38** 
BIPQ-4 
       .09 .18 .44** .26** 
BIPQ-5 
        .45** .00 .46** 
BIPQ-6 
         .21* .54** 
BIPQ-7 
          .20 
PHQ-patient health questionnaire, BMQ-beliefs about medicine, ESSI-social support, BIPQ-beliefs about illness *=p<.05 **=p<.01 
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Significant positive correlations were shown between depressive symptoms 
and negative general beliefs about medicine,  the perception of how long the 
illness is going to last, perceived control over the illness, symptoms, concerns 
over the illness and how it affects the subject emotionally. There was a large 
correlation between depressive symptoms and how the illness affects the 
patients emotionally as expected. 
There was a strong positive correlation between concerns over the illness and 
how the illness affects the subject emotionally.   
Significant negative correlations were shown between depression and social 
support, and positive beliefs about medicine specific. 
There was also a negative correlation between social support and negative 
beliefs about medicines in general, and perception of the treatment helping. 
There was a strong negative correlation between social support and how the 
illness affects the subject emotionally and also concerns over the illness, the 




TABLE 8.6 - The relationship between self reported adherence and the 














Social support ESSI  19.5(6.1) 21.1(4.0) -.865,df103 0.389 
PHQ-2 Total Depressive symptoms 1.10(1,64) .55(1.03) 1.081,df103 0.282 
Beliefs about Medicines BMQ (specific) 33.6(5.8) 33.6(3.6) -.022,df103 0.982 
Beliefs about Medicines BMQ (general) 20.3(4.6) 21.8(5.6) -.960,df103 0.339 
BIPQ-1, how the illness effects your life 4.13(2.77) 4.18(2.08) -.062,df103 0.950 
BIPQ-2, how long the illness will last 9.15(2.27) 8.18(2.48) 1.321,df103 0.189 
BIPQ-3, how much control you have over your 
illness  
4.11(2.9) 2.91(1.57) 1.333df103 0.185 
BIPQ-4,how much you think your treatment can help 
your illness 
1.57(1.87) 2.00(2.19) -7.00,df103 0.486 
BIPQ-5,how much do you experience symptoms 
from your illness 
4.15(2.80) 3.27(2.37) .995,df103 0.322 
BIPQ-6,how concerned are you about your illness 5.29(3.48) 5.18(2.96) .096,df103 0.923 
BIPQ-7,how well you feel you understand your 
illness 
2.31(2.70) 1.27(1.84) 1.233,df103 0.221 
BIPQ-8,how much does your illness affect you 
emotionally 
3.70(3.38) 2.91(2.54) .750,df103 0.455 
 
 
There was no relationship between the psychological questionnaires and self 
reported adherence. 
There were also no significant correlations between the psychological 
variables and self-reported missed doses of aspirin using Logistic Regression. 
See Appendix TABLE A5 
 
 
The association between the psychological predictors of adherence and 
thromboxane levels are reported in table 8.7 
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TABLE 8.7- The association between the psychological predictors of 











Social support ESSI total  19.3(6.2) 20.3(5.2) .844,df104 0.401 
PHQ-2 Total Depressive symptoms) 1.04(1.76) 1.00(1.21) -.130,df104 0.896 
Beliefs about Medicines (BMQ specific)  33.8(5.2) 33.0(6.4) -.689,df104 0.492 
Beliefs about Medicines (BMQ general  20.7(4.8) 20.1(4.5) -.605,df104 0.546 
BIPQ-1, how the illness effects your life, Mean (SD) 4.11(2.78) 4.11(2.58) .006,df104 0.995 
BIPQ-2, how long the illness will last, Mean (SD) 8.96(2.52) 9.08(1.97) .261,df104 0.795 
BIPQ-3, how much control you have over your 
illness, Mean (SD) 
4.09(2.99) 3.81(2.45) -.483,df104 0.630 
BIPQ-4, how much you think your treatment can help 
your illness, Mean (SD) 
1.69(1.73) 1.53(2.21) -.404,df104 0.687 
BIPQ-5, how much do you experience symptoms 
from your illness, Mean (SD) 
4.21(2.98) 3.75(2.22) -.822,df104 0.413 
BIPQ-6, how concerned are you about your illness, 
Mean (SD) 
5.06(3.30) 5.69(3.60) .913,df104, 0.363 
BIPQ-7, how well you feel you understand your 
illness, Mean (SD) 
2.40(2.71) 1.81(2.45) -1.10,df104 0.273 
BIPQ-8, how much does your illness affect you 
emotionally, Mean (SD) 
3.54(3.46) 3.72(2.99) .264,df104 0.792 
 
 
There was no significant relationship between the psychological 
questionnaires and adherence measured with thromboxane B2. 
Rejecting the hypothesis, the psychological questionnaires would correlate 












In order to determine if any of the group differences could be masking 
associations, a multivariate analysis was conducted to determine the most 
important predictors of thromboxane response. This is shown in Table 8.8: 
 
TABLE 8.8 Multivariate analysis of the most important clinical and 
demographic predictors of thromboxane response. 
 
 






Gender male .000   .000  .999 
Living with 
spouse/partner 
  .325 .067 1.56 .161 
Alcohol intake 
in the last 4ks 
mean  
.979 .963 .996 .017** 






The above logistic regression was repeated without gender, which is shown in 
the appendix A8 - showing more significance in alcohol intake and weight. 
 
Both alcohol and weight seemed to be important factors, and therefore further 
analysis for each psychological predictor was conducted, adjusting for alcohol 
and weight. The results are in Table 8.9: 
 
TABLE 8.9- Multivariate analysis of the psychological indicators 
adjusting/controlling for alcohol and weight 








Social support ESSI  0.961 0.871 1.06 .431 
PHQ-2 Total Depressive symptoms 0.867 0.578 1.29 .488 
Beliefs about Medicines BMQ (specific) 1.013 .913 1.12 .807 
Beliefs about Medicines BMQ (general) .902 .777 1.04 .178 
BIPQ-1, how the illness effects your life .934 .750 1.16 .539 
BIPQ-2, how long the illness will last .985 .755 1.28 .911 
BIPQ-3, how much control you have over your 
illness  .985 .815 1.19 .878 
BIPQ-4,how much you think your treatment can 
help your illness 1.08 .769 1.54 .631 
BIPQ-5,how much do you experience symptoms 
from your illness .963 .776 1.19 .730 
BIPQ-6,how concerned are you about your 
illness .983 .835 1.15 .832 
BIPQ-7,how well you feel you understand your 
illness 1.104 .833 1.38 .387 
BIPQ-8,how much does your illness affect you 
emotionally .967 .807 1.16 .737 
 
 
Again, no psychological variable predicted adherence, even while controlling 




CHAPTER 9 – Discussion 
Introduction 
The current research study found no association between established 
psychological predictors of adherence and self reported non-adherence or 
objectively measured non-adherence. 
This chapter will give an overview of what we know already from previous 
research on the psychological indicators of medication adherence. It will 
compare the findings from the national study and then discuss how the 
current sub-study results are similar to the original national study. Exploring 
the relationships between the clinical characteristics of the sample and 
adherence measured by a thromboxane level of <2.2ng/ml. It will then discuss 
the results of the psychological aspects, which have predicted adherence in 
previous studies but had no significant correlation in this study. Finally it will 
discuss the limitations and the need for more randomised clinical trials before 
suggestions for interventions can be recommended to improve medication 
adherence. 
 
Previous research on the predictors of adherence  
Several studies have shown that adherence can range between nine percent 
in low income countries to sixty two percent in high income countries (8, 10, 
11).  
As described in Chapter 1, cardiovascular disease remains the single largest 
cause of death in Ireland (1). Low socio-economic status, lack of social 
support, stress at work and in family life, depression, anxiety and type D 
personality all contribute to the risk and poorer prognosis of CVD (3). These 
risk factors have also shown to act as barriers to effective treatment 
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adherence including medication adherence (4). Osterberg et al. (14) points 
out the importance of considering the psychological reasons for non-
adherence and to avoid labelling patients, which may stigmatise them in their 
future relationship with health care providers.  
Previous literature also supports the theory that the optimal threshold for 
adherence between medications is quite different due to pharmacokinetic and 
pharmacodynamic properties depending on the clinical setting. Immediately 
post coronary stenting the optimal threshold may be as high as 100%, 
whereas in other settings where patients are of low cardiovascular risk 
requiring statins, a clinically relevant threshold for defining adherence may be 
lower (23). Kronish and Ye (18) suggest that increasing our understanding of 
the optimal cut off point for adherence in cardiovascular medications may lead 
to a more precise understanding of the problem and the populations that 
adherence interventions should be targeted towards. 
 
It is estimated that there are 194,000 deaths and a cost of 1.25 billion a year 
due to medication non-adherence (24), so these figures indicate the potential 
improving medication adherence could have on improving health outcomes. 
When we look at the literature, most studies as shown in Tables 1, 2, 3 and 4 
have used self reported adherence which has been shown to overestimate 
adherence by 10-20% compared to objective measures (39), thus the savings 





The literature on adherence is inconsistent and often has conflicting findings, 
possibly due to the nature of non-adherence being complex and multifactorial 
(43). The literature on the Beliefs about Medicines Questionnaire (BMQ) 
claims peoples beliefs about medicines remain stable over time (17), but it is 
also claimed that patients’ conditions and circumstances have been shown to 
have an effect on adherence for example socio-demographic status, lifestyle 
including alcohol intake, disease severity and patient education (21, 68, 69). 
Previous consistent predictors have been beliefs about medicines, beliefs 
about illness, depression and social support (21, 71, 72) but these 
psychological predictors are also interdependent and can be influenced by the 
patient’s circumstances at the time. Research has suggested that the severity 
of the patient’s condition can also be a barrier to adherence, particularly if this 
is causing depression  
 
We can see from the previous study carried out by O’Carroll and colleagues 
(13) funded by the Scottish government looking at secondary prevention of 
stroke with aspirin therapy, that this study highlighted the importance of a 
valid and reliable tool to measure adherence, as patients generally over report 
medication adherence in a sociably desirable way. Unfortunately they found 
their measure of adherence using urine measurements of salicylate levels to 
be unreliable therefore this measure could not be used in their final analysis. 
A previous study looking at the role of weight and enteric coating on aspirin 
response in coronary artery disease patients showed the Thromboxane B2 
141 
 
ELISA assay to be a reliable measure in detecting aspirin adherence as 
several other studies (58, 214, 217) 
 
Beliefs about medicines 
The literature also suggests that the clinical nurse specialist plays an 
important role in identifying patients that are non-adherent in the clinical 
setting. Horne et al. (2) have demonstrated that beliefs about medicines were 
more powerful predictors of self-reported adherence than the clinical and 
socio-demographic factors in patients with coronary artery disease. 
Measurement of adherence if asked in a non-accusatory way by a research 
nurse have also correlated with 50% of the non-adherence measured with 
thromboxane B2 ELISA in a study carried out in our own institution previously 
(12). 
A review of the literature on beliefs about medicines showed mainly self 
reported adherence measures, and only two studies that used an objective 
measure of adherence- the UMPIRE study which included high risk 
cardiovascular disease patients (but not established coronary artery disease 
therefore not included in the table) where blood pressure and cholesterol 
levels in patients that were randomised to the “polypill” were monitored. There 
were significant but small reductions in systolic blood pressure and 
cholesterol levels. The Bermingham (104) study found a correlation with the 
Beliefs about Medicines Questionnaire and self reported adherence but not 
cholesterol level goal achievement. Thus there were no studies that used a 
reliable objective measure in patients with coronary artery disease. 
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As this is the first study to use the objective measure of thromboxane, it is 
possible this is why there were no correlations found with the Beliefs about 
Medicines Questionnaire. It is also of note that as patients were recruited in 
clinic by some-one that may not be viewed as completely independent to the 
clinical team, patients may have responded in a socially desirable way or 
worried how their answered might be perceived. There is also the possibility 
that the study wasn’t powered sufficiently to take this bias into consideration. 
 
Beliefs about illness 
The beliefs about illness questionnaire has not been without criticism (225), 
Van Out et al. (225) describes how in a cross-sectional observational study 
they found that patients had a number of problems completing the 
questionnaire and call into question the construct validity of this measure; 
Broadbent et al. (2011) disputes this study suggesting translational problems 
(226), but French et al. (2011) argue that it does not have robust 
psychometrics (135). 
A previous study by Petrie et al. (106) found that whether patients were sent 
the questionnaire in the post or recruited in the clinical area, was unlikely to 
have on the effect on patient’s perceptions of their illness. Byrne et al.’s study 
(100) looked at 1611 patients with established coronary heart disease; this 
study was designed to evaluate the use of the illness perception and 
medication beliefs in predicting secondary prevention behaviour among 
patients with coronary artery disease. Patients over 80 years old were 
excluded, and patients were recruited from GP practices so were likely to be 
less acute that patients recruited from a hospital. They also found that beliefs 
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about medicines were only moderately related to self-reported non-adherence 
explaining only seven percent of the variance. 
 
Aalto et al. (128) found that older patients perceived less symptoms of 
coronary artery disease and shorter expected timeline of the duration of the 
illness. It has been argued that older patients may have developed more 
effective coping skills and self-efficacy than the younger patients. They 
suggest that if we modify patients’ perceptions on self-efficacy and resource 
support, this may have a positive effect on medication and behavioural 
adherence, thus medical outcomes. Table 2 shows only two studies that used 
an objective measure of adherence and these studies were not predictive of 
other health outcomes. Brandes and Mullen (109) have concluded from their 
meta-analysis that the Brief Illness Perception Questionnaire (BIPQ) is weak 
in predicting adherence and may be more predictive of adherence in acute 
patients. Therefore the results from the current study of patients who are 
stable with coronary artery disease showing no correlation with the Brief 
Illness Perception Questionnaire (BIPQ) may not be entirely surprising. It is 
also possible that the full version of the illness perception questionnaire may 
have shown correlations but as discussed in chapter 3, the brief version has 
been shown to be valid and reliable and more user and patient friendly 
particularly when used with multiple questionnaires. 
 
Depression 
Several studies have shown a direct relationship between depression and 
non-adherence to cardiac medications and as well as a higher prevalence of 
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depression in cardiovascular patients (214). It has also been shown that there 
is a higher risk of cardiovascular disease in patients that suffer with 
depression than patients that do not. Positive beliefs and expectations are 
known to be essential for patients to adhere to a healthy lifestyle including 
adhering to prescribed medications. Only four studies in Table 3 show the 
relationship between depression and medication adherence in coronary artery 
disease patients. Two of these studies used self-reported measures of 
adherence (160,176) and two used electronic monitoring devices (173,175) 
where the patients were aware their medication adherence was being 
monitored and in a small group of patients (65-patients) that didn’t include 
patients over 75 yrs. This reduces the generalisability of the findings. 
Doyle et al. (227) found in their study of symptoms in patients with acute 
coronary syndrome (ACS), that people with symptoms of fatigue-sadness 
consistently predict prognosis whereas anhedonia and depressive cognitives 
did not. They suggest some aspects of depression are more cardiotoxic than 
others and it’s possible these were not measured in the current study using 
the brief depressive symptoms measure (PHQ-2). 
This is the first study to use the objective measure of thromboxane and 
although the patients knew their aspirin effectiveness was being measured 
they may not have realised non-adherence might also be inferred, thus this 
may be the reason why no correlation was found. Patients who know they are 
signing up for studies that will monitor adherence will generally behave 
differently if they know they are being monitored, “Hawthorne effect”. This is 





Previous studies have shown the strong link between social support and 
health outcomes in cardiovascular disease patients. Aggarwal et al. (201) 
found a significant correlation between patients who reported planning or 
having a paid caregiver and a 40% increase in medication adherence. 
Cardiac patients often rely on reminders from family members to carry out 
daily tasks such as medication taking and the theory is that paid caregivers 
are more accountable and trained than informal caregivers. There does 
appear to be more research showing that the presence of a spouse or partner 
increases medication adherence as well as health outcomes (202,205). The 
literature suggests that there is a two way link between social support and 
adherence in that the adherent patient tends to receive more support and vice 
versa. There is also the strong relationship between social support and 
depression, where patients that suffer from depression tend to isolate 
themselves and isolation tends to increase depression and can in turn lead to 
neglect of daily self-care activities including medication adherence. 
It can be seen from table 4 that there appears to be a lack of research on 
social support and medication adherence in coronary artery disease patients, 
with no studies using a direct measure of medication adherence with other 
important variables such as depression and beliefs about illness and 
medication. There was no correlation found between social support and 
thromboxane, possibly due to this being the first study to use this objective 
measure in coronary artery disease patients. There was a significant 
correlation found between patients that were married or living with a spouse 
and adherence (p=0.01). There was no remaining significance after 
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multivariate analysis of the most important clinical and demographic 
predictors; gender, weight and alcohol intake-Table 8.8. This is likely due to 
higher number of males and married/living with spouse patients in the sample 
population and also found in previous studies.    
A comparison of results from national study and sub-study 
The objective of the national study was to measure aspirin effectiveness in 
stable coronary artery disease using the thromboxane B2 ELISA assay in 8 
different centres in Ireland, there were 700 patients recruited in total (219). 
The results from this study shows good comparability to other studies with 
regard to the types of patients recruited, therefore should have a degree of 
generalisability. 
 
For the current sub-study, there were similar representations of patients by 
age, weight, gender, diabetes, hypertension, hyperlipidaemia, family and 
smoking history, and alcohol intake as shown in table 8.1.  The response rate 
was 56% n= 106 out of a sample frame of 189 patients in Beaumont which is 
acceptable and expected when using postal questionnaires (138, 228). The 
mean age of patients in total Beaumont sample was 65 years, whereas the 
mean age in the responders to the questionnaire group was slightly lower at 
63 years. There was a higher percentage of non-responders to aspirin in the 
current sub-study 34% compared to the national study 20%, this may be due 
to the areas where the patients were recruited i.e. patients recruited in 
Beaumont were mainly from the out patients department, 92% compared with 
other sites where patients were recruited in cardiac rehabilitation (8% of 
Beaumont hospital patients were recruited from cardiac rehabilitation, 100% 
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had an effective response to aspirin). The remainder of the patients were 
recruited from out-patients. Patients are more likely to be adherent due to a 
more recent cardiac event and closer monitoring as well as showing signs of 
adherence by attending cardiac rehabilitation, as shown in previous studies 
(229). 
 
The findings from the national study were that patients that were overweight 
and had a higher alcohol intake were more likely to have an ineffective 
response to low a dose aspirin of 75mgs (215). The findings in the sub-study 
supported these conclusions as with similar studies recently (13). There was a 
significant negative correlation between alcohol consumption and aspirin 
effectiveness as with the larger national study. This is consistent with the 
literature that shows significant correlations between high alcohol intake and 
lack of medication adherence (230). This has been previously shown in 
studies looking at adherence to HIV medication (230), but the interventions  
used to increase adherence in this cohort of patients failed to deliver 
significant improvements (231). The randomised clinical trial that was carried 
out by Somet et al. (230) to enhance antiretroviral medication in patients with 
a history of alcohol problems did not show significant improvements using  a 
targeted intervention on adherence to medication, but they do suggest that 
addressing alcohol problems may lead to an increase in medication 
adherence as this was the main predictor of non-adherence (236). They found 
that patients that managed to abstain from alcohol increased their adherence 
therefore addressing the issue of high alcohol consumption is likely to 
increase adherence in other groups of patients, including patients with 
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coronary artery disease. Several studies have been completed on patients in 
Ireland that suggest 25% of all admissions to hospital are alcohol related 
(232). Addressing high alcohol consumption is likely to have a beneficial effect 
on adherent behaviours including medication adherence. There was no 
correlation between alcohol consumption and self reported adherence or the 
psychological variables, possibly due to patients responding in a socially 
desirable way. It is interesting that patients admit to their high alcohol intake, 
possibly due to an accepting alcohol culture that can be seen in practice and 
from the above literature.  
The current sub-study found responders to the questionnaire were found to be 
significantly younger in age with a significantly greater likelihood of having a 
higher weight and higher level of education. There were no significant 
differences between the patients that responded by interview questionnaire or 
by post, in either the demographic data or the psychological questionnaires, 
although the responders by post were marginally more likely to be currently 
living with a partner or spouse. 
 
Strategies suggested by the Department of Psychiatry and Behavioural 
Medicine from the University of Florida, advise on the importance of the 
provider–patient relationship. They advise on establishing a trusting 
relationship with the patient, assessing patients’ understanding of the disease 
state and treatment, involving the patients in setting treatment goals, while 
assessing the patient’s readiness to adhere to a plan. They suggest tailoring 
regimens to fit within a daily routine, providing written instructions (233). This 
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has been previously recommended by researchers suggesting a 
multidisciplinary approach is the way forward (234).  
This is the approach that can be observed currently in the outpatients 
department and cardiac rehabilitation where the experienced health care 
providers understand the importance of adherence and take the time to 
reinforce the necessity of anti-platelet therapy. The success of the 
experienced multidisciplinary approach can be seen from the 8% of patients 
that were recruited from cardiac rehabilitation, where there was a 100% 
response rate to aspirin therapy.     
 
Thromboxane level as an indicator of adherence 
The results from the national study and the sub-study are consistent with 
previous findings looking at aspirin resistance or lack of adherence (12, 14) 
showing that between 20-35% of patients are inadequately inhibited.  
Self reported adherence was assessed in the initial national study ”Aspirin 
effectiveness in stable coronary artery disease”, whereby patients were asked 
if they had missed their aspirin dose in the last week either intentionally or 
unintentionally (235). There is conflicting evidence in the literature which 
supports this as an accurate measure of adherence due to socially desirable 
responding (13), but it is expected that if patients admit to not taking their 
aspirin that this should correlate with the measure of thromboxane (12).  
Grove et al. (236) found in their comparison of platelet function tests and 
thromboxane metabolites to evaluate aspirin response that conclusions based 
on platelet function testing strongly depend on the assay used. They found 
that serum thromboxane and the VerifyNow aspirin test were the most reliable 
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assays. Blais et al. (237) suggest that some of the variability in the reported 
“resistance to aspirin” is unrelated to aspirin intake, but more likely to do with 
the limitations of the assays to detect aspirin or due to the variability of platelet 
activity independent of aspirin mediated cyclooxygenase-1 inhibition. 
Frelinger’s (238) study supports the above findings stating that the term 
aspirin resistance is inappropriate for the same reasons, although suggests a 
cut-off point of < 3.1ng/ml rather than < 2.2ng/ml, whereas Seidel (239) 
suggests a serum thromboxane level of <2ng/mg reflects aspirin induced 
inhibition with high sensitivity. Cattaneo (65) states that sub optimal response 
to aspirin as determined by serum thromboxane is rare and in most cases 
caused by poor adherence. Overall, it seems that <2.2ng/ml is an optimal 
threshold, and this is what was used in the present study. 
This measure of aspirin effectiveness on thromboxane level appears to be the 
most reliable from looking at the literature (238) i.e. compared with urine 
salicylic acid which was used in a similar study (13) and was not a reliable 
indicator.  
The results from the Beaumont Hospital cohort (189 patients) showed a 
significant direct correlation between self reported missed days and lack of 
response to aspirin using the binary variable of 2.2ng/l as suggested by 
Maree et al. (217). Although the correlation wasn’t as strong as one would 
expect, this was thought possibly due to confounding variables, such as 
hyperlipidaemia or hyperglycaemia, found to have an effect on platelet 
aggregation in previous studies (14, 240), which the authors suggest may 
have an effect on the aspirin response. However, there was no significant 
correlation between patients with hyperlipidaemia and diabetes and an 
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ineffective response to aspirin therapy that would suggest the presence of 
these conditions would have a confounding effect. It should also be 
remembered, that emotional stress has been shown to increase platelet 
aggregation (241), although this was not directly measured in the current 
study, there were no correlations found between the psychological variables 
and thromboxane effectiveness that would suggest this had an effect on 
thromboxane inhibition. 
  
The patients may also be responding in a way that is socially desirable. As the 
information was being taken by a nurse who was not completely independent 
from the medical team there is the possibility that patients were not 
completely reassured that their information regarding non-adherence would 
be completely confidential (13), fearing being labelled as non-compliant or 
non-adherent in the future (15). This is also a possible reason for not seeing a 
correlation in self-reported non-adherence and non-response measured by 
thromboxane.  
 
Although there are substantial improvements in the platelet function assays 
available, there still remains uncertainty surrounding how best to use the 
available assays and insufficient evidence to support adjusting anti-platelet 
therapy that will improve clinical outcomes (8, 65). 
 
Cattaneo (59) states that two important issues should be taken into 
consideration when measuring platelet function in Vitro in patients on 
treatment with anti-platelet agents: the specificity of the laboratory tests for the 
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platelet activation pathway targeted by the drug and whether or not the 
laboratory test is performed both before and after administration of the drug. 
Due to the risk involved in stopping aspirin therapy in cardiovascular patients 
for the purpose of this study thromboxane B2 was only measured after 
ingestion. It could also be argued that clinically the therapeutic effect after 
prescription is the most important measure particularly in the acute situation, 
post-acute coronary syndrome or pre-percutaneous coronary intervention 
(PCI). 
  
Overview of the Psychological variables in the current study 
There was no significant correlation between the psychological variables and 
thromboxane level either as a binary variable (or as a continuous variable – 
see Appendix B). This raises the question whether the psychological variables 
are good predictors of adherence in a random sample which previous 
substantial research including systematic reviews, have shown they do. 
Findings from the Beaumont Hospital sub-study show some support for self-
reported non-adherence where there was a significant negative correlation 
with thromboxane response when looking at the whole sample frame of 189 
patients r= -162. Whereas the correlation from the responders to the 
questionnaire group was r= -080. It is possible, that if the response to the 
psychological questionnaires were higher, the study would have more power 





The literature in previous studies has found significant correlations between 
psychological indicators and medication adherence therefore it is surprising 
that there were no significant correlations in this current sub-study. As 
patients in the present study were recruited from the precursor study, patients 
suffering with extreme depression were less likely to be overly represented, 
due to practical and ethical requirements (48). It is also possible that patients 
with more severe depression may be less likely to attend for their outpatients’ 
appointment. A recent meta-analysis of studies looking at the association of 
depression following myocardial infarction and cardiovascular events, showed 
forty percent of patients had major or elevated symptoms of depression (141). 
The authors suggest that some studies may over represent depression due to 
the oversampling of patients with depression. This may explain the lack of 
associations found with depression and adherence in the current sample.  
 
Recent studies suggest, that in most cases non-adherence is intentional and 
due to perceptual barriers (51, 242). Researchers point out that the common 
sense model does not take intention into account, but the theory of planned 
behaviour does, and this may be superior in predicting adherence. Here again 
the research and evidence is conflicting. Sniehotta et al. (91) state that the 
theory of planned behaviour is no longer a plausible theory of behaviour 
change, and social cognitive models seem to be most predictive in the young 
and fit who are not representative of the population where behaviour change 
is most needed. DiMatteo and colleagues (112) suggests mental 
representations may be more appropriately measured via interviews. 
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Brandes and Mullen (109) point out that there is no “gold standard” for 
measuring mental representations or adherence and this could account for 
variations across studies confounding the results and findings. The authors 
conclude from their research that the relationships between different mental 
representations of the common sense model and adherence are very weak 
ranging from –0.02 to 0.12 and thus may not be the most appropriate model 
to use in predictive studies of adherence, although they acknowledge the 
Common Sense model may predict adherence in acute patients. 
 
There was a strong inverse correlation between depression score and 
perception of social support as seen in previous studies (221). There was a 
significant direct positive correlation between depression and the length of 
time the patients felt their illness would last; more symptoms; and the more 
concerned they were about their illness (243). The higher the depression 
score the more the illness affected them emotionally but also the more they 
felt they had control over their illness. The higher the depression score the 
more negative in general regarding medications, similar to other recent 
studies (13). In general the more strongly the person felt about their illness or 
their medications the higher they scored on the depression scale which is 
similar to previous research (3). Therefore, the correlations between 
depression and the other psychological constructs were largely as expected, 
yet depression still did not predict thromboxane level. It is possible that using 
diagnostic interviews would demonstrate an association with thromboxane, 




There have been recent discussions on the reliability and validity of shortened 
versions of psychological questionnaires (244) suggesting that they may be 
practical from a clinical point of view but not as reliable or valid from a 
psychometric point of view. Longer questionnaires tend to ask the same 
question in different ways adding to their validity and reliability, but 
measurement precision may be impaired considerably without the 
investigators realising (244, 245).  
 
Interventions to promote adherence  
Zimmerer et al. (2009) (246) describes how a Cochrane review showed only 5 
out of 21 randomized and controlled studies concerning the improvement of 
adherence demonstrated significant success. However, half of the studies 
displayed methodological errors that weakened the statistical detection of 
improvement because of the low numbers of patients. 
Electronic methods for compiling drug dosing histories are now the 
recognised standard for quantifying adherence advised by some authors 
(247) suggesting that the frequency of inadequate adherence is usually 
underestimated by pre-electronic methods. With some researchers 
suggesting that in the near future, one could imagine that medication 
adherence data over an entire therapy plan would be available as soon as the 
electronic wires are activated, so that a failure to take medication could be 
detected immediately and intervention could be taken if appropriate. 
Others suggest the need for further study and dissemination of findings 




Recent recommendations from authors in the United States suggest a 
translational research approach (249, 250) whereby a point of care device will 
show the effectiveness of aspirin and other anti-platelet medication at the 
bedside to determine effectiveness regardless of the reason for lack of 
effectiveness. This will not be possible until there is consensus on the gold 
standard for measuring aspirin effectiveness at the bedside that proves to be 
cost effective on patient clinical outcomes (65). The Fifth Joint Task Force 
suggests that once acute emotional triggers and their mechanisms of action 
are understood and patients who are at risk are identified, strategies can be 
drawn up to prevent or minimize the risk to these patients. They acknowledge 
that it is difficult to speculate on the types of interventions and give examples 
of prophylactic therapies for high risk populations, anger or stress 
management, prescribing B-adrenergic blocking agents or avoiding the known 
triggers (4). Current recommendations and guidelines from the Fifth Joint 
Task Force states ‘evidence suggests that reducing dosage demands is the 
most effective single approach to enhancing medication adherence.’ 
Several studies have shown that the most effective time for intervention for 
education regarding healthy lifestyle and adherence is immediately post an 
acute coronary event. This is likely to be due to firstly the knowledge that 
medication has saved the patient’s life and trust in the treating health care 
providers, but also due to the support and environment that promote patients’ 
adherence. It would appear from the current literature that if the support and 
encouragement is continued post discharge as with cardiac rehabilitation 
patients, this can increase medication adherence as well as adherence to a 




Gaps in the evidence 
The Fifth Joint Task Force (4) has acknowledged that there are major gaps in 
the evidence. They state that there is limited evidence about which 
interventions are the most effective and in whom (e.g. young–old, male–
female, high–low socio-economic status) while also suggesting that reducing 
the amount of medications dosages such as using the ‘polypill’ requires 
further evaluation before it can be judged suitable for use in routine care (4).  
Meanwhile the Agency for Healthcare Research and Quality in the United 
States has recently published a report (251) where their aim is to close the 
quality gap in healthcare by improving medication adherence interventions 
and their effectiveness. They found the least evidence for interventions for 
Myocardial Infarction (MI), only one study where there was an insignificant 
result from an education and behavioural intervention, suggesting low 
strength of evidence in the benefit of interventions in this group of patients. 
Thus, pointing out the need for further research in this cohort of patients in the 
future. 
They state that there is no “silver bullet” to improve medication adherence but 
it is typically the result of patient, provider and policy factors.  
Further research is required using psychological questionnaires and objective 
measures of adherence. 
 
Implications for practice 
This study would support the use of reliable assays, such as the ELISA 
thromboxane B2 assay, in identifying patients that may be non-adherent and 
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addressing the reasons why, at the time, in a non-judgemental way. It is 
important that this is acceptable to the patients and the development of more 
patient friendly point of care assays, would be an advantage.  
 
The World Health Organisation (WHO) states that: “Without a system that 
addresses the determinants of adherence, advances in biomedical technology 
will fail to realize their potential to reduce the burden of chronic illness”(45). It 
is recommended by the WHO that non-adherence is most effectively solved 
by individualised interventions addressing the multiple factors affecting 
adherence which include; socio-economic factors such as unemployment, 
lack of health insurance and limited social support networks. 
 
We can see from the literature review above the importance of the different 
types of support including practical and social on medication adherence. It is 
also noted that information in itself is not sufficient to promote change but 
motivation, and behavioural skills are also critical determinants (3). This report 
by the WHO recommends self-management programs that provide both 
supportive and educational coaching interventions as multiple studies have 
associated coaching with improved health behaviours (252). The report also 
highlights the association between non-adherence and lack of health literacy, 
motivation and self efficacy in one’s ability to manage one’s condition; this can 
be explored with the questions included in the illness perception questionnaire 
and the beliefs about medicines questionnaire. Researchers from the COPE 
study (202) suggest that healthcare providers use the mnemonic COPE to 
assist them in using the four significant coaching concepts; connectedness 
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and collaboration, open ended questions, positive attitude and 
encouragement and support which have been shown to improve medication 
adherence.  
 
The WHO advises that dealing with the factors above as well as addressing 
complex medication regimens and side effects, will enhance patient 
motivation and behavioural skills which are crucial in improving medication 
adherence. The 2010 Patient protection and Affordable Care Act (ACA) for 
healthcare reform provides financial incentives for health coaching where 
health plans will include expenditures for interventions that increase wellness 
and promote health (253). Dulmen (197) found in their review of interventions 
to medical treatments that interventions based on reminders and incentives 
can be successful in improving patient adherence and reflect the behavioural 
theories that show human behaviour depends on stimuli or cues that produce 
certain responses or rewards that reinforce behaviour. Reminders can act as 
cues or stimuli and incentives can act as rewards, which may maintain the 
behaviour after sufficient repetition. The authors note however that reminders 
to take medication can be less amenable than other forms of behavioural 
change and this is a question for future research. 
 
Dulmen’s (86) research re-enforces what Leventhal et al. (136) has previously 
shown, that not only do patients need to be adequately informed and believe 
in the message, but also believe in the messenger, which is helped by the 
healthcare professional having adequate training, empathy, friendliness, 
interest and concern (197). This is echoed by Zolnierek and DiMateo’s (254) 
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meta-analysis looking at physician communication and patient adherence to 
treatment, where they found a nineteen percent higher risk of non-adherence 
in patients whose physician communicated poorly, than those whose 
physician communicated well (the odds of a patient adhering were 2.16 times 
better if the physician is a good communicator P<.001) and training 
physicians in communication skills improved patient adherence by twelve 
percent. The authors argue that this figure is quite impressive when compared 
to medical interventions such as Tamoxifen in the prevention of breast cancer 
(.04%), plavix for reducing risks of cardiac events (.04%), and low dose 
warfarin preventing blood clots (15) (75). 
 
Recent studies advise that because of the potential impact on patient 
outcomes, there is a pressing need to improve not only on patient anti-platelet 
adherence but also on provider anti-platelet therapy adherence management 
in cardiovascular disease (115). 
 
Implications for future research 
The previous research appears to be convincing supporting serum 
thromboxane B2 ELISA level of 2.2ng/l as a measure of effectiveness and/or 
a measure of adherence to low dose aspirin 75mgs (217). Gremmel (255) 
suggests that large trials with clinical outcome data are required to determine 
the diagnostic value of the various test systems and to define the gold 
standard method for assessing platelet activity, this is supported by a recent 
study (216). It would be an advantage if future studies incorporated other 
measures of adherence, such as Medication Event Monitoring Systems, pill 
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counts or pharmacy refill data to further validate the assay. The disadvantage 
of these measures has previously been discussed, i.e., they are expensive 
and patients may know that their behaviour is being monitored. 
It would be of benefit if the study could be repeated in larger samples or other 
sites to determine if the findings are by chance or replicated. 
Longitudinal studies would be an added advantage observing for fluctuations 
of adherence over time rather than a once off and examining whether there is 
a relationship with the psychological variables and adherence over time.    
Beliefs about Medicines and illness 
The NICE Medicines Adherence Guidelines suggest applying a perceptions 
and practicalities approach when addressing non-adherence issues (111). 
Horne et al. (111) describe how non-adherence can be unintentional when the 
patient lacks capacity or resources, or intentional when the patient decides 
not to follow the recommendations which they describe as perceptual factors, 
where the beliefs and preferences influence whether the patient starts and 
continues with the prescribed medication regimen. The authors highlight how 
prescribing consultations are influenced by pre-existing beliefs about the 
illness and treatment by both prescriber and patient. This needs to be 
considered by healthcare providers when prescribing in order to optimise 
adherence and outcomes. They acknowledge the influence the economic and 
health care system have on adherence, but suggest that beliefs are 
fundamental in the prescriber/patient shared decision making process. 
 
In this meta-analysis of studies using the Necessity Concerns Framework 
(Beliefs about Medicines) Horne et al. (111) found that eighty three studies 
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(88%) used measures of self reported adherence and eleven (11.7%) used 
other measures of adherence, such as pharmacy re-fill data and electronic 
monitoring. The association between concerns and adherence were smaller 
but still significant when objective measures were used and the heterogeneity 
around this estimate was small. The association between necessity beliefs 
and adherence did not differ between self report and an objective measure. 
They suggest that self report measures have high face validity and high 
specificity for non-adherence but agree that self report may be subject to 
recall bias and responding in a socially desirable way which may over 
represent adherence rates. The authors claim that this does not diminish their 
confidence in their findings that beliefs about medicines were related to 
adherence, since there is no evidence that such bias would be associated 
with medication beliefs. They argue that some patients with low necessity 
beliefs and high concerns about medicines could be expected to report higher 
rates of adherence in order to represent themselves positively and this pattern 
would increase the relationship between adherence and medication beliefs.  
 
However it could be hypothesised that patients with more concerns would 
report their concerns but still remain adherent due to their concerned nature 
and worrying about their health i.e. Neuroticism (132). Horne et al. (111) state 
that the relationship between adherence and beliefs about medicines 
remained when objective measures were used, therefore this was not an 
artefact arising from the use of self reported measures. They do suggest 
using objective measures of adherence in future research and concentrating 
on conditions where there is further evidence needed. There were only four 
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studies in patients with Coronary Artery disease in this meta-analysis since 
the development of the Beliefs about Medicines Questionnaire( BMQ), with 
only one using the objective measure of blood pressure medication and lipid 
lowering therapy (103). Eighteen of the studies reviewed in this meta-analysis 
assessed whether beliefs about medicines could predict adherence using 
longitudinal or prospective designs. The authors state that the relationship 
was not reduced in these studies therefore they believe that medication 
beliefs have an influence on the self-regulation of illness and continued 
adherence. Using the self-regulation theory of beliefs about illness, the patient 
is guided by the nature, duration, cause, consequences and potential for cure 
or control of the illness and this is linked to whether they will adhere to their 
medication or not (70). 
 
Another limitation noted in the above literature review of the BMQ (beliefs 
about medicine Questionnaire) was that studies outside of the United 
Kingdom (UK), where the disease specific modifications have mainly been 
developed, have reduced associations with adherence. Again, they 
encourage future research, which will examine the variations in the 
relationships that may be due to cultural differences, and differences in the 
health care system accessibility and economics. 
 
Non-adherence may seem irrational particularly from the perspective of 
biomedicine and prescribers but non-adherence may be a common sense or 
informed choice response for some patients. The challenge going forward 
would be to assess misconceptions about illness and treatment and to avoid 
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prescribing unwanted treatments for the benefit of patients, prescribers and 
taxpayers.  
 
Patient’s beliefs about their illness and medicines specifically and in general 
has previously been shown to have a significant effect on behaviour and 
medication adherence, where the patient will carry out a cost/benefit analysis 
which may not always be rational as previously explained in Chapter 2 and 
Chapter 3. Concerns regarding medications are not limited to side effects but 
are also common even when they are well tolerated, patients worry about the 
long term effects, dependence, and cost of medications (17). More general 
beliefs perceiving medications as intrinsically harmful and over prescribed by 
doctors have also been shown in the literature (84), while package information 
leaflets dispensed with many prescription medicines have been shown to 
exacerbate concerns listing all possible side effects leaving patients confused 
regarding the likely risks and benefits in taking the medication. 
 
Horne et al. (84) highlights non-adherence as a hidden problem due to patient 
reluctance to express doubts regarding their illness and treatment for fear of 
being perceived as non-compliant or untrusting in the prescriber. They 
suggest that the first step in promoting adherence is a “no-blame approach” 
that encourages an open and honest discussion to identify non-adherence 





Future studies should consider personality measures i.e. type D personality, 
as recommended by the literature (256) and by the Fifth Joint Task Force (4). 
Also Uchino et al. (187) has pointed out that there may be design issues when 
it comes to previous studies looking at psychological measurements and 
health related outcomes and advises that researchers may need to model 
changes over time in social support. Most studies use a cross sectional 
design and in such studies it is assumed that the health related state is 
captured adequately at that point in time, whereas there may be other 
confounding variables.  
 
Emilsson et al.’s (132) study, on personality traits and beliefs about medicines 
showed that personality traits, such as neuroticism particularly in men, was 
associated with lower adherence to medication. They advise that healthcare 
professionals be aware that a person who has a tendency towards 
neuroticism is likely to have barriers to taking medication grounded on 
concerns about potential adverse effects and the way they balance the 
perceived benefit (necessity) against the perceived risks (concerns). Williams 
et al. (256) agree that there has been considerable uncertainty regarding the 
role of personality factors and the risk of CVD with the resurgence of looking 
at personality type as a risk factor in the long term prognosis of cardiac 
patients. They suggest studies over the last 10 years have shown type D 
personality to be predictive of adverse clinical and psychological outcomes in 
cardiac patients. They describe how a 6-10 year follow up study of cardiac 
patients who were classified as type D had a fourfold mortality risk compared 
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with non type D patients. Type D construct has been criticised by some 
theorists who argue that type D personality is simply another measure of 
negative affectivity or neuroticism which tells us nothing new about the 
psychological risk factors associated with CVD. However it is the combination 
of negative affectivity and social isolation that is crucial (256). They advise 
that if type D is associated with health related behaviour, then this provides a 
clear target for intervention.  
 
The European Society of Cardiology- Fifth Joint Task Force (4) suggests 
evidence that treatment of clinically significant depression and anxiety will 
improve cardiac endpoints is still inconclusive. They advise a focus on acute 
emotional triggers that may represent the final steps in a pathophysiological 
pathway that culminates in an occlusion or thrombosis, either by triggering the 
occlusion by vasoconstriction, or by exacerbating an already ongoing 
occlusion through thrombotic effects. The Task Force suggests that by 
studying experimental or naturalistic exposure to acute emotions, we can 
begin to understand the neuroendocrine/vascular/thrombotic reactions to 
emotions that could then be targeted for future novel and preventative 
therapies. The study of emotional triggers offers the possibility of improving 
our predictive models if we include them in future randomised clinical trials. 
Identifying patients that are vulnerable to emotional triggers may lead to both 
pathophysiological insights and improved risk stratification (4). 
 
The questionnaires used need further validation as tools for predicting 
adherence in the clinical setting, preferably with other objective measures of 
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adherence. A recent study by Allenet et al. (37) identifies the difficulties in the 
various methods of measuring adherence either directly or indirectly, 
suggesting a crossover of the various methods that allow an idea of the 
adherence of the behaviour of the patient which will inform health care 
providers which dimension to concentrate on. The importance of adherence 
has been well recognised by the World Health Organisation and researchers 
showing that patients who adhere to their medical treatment regime are three 
times more likely to experience positive health outcomes (257). 
As Halaris (170) advises, it is only through a multidisciplinary approach and 
cohesive intervention that we can succeed in unravelling the complex 
relationships between mental stress, inflammation, immune responses and 
cardiovascular disease. Uchino et al. (198) suggests a multilinear approach 
with a longitudinal design that incorporates social economic status may have 
success in documenting mechanisms responsible for the links between 
psychological variables and health.  
 
Limitations and strengths 
This study has several design limitations that should be noted. 
The size and diversity of the sample is limited to the patients that took part in 
the initial study “Aspirin Effectiveness in Stable Coronary Artery Disease 
Patients in Ireland” that attended Beaumont Hospital and were interested in 
taking part in the initial study and then the sub-study. The population number 
and make-up limits the ability to generalize these results to the general 
population, although all patients were selected at random in the original 
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sample and are thought to be a good representation of outpatients attending 
Beaumont hospital with documented stable coronary artery disease.  
 
Due to the practicalities and time constraints of the busy cardiac outpatients, 
the psychological questionnaires used were limited to four constructs that 
have previously shown correlations with adherence, although mainly self-
reported. The use of a brief scale instead of a diagnostic interview for 
depression may have detracted from the findings. A recent study by Phillips et 
al. (245) suggest the BMQ should be analysed differently and researchers in 
the field are using suboptimal methods. 
The type of medication dispenser was not recorded (blister packs or not) as 
Glynn et al. (258) have previously found in their systematic review of the  
literature on interventions to improve cardiovascular medications, this had  no 
effect on adherence , although it may be of value in future larger studies. 
 
 The study was strengthened by using a direct assay measure, and the 
simultaneous measures of each construct, in a relatively large sample of 
patients with stable coronary heart disease. Although the response rate would 
have been higher if all patients were recruited by interview rather than by 
post. This would have added to the power of the study and may have shown 
more significant correlations as seen between the self-reported non-






Although most psychological variables correlated with each other as 
expected, no psychological variable was associated with adherence as 
assessed by thromboxane B2 ELISA assay level. Researchers have 
consistently found testing patients’ inhibition to anti-platelet therapy will detect 
significantly larger numbers of non-adherent patients than verbal questioning. 
Previous studies have also shown that a single low dose of aspirin 75mgs, will 
inhibit arachadonic acid measured by light transmission aggregometry (LTA) 
or thromboxane B2 for greater than or equal to three days. This would 
suggest that patients who were not adequately inhibited had been non-
adherent for greater than three days (66). It therefore seems that the 
psychological factors measured in this study were not correlated with 
adherence to aspirin therapy in stable coronary artery disease patients, 
although further research is required to confirm this. 
 
As with the national study, high weight and high alcohol intake had a 
significant correlation with non-adherence. It would appear due to the clinical 
time and cost constraints in the hospitals that the way forward would be to 
identify non-adherent patients in the clinic who may benefit from a multi-
disciplinary approach with the help of pharmacists, psychologists, social 
workers doctors and clinical nurse specialists.  
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Table Appendix 1 shows the descriptive statistics of the sample of patients 
who were approached to participate.
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Table Appendix A1: Demographic differences between postal and interview groups. . 
 
DEMOGRAPHIC TOTAL POSTAL INTERVIEW Statistic. result p-value 
Questionnaire administered 189 156 33   





Mean weight (kgs) 
Minimum weight (kgs) 
Maximum weight (kgs) 


























Sex – Males 
           
136/189(72%) 
   
110/156(71%) 
    
26/33(79%) 




living with spouse/partner(whole 
sample) 
living with spouse/partner who 


























































































































































The only significant difference that can be seen between the postal and interview group in the sample who were approached to 




A table showing the relationship between the demographic data of the whole sample and thromboxane effectiveness is shown in 
table APPENDIX- table A 2 
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TABLE A2-Demographic data and thromboxane effectiveness. 
DEMOGRAPHIC TOTAL Statistic.result TxB2 effective p 
value 














Sex – Males 
          Females 
136/189(72%) 
  53/189(28%) 
Χ²-5.6, df1. .018 
Living with spouse/partner (whole 
sample) 
Living with spouse/partner who 

































Private health insurance 57/189(30%) Χ²=2.93,df=2 .231 
Alcohol units in 4wks 
 






















The average age was 65 years. There was a significant difference between the age of the responders and the non-responders to 
aspirin therapy with non-responders more likely to be younger.  Non-responders to aspirin were also significantly more likely to be 
male, with higher body weight with higher alcohol intake and less likely to be married. The majority (72%) of the sample were male, 
with 85% of the total sample having a diagnosis of hypertension or currently prescribed ant-hypertensive medication. The 
percentage of patients with a diagnosis of diabetes was 17% of the total sample.  All these statistics are similar to the results from 
the national study of patients with stable coronary artery disease on aspirin therapy, thus there should be good generalisability to 
this sample (219). 
Appendix Table A3 shows the difference between the postal and interview group looking at adherence (objective and self reported) 
looking at the whole sample of 189 patients. 
TABLE A3- Adherence in postal and interview group 











      














There was no significant difference in the thromboxane effectiveness between the responders and the non-responders using Χ² 
p=0.069. There was no significant difference between self-reported adherence of missed days in the previous week between the 
postal and interview group. 
69% showed an effective response of thromboxane to aspirin, with 31% showing and ineffective response of below the cut off of 
2.2ng/ml (looking at the whole Beaumont sample of 189). There was a 66% effective response and 34% ineffective response in the 
n106 sample that responded to the questionnaire.  
10% of patients reported missing at least one aspirin dose in the last week in both samples (Beaumont sample n189 and 
responders n106). 
There was a significant biserial correlation -.162(sig p-value at 0.05), between self reported non-adherence (missed days in the last 
week) and thromboxane effectiveness<2.2ng, when looking at the whole sample of 189 patients. 
There was a significant correlation between self-reported adherence (not missing any doses of aspirin in the last week) and 
thromboxane level <2.2ng (OR=.350, 95% confidence interval (CI) .134-.914, p=0.03) using logistic regression when looking at the 
whole group n=189. Patients that admitted non-adherence were 65% less likely to have an effective response to aspirin. There was 
a significant correlation between patients that admitted missing their aspirin dose in the last week and a thromboxane level 
>2.2ngusing Logistic regression. 
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Table A4 - Logistic Regression of missed days and Thromboxane  effectiveness.  
Variable B df Sig. Exp(B) 95% C.I for EXP(B) 
Lower            Upper 
Missed days -1.051 1 .032 .350 .134 .914 
 
There was also a significant correlation (p=0.027 df1) between self reported missed days in the last week and an ineffective 











TABLE A5 - Crosstabulation of adherence 
 Ineffective TxB2 response 
>2.2 
Effective TxB2 response 
<2.2 
Total 
Missed days = No 
% within missed days 
% within TxB2effective 













Missed days =yes 
% within missed days 
% within TxB2effective 














% within missed days 
% within TxB2effective 
















The above table shows that ten out of nineteen patients that reported missing their daily dose of aspirin in the last week (52.6%) 
had an ineffective response their aspirin. Therefore for over half of the nineteen patients that reported missed days; their ineffective 
response could be explained by lack of adherence.  
TABLE A6 - Demographic differences between the adherent patients and the non-adherent patients in the responders to 
the questionnaire only group N=106. 
Adherence 
measure 
Demographic Adherent Non-adherent Statistic P-value 
Self report 
Thromboxane 
Age mean (yrs) 










































    
 
  7 (78%) /5 (56%)           
  23 (77%)/17(57%)    
 10 (100%)/9 (90%) 
47 (96%)/35 (71%)    




2 (22%)/4 (44%) 
7 (23%)/13 (43%) 
0 (0%) /1 (10%) 
 2 (4%)/14 (29%) 
  0 (%)/3 (43%)  
  












 .030 /.220 






27 (93%)/20 (69%) 
53 (89%)/41(69%) 
14 (82%)/8 (48%) 
2 (7%)/9 (31%) 
6 (10%)/18 (31%) 






35(92%) 3(8%) Χ²=.10,df=1 .75 
Self report 
Thromboxane 





























































The results of the logistic analysis predicting objective adherence of thromboxane<2.2ng are shown in Table A7 
 
TABLE A7 - Logistic analysis predicting objective adherence 
 Exp(B)OR’s 95% C.I 
lower 
95% C.I upper Sig p-
value 
PHQ-total 1.01   .78 1.31  .89 
ESSI-total   .97   .90 1.04 .39 
BMQ-total 
spec 
1.02   .95 1.10 .48 
BMQ-general   1.02   .94 1.10 .54 
BIPQ-01   1.0   .86 1.1 .99 
BIPQ-02   .97   .81 1.1 .79 
BIPQ-03   1.0   .89 1.1 .62 
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BIPQ-04   1.0   .84 1.3 .68 
BIPQ-05   1.0   .91 1.2 .40 
BIPQ-06   .94   .83 1.00 .36 
BIPQ-07 1.0   .92 1.20 .27 
BIPQ-08   .98   .87 1.10 .79 
 
TABLE A8 - Difference between the postal and interview group looking at adherence (objective and self reported)  












There were no significant differences between the psychological mean scores of the postal group and the interview group 
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There was no significant correlation with thromboxane and missed days when controlling for weight and age, using Logistic 
regression. 
 Exp(B)OR’s 95% C.I 
lower 




.303 .065 1.42 .128 
Alcohol intake 
in the last 4ks 
mean  
.976 .959 .993 .005 











There was no significant correlation with gender using logistic regression when looking at weight and alcohol consumption.  
There was no relationship between missed days and thromboxane effectiveness when controlling for age and weight with logistic 
regression. This is possibly due to the emerging profile of the non-adherent patient, which appears to be the younger male, who is 
overweight with a higher alcohol intake. It may also show us that self reported non-adherence could also be an unreliable tool due 
to patients responding in a sociable desirable way.  
 
 
 
 
 
